Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2021-04-20
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
## x
## A1BG 2.6192564
## A1BG-AS1 0.5230655
## A1CF 0.5526173
## A2M -3.3389616
## A2M-AS1 -3.1580711
## A2ML1 -0.3535245Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2408 |
| num_genes_in_profile | 21907 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 8450 |
| num_profile_genes_not_in_sets | 13457 |
Here is a plot of the input profiles. Note the dynamic ranges. 
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2408 |
| num_genesets_excluded | 1042 |
| num_genesets_included | 1366 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Results table
Top N= 100 gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| IRAK4 deficiency (TLR2/4) | 10 | 8.37e-07 | 0.899 | 1.05e-05 |
| MyD88 deficiency (TLR2/4) | 10 | 8.37e-07 | 0.899 | 1.05e-05 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 2.46e-06 | 0.785 | 2.63e-05 |
| alpha-linolenic acid (ALA) metabolism | 12 | 2.46e-06 | 0.785 | 2.63e-05 |
| Regulation of TLR by endogenous ligand | 11 | 1.93e-05 | 0.744 | 1.45e-04 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 2.81e-10 | -0.744 | 8.34e-09 |
| Hyaluronan uptake and degradation | 12 | 8.85e-06 | 0.741 | 7.24e-05 |
| Uptake and function of anthrax toxins | 10 | 1.14e-04 | 0.705 | 6.52e-04 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 9.46e-05 | 0.680 | 5.53e-04 |
| O2/CO2 exchange in erythrocytes | 11 | 9.46e-05 | 0.680 | 5.53e-04 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 1.17e-04 | 0.671 | 6.58e-04 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 1.32e-04 | 0.665 | 7.22e-04 |
| Advanced glycosylation endproduct receptor signaling | 12 | 9.48e-05 | 0.651 | 5.53e-04 |
| Unwinding of DNA | 12 | 1.32e-04 | -0.637 | 7.22e-04 |
| RNA Polymerase I Promoter Opening | 19 | 3.29e-06 | 0.616 | 3.28e-05 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 4.57e-10 | 0.609 | 1.33e-08 |
| ROS and RNS production in phagocytes | 31 | 8.23e-09 | 0.598 | 1.76e-07 |
| Neutrophil degranulation | 457 | 0.00e+00 | 0.587 | 2.00e-100 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 4.97e-04 | 0.580 | 2.29e-03 |
| PD-1 signaling | 28 | 1.11e-07 | -0.579 | 1.87e-06 |
| Insulin receptor recycling | 21 | 6.43e-06 | 0.569 | 5.70e-05 |
| Dissolution of Fibrin Clot | 12 | 6.70e-04 | 0.567 | 2.93e-03 |
| Retrograde neurotrophin signalling | 12 | 6.74e-04 | 0.567 | 2.93e-03 |
| Signaling by Leptin | 10 | 1.97e-03 | 0.565 | 7.07e-03 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 2.11e-08 | 0.563 | 4.24e-07 |
| Detoxification of Reactive Oxygen Species | 32 | 3.64e-08 | 0.562 | 6.90e-07 |
| RHO GTPases Activate NADPH Oxidases | 21 | 9.01e-06 | 0.560 | 7.33e-05 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 5.15e-04 | 0.556 | 2.35e-03 |
| Platelet sensitization by LDL | 16 | 1.28e-04 | 0.553 | 7.08e-04 |
| Hyaluronan metabolism | 15 | 2.20e-04 | 0.551 | 1.13e-03 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 3.65e-04 | 0.550 | 1.75e-03 |
| RHO GTPases Activate ROCKs | 18 | 6.85e-05 | 0.542 | 4.20e-04 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 1.38e-06 | -0.537 | 1.62e-05 |
| Diseases associated with the TLR signaling cascade | 23 | 8.79e-06 | 0.535 | 7.23e-05 |
| Diseases of Immune System | 23 | 8.79e-06 | 0.535 | 7.23e-05 |
| IRAK1 recruits IKK complex | 10 | 3.46e-03 | 0.534 | 1.14e-02 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 3.46e-03 | 0.534 | 1.14e-02 |
| MET activates RAP1 and RAC1 | 10 | 3.66e-03 | 0.531 | 1.19e-02 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 3.85e-03 | 0.528 | 1.23e-02 |
| Negative regulation of MET activity | 18 | 1.11e-04 | 0.526 | 6.39e-04 |
| Budding and maturation of HIV virion | 26 | 3.45e-06 | 0.526 | 3.41e-05 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 1.61e-03 | 0.526 | 6.05e-03 |
| DNA strand elongation | 32 | 3.21e-07 | -0.522 | 4.92e-06 |
| Cargo concentration in the ER | 30 | 7.76e-07 | 0.521 | 1.03e-05 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 1.25e-06 | 0.520 | 1.49e-05 |
| DNA methylation | 20 | 6.16e-05 | 0.517 | 3.82e-04 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 21 | 4.10e-05 | 0.517 | 2.74e-04 |
| Neurodegenerative Diseases | 21 | 4.10e-05 | 0.517 | 2.74e-04 |
| MAP2K and MAPK activation | 34 | 1.81e-07 | 0.517 | 2.91e-06 |
| VLDLR internalisation and degradation | 12 | 2.16e-03 | 0.511 | 7.59e-03 |
| Transferrin endocytosis and recycling | 26 | 6.92e-06 | 0.509 | 5.98e-05 |
| EPHB-mediated forward signaling | 32 | 7.98e-07 | 0.504 | 1.03e-05 |
| Gap junction trafficking | 14 | 1.16e-03 | 0.501 | 4.58e-03 |
| Platelet Adhesion to exposed collagen | 13 | 1.76e-03 | 0.501 | 6.49e-03 |
| Signaling by high-kinase activity BRAF mutants | 31 | 1.54e-06 | 0.499 | 1.77e-05 |
| Smooth Muscle Contraction | 31 | 1.87e-06 | 0.495 | 2.10e-05 |
| Pentose phosphate pathway | 13 | 2.26e-03 | 0.489 | 7.94e-03 |
| RHO GTPases activate PAKs | 20 | 1.70e-04 | 0.486 | 9.02e-04 |
| RHO GTPases activate PKNs | 48 | 6.95e-09 | 0.483 | 1.56e-07 |
| Amyloid fiber formation | 51 | 2.44e-09 | 0.483 | 5.64e-08 |
| Activation of the pre-replicative complex | 32 | 2.43e-06 | -0.481 | 2.63e-05 |
| SHC1 events in EGFR signaling | 12 | 3.92e-03 | 0.481 | 1.25e-02 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 4.12e-03 | 0.478 | 1.30e-02 |
| Diseases of hemostasis | 12 | 4.12e-03 | 0.478 | 1.30e-02 |
| GRB2 events in EGFR signaling | 11 | 6.02e-03 | 0.478 | 1.77e-02 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 6.19e-03 | 0.477 | 1.81e-02 |
| Platelet Aggregation (Plug Formation) | 28 | 1.27e-05 | 0.477 | 1.00e-04 |
| Spry regulation of FGF signaling | 16 | 9.96e-04 | 0.475 | 4.05e-03 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 1.29e-04 | 0.472 | 7.08e-04 |
| Signaling by RAF1 mutants | 34 | 1.94e-06 | 0.472 | 2.16e-05 |
| Josephin domain DUBs | 10 | 9.89e-03 | 0.471 | 2.61e-02 |
| GAB1 signalosome | 15 | 1.59e-03 | 0.471 | 5.97e-03 |
| Trafficking of GluR2-containing AMPA receptors | 12 | 4.79e-03 | 0.470 | 1.48e-02 |
| Generation of second messenger molecules | 38 | 7.20e-07 | -0.464 | 9.74e-06 |
| EGFR downregulation | 27 | 3.34e-05 | 0.461 | 2.28e-04 |
| Response of Mtb to phagocytosis | 22 | 1.91e-04 | 0.459 | 9.90e-04 |
| Antimicrobial peptides | 33 | 4.93e-06 | 0.459 | 4.52e-05 |
| The NLRP3 inflammasome | 15 | 2.13e-03 | 0.458 | 7.51e-03 |
| Integrin signaling | 22 | 2.08e-04 | 0.457 | 1.08e-03 |
| Response to elevated platelet cytosolic Ca2+ | 110 | 1.25e-16 | 0.457 | 1.22e-14 |
| activated TAK1 mediates p38 MAPK activation | 19 | 5.78e-04 | 0.456 | 2.60e-03 |
| Mucopolysaccharidoses | 11 | 8.83e-03 | 0.456 | 2.41e-02 |
| Platelet degranulation | 106 | 5.81e-16 | 0.455 | 5.29e-14 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 2.30e-03 | 0.455 | 8.05e-03 |
| Lagging Strand Synthesis | 20 | 4.63e-04 | -0.452 | 2.15e-03 |
| Prolonged ERK activation events | 13 | 4.76e-03 | 0.452 | 1.47e-02 |
| Infection with Mycobacterium tuberculosis | 26 | 7.20e-05 | 0.450 | 4.39e-04 |
| WNT5A-dependent internalization of FZD4 | 13 | 5.02e-03 | 0.449 | 1.53e-02 |
| Packaging Of Telomere Ends | 20 | 5.17e-04 | 0.448 | 2.35e-03 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 1.44e-02 | 0.447 | 3.52e-02 |
| Membrane binding and targetting of GAG proteins | 13 | 5.40e-03 | 0.446 | 1.62e-02 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 5.40e-03 | 0.446 | 1.62e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 1.57e-04 | -0.446 | 8.44e-04 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.09e-02 | 0.443 | 2.79e-02 |
| Signal amplification | 28 | 5.41e-05 | 0.441 | 3.45e-04 |
| Biotin transport and metabolism | 11 | 1.16e-02 | -0.440 | 2.91e-02 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 92 | 3.03e-13 | 0.440 | 1.53e-11 |
| Toll Like Receptor 2 (TLR2) Cascade | 92 | 3.03e-13 | 0.440 | 1.53e-11 |
| Toll Like Receptor TLR1:TLR2 Cascade | 92 | 3.03e-13 | 0.440 | 1.53e-11 |
| Toll Like Receptor TLR6:TLR2 Cascade | 92 | 3.03e-13 | 0.440 | 1.53e-11 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| IRAK4 deficiency (TLR2/4) | 10 | 8.37e-07 | 8.99e-01 | 1.05e-05 |
| MyD88 deficiency (TLR2/4) | 10 | 8.37e-07 | 8.99e-01 | 1.05e-05 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 2.46e-06 | 7.85e-01 | 2.63e-05 |
| alpha-linolenic acid (ALA) metabolism | 12 | 2.46e-06 | 7.85e-01 | 2.63e-05 |
| Regulation of TLR by endogenous ligand | 11 | 1.93e-05 | 7.44e-01 | 1.45e-04 |
| Translocation of ZAP-70 to Immunological synapse | 24 | 2.81e-10 | -7.44e-01 | 8.34e-09 |
| Hyaluronan uptake and degradation | 12 | 8.85e-06 | 7.41e-01 | 7.24e-05 |
| Uptake and function of anthrax toxins | 10 | 1.14e-04 | 7.05e-01 | 6.52e-04 |
| Erythrocytes take up carbon dioxide and release oxygen | 11 | 9.46e-05 | 6.80e-01 | 5.53e-04 |
| O2/CO2 exchange in erythrocytes | 11 | 9.46e-05 | 6.80e-01 | 5.53e-04 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 1.17e-04 | 6.71e-01 | 6.58e-04 |
| p130Cas linkage to MAPK signaling for integrins | 11 | 1.32e-04 | 6.65e-01 | 7.22e-04 |
| Advanced glycosylation endproduct receptor signaling | 12 | 9.48e-05 | 6.51e-01 | 5.53e-04 |
| Unwinding of DNA | 12 | 1.32e-04 | -6.37e-01 | 7.22e-04 |
| RNA Polymerase I Promoter Opening | 19 | 3.29e-06 | 6.16e-01 | 3.28e-05 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 4.57e-10 | 6.09e-01 | 1.33e-08 |
| ROS and RNS production in phagocytes | 31 | 8.23e-09 | 5.98e-01 | 1.76e-07 |
| Neutrophil degranulation | 457 | 0.00e+00 | 5.87e-01 | 2.00e-100 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 4.97e-04 | 5.80e-01 | 2.29e-03 |
| PD-1 signaling | 28 | 1.11e-07 | -5.79e-01 | 1.87e-06 |
| Insulin receptor recycling | 21 | 6.43e-06 | 5.69e-01 | 5.70e-05 |
| Dissolution of Fibrin Clot | 12 | 6.70e-04 | 5.67e-01 | 2.93e-03 |
| Retrograde neurotrophin signalling | 12 | 6.74e-04 | 5.67e-01 | 2.93e-03 |
| Signaling by Leptin | 10 | 1.97e-03 | 5.65e-01 | 7.07e-03 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 2.11e-08 | 5.63e-01 | 4.24e-07 |
| Detoxification of Reactive Oxygen Species | 32 | 3.64e-08 | 5.62e-01 | 6.90e-07 |
| RHO GTPases Activate NADPH Oxidases | 21 | 9.01e-06 | 5.60e-01 | 7.33e-05 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 5.15e-04 | 5.56e-01 | 2.35e-03 |
| Platelet sensitization by LDL | 16 | 1.28e-04 | 5.53e-01 | 7.08e-04 |
| Hyaluronan metabolism | 15 | 2.20e-04 | 5.51e-01 | 1.13e-03 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 3.65e-04 | 5.50e-01 | 1.75e-03 |
| RHO GTPases Activate ROCKs | 18 | 6.85e-05 | 5.42e-01 | 4.20e-04 |
| Phosphorylation of CD3 and TCR zeta chains | 27 | 1.38e-06 | -5.37e-01 | 1.62e-05 |
| Diseases associated with the TLR signaling cascade | 23 | 8.79e-06 | 5.35e-01 | 7.23e-05 |
| Diseases of Immune System | 23 | 8.79e-06 | 5.35e-01 | 7.23e-05 |
| IRAK1 recruits IKK complex | 10 | 3.46e-03 | 5.34e-01 | 1.14e-02 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 3.46e-03 | 5.34e-01 | 1.14e-02 |
| MET activates RAP1 and RAC1 | 10 | 3.66e-03 | 5.31e-01 | 1.19e-02 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 3.85e-03 | 5.28e-01 | 1.23e-02 |
| Negative regulation of MET activity | 18 | 1.11e-04 | 5.26e-01 | 6.39e-04 |
| Budding and maturation of HIV virion | 26 | 3.45e-06 | 5.26e-01 | 3.41e-05 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 1.61e-03 | 5.26e-01 | 6.05e-03 |
| DNA strand elongation | 32 | 3.21e-07 | -5.22e-01 | 4.92e-06 |
| Cargo concentration in the ER | 30 | 7.76e-07 | 5.21e-01 | 1.03e-05 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 1.25e-06 | 5.20e-01 | 1.49e-05 |
| DNA methylation | 20 | 6.16e-05 | 5.17e-01 | 3.82e-04 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 21 | 4.10e-05 | 5.17e-01 | 2.74e-04 |
| Neurodegenerative Diseases | 21 | 4.10e-05 | 5.17e-01 | 2.74e-04 |
| MAP2K and MAPK activation | 34 | 1.81e-07 | 5.17e-01 | 2.91e-06 |
| VLDLR internalisation and degradation | 12 | 2.16e-03 | 5.11e-01 | 7.59e-03 |
| Transferrin endocytosis and recycling | 26 | 6.92e-06 | 5.09e-01 | 5.98e-05 |
| EPHB-mediated forward signaling | 32 | 7.98e-07 | 5.04e-01 | 1.03e-05 |
| Gap junction trafficking | 14 | 1.16e-03 | 5.01e-01 | 4.58e-03 |
| Platelet Adhesion to exposed collagen | 13 | 1.76e-03 | 5.01e-01 | 6.49e-03 |
| Signaling by high-kinase activity BRAF mutants | 31 | 1.54e-06 | 4.99e-01 | 1.77e-05 |
| Smooth Muscle Contraction | 31 | 1.87e-06 | 4.95e-01 | 2.10e-05 |
| Pentose phosphate pathway | 13 | 2.26e-03 | 4.89e-01 | 7.94e-03 |
| RHO GTPases activate PAKs | 20 | 1.70e-04 | 4.86e-01 | 9.02e-04 |
| RHO GTPases activate PKNs | 48 | 6.95e-09 | 4.83e-01 | 1.56e-07 |
| Amyloid fiber formation | 51 | 2.44e-09 | 4.83e-01 | 5.64e-08 |
| Activation of the pre-replicative complex | 32 | 2.43e-06 | -4.81e-01 | 2.63e-05 |
| SHC1 events in EGFR signaling | 12 | 3.92e-03 | 4.81e-01 | 1.25e-02 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 4.12e-03 | 4.78e-01 | 1.30e-02 |
| Diseases of hemostasis | 12 | 4.12e-03 | 4.78e-01 | 1.30e-02 |
| GRB2 events in EGFR signaling | 11 | 6.02e-03 | 4.78e-01 | 1.77e-02 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 6.19e-03 | 4.77e-01 | 1.81e-02 |
| Platelet Aggregation (Plug Formation) | 28 | 1.27e-05 | 4.77e-01 | 1.00e-04 |
| Spry regulation of FGF signaling | 16 | 9.96e-04 | 4.75e-01 | 4.05e-03 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 1.29e-04 | 4.72e-01 | 7.08e-04 |
| Signaling by RAF1 mutants | 34 | 1.94e-06 | 4.72e-01 | 2.16e-05 |
| Josephin domain DUBs | 10 | 9.89e-03 | 4.71e-01 | 2.61e-02 |
| GAB1 signalosome | 15 | 1.59e-03 | 4.71e-01 | 5.97e-03 |
| Trafficking of GluR2-containing AMPA receptors | 12 | 4.79e-03 | 4.70e-01 | 1.48e-02 |
| Generation of second messenger molecules | 38 | 7.20e-07 | -4.64e-01 | 9.74e-06 |
| EGFR downregulation | 27 | 3.34e-05 | 4.61e-01 | 2.28e-04 |
| Response of Mtb to phagocytosis | 22 | 1.91e-04 | 4.59e-01 | 9.90e-04 |
| Antimicrobial peptides | 33 | 4.93e-06 | 4.59e-01 | 4.52e-05 |
| The NLRP3 inflammasome | 15 | 2.13e-03 | 4.58e-01 | 7.51e-03 |
| Integrin signaling | 22 | 2.08e-04 | 4.57e-01 | 1.08e-03 |
| Response to elevated platelet cytosolic Ca2+ | 110 | 1.25e-16 | 4.57e-01 | 1.22e-14 |
| activated TAK1 mediates p38 MAPK activation | 19 | 5.78e-04 | 4.56e-01 | 2.60e-03 |
| Mucopolysaccharidoses | 11 | 8.83e-03 | 4.56e-01 | 2.41e-02 |
| Platelet degranulation | 106 | 5.81e-16 | 4.55e-01 | 5.29e-14 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 2.30e-03 | 4.55e-01 | 8.05e-03 |
| Lagging Strand Synthesis | 20 | 4.63e-04 | -4.52e-01 | 2.15e-03 |
| Prolonged ERK activation events | 13 | 4.76e-03 | 4.52e-01 | 1.47e-02 |
| Infection with Mycobacterium tuberculosis | 26 | 7.20e-05 | 4.50e-01 | 4.39e-04 |
| WNT5A-dependent internalization of FZD4 | 13 | 5.02e-03 | 4.49e-01 | 1.53e-02 |
| Packaging Of Telomere Ends | 20 | 5.17e-04 | 4.48e-01 | 2.35e-03 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 1.44e-02 | 4.47e-01 | 3.52e-02 |
| Membrane binding and targetting of GAG proteins | 13 | 5.40e-03 | 4.46e-01 | 1.62e-02 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 5.40e-03 | 4.46e-01 | 1.62e-02 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 1.57e-04 | -4.46e-01 | 8.44e-04 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.09e-02 | 4.43e-01 | 2.79e-02 |
| Signal amplification | 28 | 5.41e-05 | 4.41e-01 | 3.45e-04 |
| Biotin transport and metabolism | 11 | 1.16e-02 | -4.40e-01 | 2.91e-02 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Toll Like Receptor 2 (TLR2) Cascade | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Toll Like Receptor TLR1:TLR2 Cascade | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Toll Like Receptor TLR6:TLR2 Cascade | 92 | 3.03e-13 | 4.40e-01 | 1.53e-11 |
| Signal transduction by L1 | 20 | 6.81e-04 | 4.39e-01 | 2.95e-03 |
| Suppression of phagosomal maturation | 12 | 8.51e-03 | 4.39e-01 | 2.34e-02 |
| Alpha-protein kinase 1 signaling pathway | 11 | 1.19e-02 | 4.38e-01 | 2.98e-02 |
| RHO GTPases activate IQGAPs | 11 | 1.26e-02 | 4.34e-01 | 3.13e-02 |
| ERKs are inactivated | 13 | 6.71e-03 | 4.34e-01 | 1.93e-02 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 38 | 3.90e-06 | 4.33e-01 | 3.65e-05 |
| Signaling by RAS mutants | 38 | 3.90e-06 | 4.33e-01 | 3.65e-05 |
| Signaling by moderate kinase activity BRAF mutants | 38 | 3.90e-06 | 4.33e-01 | 3.65e-05 |
| Signaling downstream of RAS mutants | 38 | 3.90e-06 | 4.33e-01 | 3.65e-05 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 25 | 1.86e-04 | 4.32e-01 | 9.72e-04 |
| Processive synthesis on the lagging strand | 15 | 3.88e-03 | -4.31e-01 | 1.24e-02 |
| HDR through MMEJ (alt-NHEJ) | 10 | 1.89e-02 | -4.29e-01 | 4.37e-02 |
| AKT phosphorylates targets in the cytosol | 14 | 5.54e-03 | 4.28e-01 | 1.65e-02 |
| Formation of ATP by chemiosmotic coupling | 18 | 1.67e-03 | 4.28e-01 | 6.23e-03 |
| Recycling pathway of L1 | 26 | 1.68e-04 | 4.26e-01 | 8.92e-04 |
| Erythropoietin activates RAS | 13 | 8.13e-03 | 4.24e-01 | 2.26e-02 |
| Late endosomal microautophagy | 30 | 6.00e-05 | 4.23e-01 | 3.78e-04 |
| Butyrophilin (BTN) family interactions | 10 | 2.05e-02 | -4.23e-01 | 4.67e-02 |
| Activation of ATR in response to replication stress | 37 | 8.43e-06 | -4.23e-01 | 7.06e-05 |
| Interleukin-1 signaling | 98 | 5.37e-13 | 4.22e-01 | 2.45e-11 |
| Growth hormone receptor signaling | 20 | 1.10e-03 | 4.21e-01 | 4.41e-03 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 8.48e-04 | -4.21e-01 | 3.59e-03 |
| Transcriptional regulation of granulopoiesis | 46 | 8.63e-07 | 4.19e-01 | 1.07e-05 |
| Assembly Of The HIV Virion | 15 | 5.09e-03 | 4.18e-01 | 1.54e-02 |
| Regulated proteolysis of p75NTR | 11 | 1.65e-02 | 4.18e-01 | 3.92e-02 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 1.23e-02 | 4.17e-01 | 3.07e-02 |
| Glycogen breakdown (glycogenolysis) | 13 | 1.01e-02 | 4.12e-01 | 2.65e-02 |
| Pre-NOTCH Processing in Golgi | 18 | 2.51e-03 | 4.11e-01 | 8.75e-03 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 2.45e-02 | 4.11e-01 | 5.44e-02 |
| SUMOylation of immune response proteins | 11 | 1.84e-02 | 4.11e-01 | 4.27e-02 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 7.84e-03 | 4.10e-01 | 2.20e-02 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 87 | 3.99e-11 | 4.09e-01 | 1.36e-09 |
| ERK/MAPK targets | 22 | 8.93e-04 | 4.09e-01 | 3.71e-03 |
| Notch-HLH transcription pathway | 28 | 1.86e-04 | 4.08e-01 | 9.71e-04 |
| Signal regulatory protein family interactions | 12 | 1.44e-02 | 4.08e-01 | 3.52e-02 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 1.25e-03 | 4.07e-01 | 4.82e-03 |
| Lysosome Vesicle Biogenesis | 32 | 7.32e-05 | 4.05e-01 | 4.44e-04 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 36 | 2.62e-05 | 4.05e-01 | 1.86e-04 |
| Glycogen synthesis | 13 | 1.16e-02 | 4.04e-01 | 2.92e-02 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 89 | 4.41e-11 | 4.04e-01 | 1.47e-09 |
| Heme degradation | 10 | 2.73e-02 | 4.03e-01 | 5.97e-02 |
| DARPP-32 events | 22 | 1.08e-03 | 4.02e-01 | 4.34e-03 |
| Signalling to ERKs | 32 | 8.47e-05 | 4.01e-01 | 5.01e-04 |
| Interleukin-6 signaling | 10 | 2.81e-02 | 4.01e-01 | 6.11e-02 |
| Inflammasomes | 20 | 1.92e-03 | 4.01e-01 | 6.90e-03 |
| Toll Like Receptor 4 (TLR4) Cascade | 121 | 3.21e-14 | 3.99e-01 | 2.09e-12 |
| Removal of the Flap Intermediate | 14 | 9.82e-03 | -3.99e-01 | 2.60e-02 |
| mTORC1-mediated signalling | 24 | 7.53e-04 | 3.97e-01 | 3.25e-03 |
| MyD88 dependent cascade initiated on endosome | 88 | 1.16e-10 | 3.97e-01 | 3.77e-09 |
| MyD88 cascade initiated on plasma membrane | 82 | 5.31e-10 | 3.97e-01 | 1.39e-08 |
| Toll Like Receptor 10 (TLR10) Cascade | 82 | 5.31e-10 | 3.97e-01 | 1.39e-08 |
| Toll Like Receptor 5 (TLR5) Cascade | 82 | 5.31e-10 | 3.97e-01 | 1.39e-08 |
| rRNA modification in the nucleus and cytosol | 59 | 1.39e-07 | -3.96e-01 | 2.32e-06 |
| Regulation of IFNG signaling | 14 | 1.04e-02 | 3.96e-01 | 2.71e-02 |
| Collagen degradation | 28 | 3.05e-04 | 3.94e-01 | 1.50e-03 |
| COPI-mediated anterograde transport | 78 | 1.90e-09 | 3.93e-01 | 4.72e-08 |
| Antigen processing-Cross presentation | 98 | 1.88e-11 | 3.92e-01 | 6.76e-10 |
| Metabolism of Angiotensinogen to Angiotensins | 11 | 2.43e-02 | 3.92e-01 | 5.40e-02 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 2.11e-04 | 3.91e-01 | 1.09e-03 |
| Signaling by BRAF and RAF fusions | 57 | 3.30e-07 | 3.91e-01 | 4.99e-06 |
| RHO GTPases activate KTN1 | 11 | 2.49e-02 | 3.91e-01 | 5.50e-02 |
| Activation of the AP-1 family of transcription factors | 10 | 3.25e-02 | 3.90e-01 | 6.85e-02 |
| COPII-mediated vesicle transport | 65 | 5.29e-08 | 3.90e-01 | 9.56e-07 |
| EPH-Ephrin signaling | 79 | 2.31e-09 | 3.89e-01 | 5.45e-08 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 12 | 1.98e-02 | 3.88e-01 | 4.56e-02 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 27 | 5.03e-04 | 3.87e-01 | 2.31e-03 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 9.64e-05 | -3.86e-01 | 5.60e-04 |
| Formation of apoptosome | 11 | 2.75e-02 | 3.84e-01 | 5.98e-02 |
| Regulation of the apoptosome activity | 11 | 2.75e-02 | 3.84e-01 | 5.98e-02 |
| Toll-like Receptor Cascades | 143 | 2.29e-15 | 3.84e-01 | 1.96e-13 |
| Toll Like Receptor 9 (TLR9) Cascade | 92 | 2.03e-10 | 3.83e-01 | 6.16e-09 |
| LDL clearance | 18 | 5.19e-03 | 3.81e-01 | 1.57e-02 |
| Sema4D in semaphorin signaling | 22 | 2.00e-03 | 3.80e-01 | 7.17e-03 |
| Apoptosis induced DNA fragmentation | 10 | 3.79e-02 | 3.79e-01 | 7.73e-02 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 48 | 5.62e-06 | 3.79e-01 | 5.08e-05 |
| Frs2-mediated activation | 11 | 3.00e-02 | 3.78e-01 | 6.43e-02 |
| Signaling by Erythropoietin | 24 | 1.35e-03 | 3.78e-01 | 5.18e-03 |
| ADP signalling through P2Y purinoceptor 12 | 18 | 5.56e-03 | 3.77e-01 | 1.65e-02 |
| G-protein beta:gamma signalling | 29 | 4.44e-04 | 3.77e-01 | 2.08e-03 |
| Sema4D induced cell migration and growth-cone collapse | 19 | 4.48e-03 | 3.77e-01 | 1.40e-02 |
| Iron uptake and transport | 52 | 2.62e-06 | 3.77e-01 | 2.72e-05 |
| Cellular response to hypoxia | 72 | 3.43e-08 | 3.76e-01 | 6.61e-07 |
| Thromboxane signalling through TP receptor | 20 | 3.68e-03 | 3.75e-01 | 1.19e-02 |
| Formation of the cornified envelope | 21 | 3.06e-03 | 3.73e-01 | 1.02e-02 |
| ER to Golgi Anterograde Transport | 129 | 2.87e-13 | 3.72e-01 | 1.53e-11 |
| trans-Golgi Network Vesicle Budding | 69 | 9.29e-08 | 3.72e-01 | 1.61e-06 |
| MTOR signalling | 39 | 6.11e-05 | 3.71e-01 | 3.81e-04 |
| Hh mutants that don’t undergo autocatalytic processing are degraded by ERAD | 54 | 2.48e-06 | 3.70e-01 | 2.63e-05 |
| Signaling by NTRK1 (TRKA) | 101 | 1.31e-10 | 3.70e-01 | 4.07e-09 |
| RHO GTPases activate CIT | 18 | 6.61e-03 | 3.70e-01 | 1.91e-02 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 1.68e-02 | 3.69e-01 | 4.00e-02 |
| Gap junction trafficking and regulation | 16 | 1.08e-02 | 3.68e-01 | 2.76e-02 |
| Golgi Associated Vesicle Biogenesis | 55 | 2.33e-06 | 3.68e-01 | 2.55e-05 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 2.81e-03 | 3.68e-01 | 9.49e-03 |
| Regulation of ornithine decarboxylase (ODC) | 50 | 6.72e-06 | 3.68e-01 | 5.89e-05 |
| Cell-extracellular matrix interactions | 14 | 1.73e-02 | 3.68e-01 | 4.06e-02 |
| MAP kinase activation | 63 | 4.52e-07 | 3.67e-01 | 6.44e-06 |
| Innate Immune System | 967 | 5.85e-84 | 3.67e-01 | 3.99e-81 |
| Signaling by MET | 61 | 7.13e-07 | 3.67e-01 | 9.74e-06 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 1.11e-02 | 3.67e-01 | 2.83e-02 |
| Calnexin/calreticulin cycle | 26 | 1.22e-03 | 3.66e-01 | 4.75e-03 |
| RAF activation | 32 | 3.35e-04 | 3.66e-01 | 1.64e-03 |
| Signaling by NTRKs | 116 | 9.74e-12 | 3.66e-01 | 3.69e-10 |
| Diseases of DNA repair | 10 | 4.55e-02 | -3.65e-01 | 9.04e-02 |
| Beta-catenin phosphorylation cascade | 17 | 9.11e-03 | 3.65e-01 | 2.46e-02 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 1.15e-02 | 3.65e-01 | 2.90e-02 |
| Leading Strand Synthesis | 14 | 1.83e-02 | -3.64e-01 | 4.27e-02 |
| Polymerase switching | 14 | 1.83e-02 | -3.64e-01 | 4.27e-02 |
| Platelet activation, signaling and aggregation | 221 | 1.35e-20 | 3.63e-01 | 2.05e-18 |
| Endogenous sterols | 17 | 1.00e-02 | 3.61e-01 | 2.64e-02 |
| Telomere C-strand synthesis initiation | 13 | 2.45e-02 | -3.60e-01 | 5.44e-02 |
| G beta:gamma signalling through CDC42 | 17 | 1.02e-02 | 3.60e-01 | 2.67e-02 |
| Cell recruitment (pro-inflammatory response) | 22 | 3.47e-03 | 3.60e-01 | 1.14e-02 |
| Purinergic signaling in leishmaniasis infection | 22 | 3.47e-03 | 3.60e-01 | 1.14e-02 |
| HDACs deacetylate histones | 47 | 2.04e-05 | 3.59e-01 | 1.51e-04 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 49 | 1.37e-05 | 3.59e-01 | 1.05e-04 |
| Glycogen metabolism | 23 | 2.91e-03 | 3.59e-01 | 9.78e-03 |
| Clathrin-mediated endocytosis | 127 | 3.15e-12 | 3.58e-01 | 1.30e-10 |
| IKK complex recruitment mediated by RIP1 | 23 | 2.99e-03 | 3.58e-01 | 9.98e-03 |
| GP1b-IX-V activation signalling | 10 | 5.04e-02 | 3.57e-01 | 9.86e-02 |
| Pexophagy | 11 | 4.02e-02 | 3.57e-01 | 8.13e-02 |
| RAB geranylgeranylation | 61 | 1.46e-06 | 3.57e-01 | 1.69e-05 |
| MET activates RAS signaling | 10 | 5.12e-02 | 3.56e-01 | 1.00e-01 |
| Nucleobase biosynthesis | 13 | 2.64e-02 | -3.56e-01 | 5.80e-02 |
| ER-Phagosome pathway | 83 | 2.17e-08 | 3.55e-01 | 4.30e-07 |
| Thrombin signalling through proteinase activated receptors (PARs) | 27 | 1.42e-03 | 3.55e-01 | 5.41e-03 |
| Post-translational protein phosphorylation | 70 | 2.94e-07 | 3.54e-01 | 4.62e-06 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 65 | 8.07e-07 | 3.54e-01 | 1.03e-05 |
| Interleukin-1 family signaling | 125 | 8.55e-12 | 3.53e-01 | 3.34e-10 |
| Negative regulation of NOTCH4 signaling | 54 | 7.02e-06 | 3.53e-01 | 6.03e-05 |
| Fanconi Anemia Pathway | 36 | 2.43e-04 | -3.53e-01 | 1.24e-03 |
| Cleavage of the damaged purine | 24 | 2.75e-03 | 3.53e-01 | 9.31e-03 |
| Depurination | 24 | 2.75e-03 | 3.53e-01 | 9.31e-03 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 24 | 2.75e-03 | 3.53e-01 | 9.31e-03 |
| Syndecan interactions | 19 | 7.70e-03 | 3.53e-01 | 2.17e-02 |
| Homologous DNA Pairing and Strand Exchange | 42 | 7.63e-05 | -3.53e-01 | 4.61e-04 |
| Pre-NOTCH Transcription and Translation | 49 | 1.95e-05 | 3.53e-01 | 1.46e-04 |
| Defective CFTR causes cystic fibrosis | 60 | 2.57e-06 | 3.51e-01 | 2.71e-05 |
| Hh mutants abrogate ligand secretion | 55 | 6.85e-06 | 3.51e-01 | 5.96e-05 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 7.33e-04 | 3.50e-01 | 3.17e-03 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 54 | 8.71e-06 | 3.50e-01 | 7.23e-05 |
| Pre-NOTCH Expression and Processing | 65 | 1.18e-06 | 3.48e-01 | 1.43e-05 |
| Resolution of Abasic Sites (AP sites) | 37 | 2.48e-04 | -3.48e-01 | 1.25e-03 |
| PKA activation in glucagon signalling | 14 | 2.47e-02 | 3.47e-01 | 5.46e-02 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 83 | 5.32e-08 | 3.45e-01 | 9.56e-07 |
| Pyrimidine salvage | 10 | 5.91e-02 | 3.45e-01 | 1.12e-01 |
| Signaling by EGFR in Cancer | 23 | 4.22e-03 | 3.45e-01 | 1.33e-02 |
| Inhibition of DNA recombination at telomere | 35 | 4.21e-04 | 3.44e-01 | 1.98e-03 |
| Degradation of DVL | 55 | 1.03e-05 | 3.44e-01 | 8.34e-05 |
| Hedgehog ligand biogenesis | 59 | 5.69e-06 | 3.41e-01 | 5.11e-05 |
| G beta:gamma signalling through PLC beta | 17 | 1.48e-02 | 3.41e-01 | 3.61e-02 |
| Vif-mediated degradation of APOBEC3G | 53 | 1.73e-05 | 3.41e-01 | 1.31e-04 |
| Cytochrome c-mediated apoptotic response | 13 | 3.33e-02 | 3.41e-01 | 6.96e-02 |
| MyD88-independent TLR4 cascade | 96 | 7.99e-09 | 3.41e-01 | 1.73e-07 |
| TRIF(TICAM1)-mediated TLR4 signaling | 96 | 7.99e-09 | 3.41e-01 | 1.73e-07 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 48 | 4.45e-05 | 3.41e-01 | 2.95e-04 |
| Regulation of Apoptosis | 52 | 2.18e-05 | 3.40e-01 | 1.60e-04 |
| Negative regulation of FGFR3 signaling | 20 | 8.81e-03 | 3.38e-01 | 2.41e-02 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 27 | 2.38e-03 | 3.38e-01 | 8.30e-03 |
| Interleukin-17 signaling | 68 | 1.45e-06 | 3.38e-01 | 1.69e-05 |
| Common Pathway of Fibrin Clot Formation | 14 | 2.97e-02 | 3.36e-01 | 6.39e-02 |
| Signaling by EGFR | 46 | 8.37e-05 | 3.35e-01 | 4.98e-04 |
| Glucagon signaling in metabolic regulation | 27 | 2.63e-03 | 3.34e-01 | 9.01e-03 |
| Oncogenic MAPK signaling | 73 | 7.76e-07 | 3.34e-01 | 1.03e-05 |
| ER Quality Control Compartment (ERQC) | 21 | 7.99e-03 | 3.34e-01 | 2.23e-02 |
| Degradation of GLI2 by the proteasome | 57 | 1.28e-05 | 3.34e-01 | 1.00e-04 |
| Cargo recognition for clathrin-mediated endocytosis | 90 | 4.34e-08 | 3.34e-01 | 8.11e-07 |
| Diseases of carbohydrate metabolism | 29 | 1.86e-03 | 3.34e-01 | 6.80e-03 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 2.62e-05 | 3.34e-01 | 1.86e-04 |
| Rev-mediated nuclear export of HIV RNA | 35 | 6.35e-04 | -3.34e-01 | 2.82e-03 |
| SHC1 events in ERBB4 signaling | 10 | 6.80e-02 | 3.33e-01 | 1.25e-01 |
| FOXO-mediated transcription of cell death genes | 16 | 2.16e-02 | 3.32e-01 | 4.89e-02 |
| Golgi-to-ER retrograde transport | 111 | 1.79e-09 | 3.30e-01 | 4.53e-08 |
| GPVI-mediated activation cascade | 31 | 1.48e-03 | 3.30e-01 | 5.63e-03 |
| Degradation of GLI1 by the proteasome | 58 | 1.42e-05 | 3.29e-01 | 1.08e-04 |
| Regulation of PTEN stability and activity | 67 | 3.28e-06 | 3.29e-01 | 3.28e-05 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 51 | 4.97e-05 | 3.28e-01 | 3.22e-04 |
| p53-Independent DNA Damage Response | 51 | 4.97e-05 | 3.28e-01 | 3.22e-04 |
| p53-Independent G1/S DNA damage checkpoint | 51 | 4.97e-05 | 3.28e-01 | 3.22e-04 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 4.00e-04 | -3.28e-01 | 1.89e-03 |
| G-protein activation | 23 | 6.68e-03 | 3.27e-01 | 1.93e-02 |
| Interactions of Rev with host cellular proteins | 37 | 5.97e-04 | -3.26e-01 | 2.65e-03 |
| VxPx cargo-targeting to cilium | 19 | 1.40e-02 | 3.25e-01 | 3.44e-02 |
| Vpu mediated degradation of CD4 | 51 | 6.08e-05 | 3.25e-01 | 3.81e-04 |
| NIK–>noncanonical NF-kB signaling | 58 | 1.99e-05 | 3.24e-01 | 1.47e-04 |
| RAB GEFs exchange GTP for GDP on RABs | 88 | 1.51e-07 | 3.24e-01 | 2.49e-06 |
| Synthesis of PC | 23 | 7.24e-03 | 3.23e-01 | 2.05e-02 |
| G beta:gamma signalling through BTK | 15 | 3.01e-02 | 3.23e-01 | 6.44e-02 |
| E3 ubiquitin ligases ubiquitinate target proteins | 52 | 5.50e-05 | 3.23e-01 | 3.50e-04 |
| Activation of Matrix Metalloproteinases | 23 | 7.33e-03 | 3.23e-01 | 2.08e-02 |
| Signaling by NOTCH4 | 79 | 6.95e-07 | 3.23e-01 | 9.58e-06 |
| Presynaptic function of Kainate receptors | 18 | 1.80e-02 | 3.22e-01 | 4.22e-02 |
| Nuclear Events (kinase and transcription factor activation) | 53 | 5.25e-05 | 3.21e-01 | 3.37e-04 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.67e-03 | -3.21e-01 | 6.23e-03 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 29 | 2.94e-03 | 3.19e-01 | 9.83e-03 |
| GLI3 is processed to GLI3R by the proteasome | 58 | 2.78e-05 | 3.18e-01 | 1.96e-04 |
| Protein ubiquitination | 72 | 3.07e-06 | 3.18e-01 | 3.15e-05 |
| Dectin-1 mediated noncanonical NF-kB signaling | 59 | 2.42e-05 | 3.18e-01 | 1.76e-04 |
| Triglyceride catabolism | 16 | 2.79e-02 | 3.17e-01 | 6.07e-02 |
| ERBB2 Regulates Cell Motility | 10 | 8.23e-02 | 3.17e-01 | 1.46e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 59 | 2.58e-05 | 3.17e-01 | 1.85e-04 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 80 | 9.74e-07 | 3.17e-01 | 1.19e-05 |
| Nucleotide salvage | 21 | 1.20e-02 | 3.17e-01 | 3.00e-02 |
| TNFR1-induced proapoptotic signaling | 12 | 5.78e-02 | -3.16e-01 | 1.10e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 1.23e-03 | 3.16e-01 | 4.77e-03 |
| Amino acids regulate mTORC1 | 50 | 1.16e-04 | 3.15e-01 | 6.57e-04 |
| Metabolism of polyamines | 58 | 3.35e-05 | 3.15e-01 | 2.28e-04 |
| Ubiquitin-dependent degradation of Cyclin D | 51 | 1.02e-04 | 3.15e-01 | 5.88e-04 |
| Apoptotic factor-mediated response | 18 | 2.10e-02 | 3.14e-01 | 4.77e-02 |
| Negative regulation of FGFR4 signaling | 21 | 1.27e-02 | 3.14e-01 | 3.15e-02 |
| Transport to the Golgi and subsequent modification | 155 | 1.60e-11 | 3.13e-01 | 5.89e-10 |
| RORA activates gene expression | 18 | 2.17e-02 | 3.12e-01 | 4.91e-02 |
| Metabolism of steroid hormones | 21 | 1.32e-02 | 3.12e-01 | 3.27e-02 |
| Metabolism of porphyrins | 22 | 1.15e-02 | 3.11e-01 | 2.90e-02 |
| Autophagy | 124 | 2.12e-09 | 3.11e-01 | 5.17e-08 |
| Activation of BAD and translocation to mitochondria | 15 | 3.69e-02 | 3.11e-01 | 7.53e-02 |
| Signaling by NOTCH | 183 | 3.84e-13 | 3.11e-01 | 1.81e-11 |
| Extension of Telomeres | 51 | 1.26e-04 | -3.10e-01 | 7.00e-04 |
| Mitochondrial tRNA aminoacylation | 21 | 1.39e-02 | -3.10e-01 | 3.41e-02 |
| Membrane Trafficking | 559 | 5.33e-36 | 3.09e-01 | 1.82e-33 |
| Vpr-mediated nuclear import of PICs | 34 | 1.87e-03 | -3.08e-01 | 6.80e-03 |
| Uptake and actions of bacterial toxins | 27 | 5.68e-03 | 3.07e-01 | 1.68e-02 |
| Regulation of RUNX3 expression and activity | 55 | 8.07e-05 | 3.07e-01 | 4.84e-04 |
| Effects of PIP2 hydrolysis | 24 | 9.24e-03 | -3.07e-01 | 2.48e-02 |
| ABC transporter disorders | 71 | 7.90e-06 | 3.07e-01 | 6.70e-05 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 3.42e-02 | 3.06e-01 | 7.11e-02 |
| Diseases of programmed cell death | 28 | 5.10e-03 | 3.06e-01 | 1.54e-02 |
| rRNA processing in the nucleus and cytosol | 190 | 3.58e-13 | -3.06e-01 | 1.75e-11 |
| Nuclear import of Rev protein | 34 | 2.04e-03 | -3.06e-01 | 7.26e-03 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 4.78e-02 | -3.06e-01 | 9.42e-02 |
| VEGFA-VEGFR2 Pathway | 92 | 4.27e-07 | 3.05e-01 | 6.14e-06 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 1.68e-12 | -3.05e-01 | 7.18e-11 |
| NS1 Mediated Effects on Host Pathways | 40 | 8.53e-04 | -3.05e-01 | 3.59e-03 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 8.38e-03 | 3.05e-01 | 2.31e-02 |
| Polymerase switching on the C-strand of the telomere | 26 | 7.19e-03 | -3.05e-01 | 2.05e-02 |
| Condensation of Prophase Chromosomes | 29 | 4.54e-03 | 3.04e-01 | 1.41e-02 |
| L1CAM interactions | 85 | 1.26e-06 | 3.04e-01 | 1.49e-05 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 22 | 1.37e-02 | 3.03e-01 | 3.38e-02 |
| Plasma lipoprotein clearance | 29 | 4.75e-03 | 3.03e-01 | 1.47e-02 |
| Acyl chain remodelling of PI | 10 | 9.74e-02 | 3.03e-01 | 1.65e-01 |
| Trafficking and processing of endosomal TLR | 13 | 5.88e-02 | 3.03e-01 | 1.11e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 29 | 4.82e-03 | 3.02e-01 | 1.48e-02 |
| Rap1 signalling | 13 | 5.95e-02 | 3.02e-01 | 1.12e-01 |
| Glycogen storage diseases | 13 | 6.01e-02 | 3.01e-01 | 1.13e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 6.05e-02 | 3.01e-01 | 1.13e-01 |
| CLEC7A (Dectin-1) signaling | 97 | 3.16e-07 | 3.00e-01 | 4.91e-06 |
| Senescence-Associated Secretory Phenotype (SASP) | 66 | 2.52e-05 | 3.00e-01 | 1.81e-04 |
| Activation of G protein gated Potassium channels | 20 | 2.03e-02 | 3.00e-01 | 4.63e-02 |
| G protein gated Potassium channels | 20 | 2.03e-02 | 3.00e-01 | 4.63e-02 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 20 | 2.03e-02 | 3.00e-01 | 4.63e-02 |
| Toll Like Receptor 3 (TLR3) Cascade | 92 | 6.70e-07 | 3.00e-01 | 9.34e-06 |
| Negative regulation of FGFR1 signaling | 24 | 1.12e-02 | 2.99e-01 | 2.83e-02 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 2.53e-04 | 2.99e-01 | 1.27e-03 |
| p38MAPK events | 13 | 6.19e-02 | 2.99e-01 | 1.15e-01 |
| Selenocysteine synthesis | 92 | 8.72e-07 | -2.97e-01 | 1.07e-05 |
| Signaling by Insulin receptor | 59 | 8.38e-05 | 2.96e-01 | 4.98e-04 |
| MET promotes cell motility | 26 | 9.05e-03 | 2.96e-01 | 2.44e-02 |
| Chondroitin sulfate biosynthesis | 12 | 7.62e-02 | 2.96e-01 | 1.38e-01 |
| CD28 dependent PI3K/Akt signaling | 22 | 1.64e-02 | -2.96e-01 | 3.91e-02 |
| PCP/CE pathway | 87 | 1.87e-06 | 2.96e-01 | 2.10e-05 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 3.50e-02 | 2.95e-01 | 7.25e-02 |
| Translesion synthesis by REV1 | 16 | 4.13e-02 | -2.95e-01 | 8.32e-02 |
| Activation of NF-kappaB in B cells | 66 | 3.57e-05 | 2.94e-01 | 2.41e-04 |
| Aquaporin-mediated transport | 38 | 1.72e-03 | 2.94e-01 | 6.37e-03 |
| p75NTR signals via NF-kB | 15 | 4.88e-02 | 2.94e-01 | 9.57e-02 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 3.22e-03 | 2.92e-01 | 1.07e-02 |
| MASTL Facilitates Mitotic Progression | 10 | 1.10e-01 | 2.92e-01 | 1.82e-01 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 3.27e-02 | 2.91e-01 | 6.86e-02 |
| tRNA processing in the nucleus | 59 | 1.15e-04 | -2.90e-01 | 6.52e-04 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 26 | 1.04e-02 | 2.90e-01 | 2.71e-02 |
| Receptor Mediated Mitophagy | 11 | 9.58e-02 | 2.90e-01 | 1.63e-01 |
| TBC/RABGAPs | 45 | 7.61e-04 | 2.90e-01 | 3.26e-03 |
| Formation of tubulin folding intermediates by CCT/TriC | 22 | 1.87e-02 | 2.90e-01 | 4.33e-02 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 51 | 3.51e-04 | 2.89e-01 | 1.70e-03 |
| Opioid Signalling | 75 | 1.55e-05 | 2.89e-01 | 1.17e-04 |
| Constitutive Signaling by EGFRvIII | 14 | 6.17e-02 | 2.88e-01 | 1.15e-01 |
| Signaling by EGFRvIII in Cancer | 14 | 6.17e-02 | 2.88e-01 | 1.15e-01 |
| Integration of energy metabolism | 86 | 3.84e-06 | 2.88e-01 | 3.65e-05 |
| Misspliced GSK3beta mutants stabilize beta-catenin | 15 | 5.33e-02 | 2.88e-01 | 1.03e-01 |
| S33 mutants of beta-catenin aren’t phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.03e-01 |
| S37 mutants of beta-catenin aren’t phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.03e-01 |
| S45 mutants of beta-catenin aren’t phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.03e-01 |
| T41 mutants of beta-catenin aren’t phosphorylated | 15 | 5.33e-02 | 2.88e-01 | 1.03e-01 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 15 | 5.33e-02 | 2.88e-01 | 1.03e-01 |
| G beta:gamma signalling through PI3Kgamma | 22 | 1.93e-02 | 2.88e-01 | 4.46e-02 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 8.43e-02 | 2.88e-01 | 1.48e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 8.43e-02 | 2.88e-01 | 1.48e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 17 | 4.00e-02 | 2.88e-01 | 8.10e-02 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 4.86e-03 | -2.88e-01 | 1.49e-02 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 16 | 4.64e-02 | 2.88e-01 | 9.20e-02 |
| Formation of Fibrin Clot (Clotting Cascade) | 26 | 1.12e-02 | 2.87e-01 | 2.84e-02 |
| EPHA-mediated growth cone collapse | 13 | 7.31e-02 | 2.87e-01 | 1.33e-01 |
| rRNA processing | 219 | 2.40e-13 | -2.87e-01 | 1.49e-11 |
| SCF-beta-TrCP mediated degradation of Emi1 | 54 | 2.64e-04 | 2.87e-01 | 1.32e-03 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 4.60e-03 | -2.85e-01 | 1.43e-02 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 88 | 3.93e-06 | 2.85e-01 | 3.65e-05 |
| Interactions of Vpr with host cellular proteins | 37 | 2.75e-03 | -2.84e-01 | 9.31e-03 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 15 | 5.77e-02 | 2.83e-01 | 1.10e-01 |
| Signalling to RAS | 19 | 3.27e-02 | 2.83e-01 | 6.86e-02 |
| Interferon alpha/beta signaling | 57 | 2.25e-04 | -2.82e-01 | 1.15e-03 |
| Carnitine metabolism | 10 | 1.23e-01 | 2.82e-01 | 1.98e-01 |
| Post-chaperonin tubulin folding pathway | 19 | 3.43e-02 | 2.80e-01 | 7.12e-02 |
| SHC1 events in ERBB2 signaling | 17 | 4.54e-02 | 2.80e-01 | 9.04e-02 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 18 | 3.97e-02 | 2.80e-01 | 8.05e-02 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 18 | 3.97e-02 | 2.80e-01 | 8.05e-02 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 1.08e-01 | 2.80e-01 | 1.79e-01 |
| XBP1(S) activates chaperone genes | 47 | 9.11e-04 | 2.80e-01 | 3.76e-03 |
| SIRT1 negatively regulates rRNA expression | 24 | 1.78e-02 | 2.79e-01 | 4.19e-02 |
| Peptide chain elongation | 88 | 5.95e-06 | -2.79e-01 | 5.31e-05 |
| Interleukin-4 and Interleukin-13 signaling | 92 | 3.68e-06 | 2.79e-01 | 3.59e-05 |
| Beta-oxidation of very long chain fatty acids | 10 | 1.28e-01 | 2.78e-01 | 2.04e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 48 | 8.53e-04 | 2.78e-01 | 3.59e-03 |
| Signaling by PTK6 | 48 | 8.53e-04 | 2.78e-01 | 3.59e-03 |
| Programmed Cell Death | 180 | 1.26e-10 | 2.78e-01 | 3.99e-09 |
| Asparagine N-linked glycosylation | 269 | 5.32e-15 | 2.77e-01 | 4.03e-13 |
| Interleukin-27 signaling | 11 | 1.12e-01 | 2.77e-01 | 1.83e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 1.28e-04 | 2.77e-01 | 7.08e-04 |
| G alpha (z) signalling events | 36 | 4.07e-03 | 2.77e-01 | 1.29e-02 |
| HDR through Single Strand Annealing (SSA) | 37 | 3.61e-03 | -2.76e-01 | 1.17e-02 |
| Mitotic Telophase/Cytokinesis | 13 | 8.47e-02 | 2.76e-01 | 1.49e-01 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 12 | 9.79e-02 | 2.76e-01 | 1.66e-01 |
| Rab regulation of trafficking | 121 | 1.59e-07 | 2.76e-01 | 2.59e-06 |
| Cleavage of the damaged pyrimidine | 29 | 1.04e-02 | 2.75e-01 | 2.71e-02 |
| Depyrimidination | 29 | 1.04e-02 | 2.75e-01 | 2.71e-02 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 29 | 1.04e-02 | 2.75e-01 | 2.71e-02 |
| Degradation of AXIN | 54 | 4.87e-04 | 2.74e-01 | 2.25e-03 |
| NOTCH1 Intracellular Domain Regulates Transcription | 45 | 1.45e-03 | 2.74e-01 | 5.52e-03 |
| Signaling by FGFR3 | 31 | 8.41e-03 | 2.73e-01 | 2.31e-02 |
| tRNA modification in the nucleus and cytosol | 43 | 1.92e-03 | -2.73e-01 | 6.90e-03 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 32 | 7.55e-03 | 2.73e-01 | 2.13e-02 |
| Macroautophagy | 110 | 7.88e-07 | 2.72e-01 | 1.03e-05 |
| TRAF6 mediated NF-kB activation | 23 | 2.38e-02 | 2.72e-01 | 5.32e-02 |
| O-glycosylation of TSR domain-containing proteins | 26 | 1.63e-02 | -2.72e-01 | 3.91e-02 |
| Myogenesis | 21 | 3.11e-02 | 2.72e-01 | 6.59e-02 |
| PLC beta mediated events | 43 | 2.09e-03 | 2.71e-01 | 7.43e-03 |
| Activation of GABAB receptors | 31 | 8.98e-03 | 2.71e-01 | 2.43e-02 |
| GABA B receptor activation | 31 | 8.98e-03 | 2.71e-01 | 2.43e-02 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 11 | 1.19e-01 | -2.71e-01 | 1.93e-01 |
| TGF-beta receptor signaling activates SMADs | 32 | 7.94e-03 | 2.71e-01 | 2.22e-02 |
| PPARA activates gene expression | 104 | 1.84e-06 | 2.71e-01 | 2.09e-05 |
| Eukaryotic Translation Elongation | 93 | 6.47e-06 | -2.71e-01 | 5.70e-05 |
| Oxidative Stress Induced Senescence | 79 | 3.24e-05 | 2.70e-01 | 2.22e-04 |
| Transport of the SLBP independent Mature mRNA | 35 | 5.65e-03 | -2.70e-01 | 1.67e-02 |
| Interleukin-10 signaling | 35 | 5.66e-03 | 2.70e-01 | 1.67e-02 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 8.22e-03 | -2.70e-01 | 2.28e-02 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 8.22e-03 | -2.70e-01 | 2.28e-02 |
| Stabilization of p53 | 55 | 5.37e-04 | 2.70e-01 | 2.43e-03 |
| Intrinsic Pathway of Fibrin Clot Formation | 16 | 6.18e-02 | 2.70e-01 | 1.15e-01 |
| Citric acid cycle (TCA cycle) | 22 | 2.86e-02 | 2.70e-01 | 6.19e-02 |
| Signaling by NOTCH1 | 67 | 1.37e-04 | 2.69e-01 | 7.37e-04 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 179 | 5.04e-10 | 2.69e-01 | 1.39e-08 |
| Signaling by VEGF | 100 | 3.27e-06 | 2.69e-01 | 3.28e-05 |
| IRE1alpha activates chaperones | 49 | 1.13e-03 | 2.69e-01 | 4.49e-03 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 1.58e-02 | 2.68e-01 | 3.79e-02 |
| Metalloprotease DUBs | 21 | 3.33e-02 | 2.68e-01 | 6.96e-02 |
| Vesicle-mediated transport | 650 | 1.64e-31 | 2.68e-01 | 4.49e-29 |
| SARS-CoV-2 Infection | 63 | 2.35e-04 | 2.68e-01 | 1.20e-03 |
| Apoptosis | 168 | 2.16e-09 | 2.68e-01 | 5.17e-08 |
| Signaling by Interleukins | 386 | 1.71e-19 | 2.68e-01 | 2.12e-17 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 5.50e-03 | 2.67e-01 | 1.64e-02 |
| PKA activation | 15 | 7.31e-02 | 2.67e-01 | 1.33e-01 |
| Respiratory electron transport | 101 | 3.58e-06 | 2.67e-01 | 3.52e-05 |
| NF-kB is activated and signals survival | 12 | 1.11e-01 | 2.66e-01 | 1.82e-01 |
| Signaling by Receptor Tyrosine Kinases | 414 | 1.68e-20 | 2.66e-01 | 2.29e-18 |
| Purine ribonucleoside monophosphate biosynthesis | 10 | 1.47e-01 | -2.65e-01 | 2.30e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 53 | 8.47e-04 | 2.65e-01 | 3.59e-03 |
| MAPK6/MAPK4 signaling | 83 | 3.05e-05 | 2.65e-01 | 2.11e-04 |
| Cristae formation | 31 | 1.08e-02 | 2.65e-01 | 2.77e-02 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 124 | 3.67e-07 | 2.64e-01 | 5.45e-06 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 2.83e-02 | 2.64e-01 | 6.13e-02 |
| Prostacyclin signalling through prostacyclin receptor | 16 | 6.82e-02 | 2.63e-01 | 1.25e-01 |
| Eukaryotic Translation Termination | 92 | 1.32e-05 | -2.63e-01 | 1.02e-04 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 1.83e-02 | -2.62e-01 | 4.27e-02 |
| Platelet homeostasis | 69 | 1.71e-04 | 2.62e-01 | 9.02e-04 |
| Translesion synthesis by POLI | 17 | 6.22e-02 | -2.61e-01 | 1.16e-01 |
| Tie2 Signaling | 16 | 7.05e-02 | 2.61e-01 | 1.29e-01 |
| Regulation of signaling by CBL | 18 | 5.52e-02 | 2.61e-01 | 1.05e-01 |
| Scavenging by Class A Receptors | 12 | 1.18e-01 | 2.61e-01 | 1.92e-01 |
| Viral mRNA Translation | 88 | 2.47e-05 | -2.60e-01 | 1.79e-04 |
| Amine ligand-binding receptors | 10 | 1.55e-01 | -2.60e-01 | 2.40e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 7.20e-02 | 2.60e-01 | 1.32e-01 |
| GABA receptor activation | 36 | 7.11e-03 | 2.59e-01 | 2.03e-02 |
| C-type lectin receptors (CLRs) | 129 | 3.78e-07 | 2.59e-01 | 5.55e-06 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 1.78e-02 | -2.59e-01 | 4.19e-02 |
| Signaling by FGFR4 | 31 | 1.28e-02 | 2.58e-01 | 3.16e-02 |
| APC/C:Cdc20 mediated degradation of Securin | 67 | 2.63e-04 | 2.58e-01 | 1.32e-03 |
| AMER1 mutants destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.63e-01 |
| APC truncation mutants have impaired AXIN binding | 14 | 9.52e-02 | 2.58e-01 | 1.63e-01 |
| AXIN missense mutants destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.63e-01 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | 14 | 9.52e-02 | 2.58e-01 | 1.63e-01 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.63e-01 |
| truncated APC mutants destabilize the destruction complex | 14 | 9.52e-02 | 2.58e-01 | 1.63e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 53 | 1.21e-03 | 2.57e-01 | 4.71e-03 |
| Hedgehog ‘on’ state | 76 | 1.08e-04 | 2.57e-01 | 6.23e-04 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 5.27e-02 | 2.57e-01 | 1.03e-01 |
| Defects in vitamin and cofactor metabolism | 21 | 4.23e-02 | -2.56e-01 | 8.50e-02 |
| Regulation of lipid metabolism by PPARalpha | 106 | 5.54e-06 | 2.55e-01 | 5.04e-05 |
| IRAK2 mediated activation of TAK1 complex | 10 | 1.62e-01 | 2.55e-01 | 2.49e-01 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 1.11e-01 | 2.55e-01 | 1.83e-01 |
| tRNA processing | 136 | 2.88e-07 | -2.55e-01 | 4.58e-06 |
| Metabolism of non-coding RNA | 53 | 1.35e-03 | -2.54e-01 | 5.18e-03 |
| snRNP Assembly | 53 | 1.35e-03 | -2.54e-01 | 5.18e-03 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 73 | 1.73e-04 | 2.54e-01 | 9.11e-04 |
| Processive synthesis on the C-strand of the telomere | 19 | 5.52e-02 | -2.54e-01 | 1.05e-01 |
| Regulation of insulin secretion | 60 | 6.70e-04 | 2.54e-01 | 2.93e-03 |
| Glycosphingolipid metabolism | 36 | 8.40e-03 | 2.54e-01 | 2.31e-02 |
| Semaphorin interactions | 57 | 9.23e-04 | 2.54e-01 | 3.79e-03 |
| G-protein mediated events | 44 | 3.65e-03 | 2.53e-01 | 1.18e-02 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 1.01e-01 | -2.53e-01 | 1.69e-01 |
| Intraflagellar transport | 39 | 6.22e-03 | -2.53e-01 | 1.82e-02 |
| Base-Excision Repair, AP Site Formation | 31 | 1.50e-02 | 2.52e-01 | 3.63e-02 |
| Complex I biogenesis | 55 | 1.21e-03 | 2.52e-01 | 4.72e-03 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 36 | 8.91e-03 | 2.52e-01 | 2.42e-02 |
| Degradation of beta-catenin by the destruction complex | 84 | 6.67e-05 | 2.52e-01 | 4.12e-04 |
| Transcriptional regulation of white adipocyte differentiation | 77 | 1.36e-04 | 2.51e-01 | 7.37e-04 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 25 | 3.08e-02 | -2.50e-01 | 6.55e-02 |
| NGF-stimulated transcription | 31 | 1.64e-02 | 2.49e-01 | 3.91e-02 |
| PI3K events in ERBB2 signaling | 11 | 1.53e-01 | 2.49e-01 | 2.37e-01 |
| p75NTR recruits signalling complexes | 12 | 1.36e-01 | 2.49e-01 | 2.15e-01 |
| FGFR1 mutant receptor activation | 23 | 3.91e-02 | 2.48e-01 | 7.96e-02 |
| TICAM1, RIP1-mediated IKK complex recruitment | 19 | 6.09e-02 | 2.48e-01 | 1.14e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 5.36e-03 | -2.48e-01 | 1.61e-02 |
| Signaling by ERBB4 | 44 | 4.37e-03 | 2.48e-01 | 1.37e-02 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 2.59e-02 | -2.48e-01 | 5.70e-02 |
| Nucleobase catabolism | 28 | 2.33e-02 | 2.48e-01 | 5.21e-02 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 1.55e-01 | 2.48e-01 | 2.40e-01 |
| Ca-dependent events | 29 | 2.11e-02 | 2.47e-01 | 4.79e-02 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 16 | 8.67e-02 | 2.47e-01 | 1.51e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 1.56e-03 | 2.47e-01 | 5.89e-03 |
| Asymmetric localization of PCP proteins | 61 | 8.66e-04 | 2.47e-01 | 3.63e-03 |
| CDT1 association with the CDC6:ORC:origin complex | 58 | 1.18e-03 | 2.46e-01 | 4.64e-03 |
| SCF(Skp2)-mediated degradation of p27/p21 | 60 | 9.73e-04 | 2.46e-01 | 3.97e-03 |
| GRB2 events in ERBB2 signaling | 11 | 1.58e-01 | 2.46e-01 | 2.43e-01 |
| Signaling by SCF-KIT | 40 | 7.17e-03 | 2.46e-01 | 2.05e-02 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 1.08e-02 | -2.46e-01 | 2.76e-02 |
| HDMs demethylate histones | 22 | 4.64e-02 | 2.45e-01 | 9.20e-02 |
| Aggrephagy | 22 | 4.66e-02 | 2.45e-01 | 9.23e-02 |
| Pyruvate metabolism | 28 | 2.48e-02 | 2.45e-01 | 5.49e-02 |
| Hemostasis | 549 | 9.70e-23 | 2.45e-01 | 1.89e-20 |
| SARS-CoV-1 Infection | 47 | 3.74e-03 | 2.44e-01 | 1.20e-02 |
| RHO GTPase Effectors | 250 | 2.78e-11 | 2.44e-01 | 9.74e-10 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 32 | 1.70e-02 | 2.44e-01 | 4.04e-02 |
| Surfactant metabolism | 22 | 4.79e-02 | 2.44e-01 | 9.42e-02 |
| Nuclear signaling by ERBB4 | 24 | 3.90e-02 | 2.43e-01 | 7.94e-02 |
| Listeria monocytogenes entry into host cells | 17 | 8.25e-02 | 2.43e-01 | 1.46e-01 |
| Apoptotic execution phase | 45 | 4.77e-03 | 2.43e-01 | 1.47e-02 |
| Heme biosynthesis | 14 | 1.15e-01 | 2.43e-01 | 1.89e-01 |
| cGMP effects | 12 | 1.45e-01 | 2.43e-01 | 2.28e-01 |
| Gluconeogenesis | 28 | 2.62e-02 | 2.43e-01 | 5.75e-02 |
| ESR-mediated signaling | 161 | 1.07e-07 | 2.43e-01 | 1.83e-06 |
| Laminin interactions | 21 | 5.43e-02 | 2.43e-01 | 1.04e-01 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 4.84e-05 | -2.42e-01 | 3.18e-04 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 3.26e-02 | -2.42e-01 | 6.85e-02 |
| tRNA Aminoacylation | 42 | 6.78e-03 | -2.41e-01 | 1.95e-02 |
| Mismatch Repair | 15 | 1.06e-01 | -2.41e-01 | 1.77e-01 |
| Translesion synthesis by POLK | 17 | 8.56e-02 | -2.41e-01 | 1.50e-01 |
| Regulation of RAS by GAPs | 67 | 6.68e-04 | 2.40e-01 | 2.93e-03 |
| The citric acid (TCA) cycle and respiratory electron transport | 172 | 5.61e-08 | 2.40e-01 | 9.82e-07 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 40 | 8.86e-03 | 2.39e-01 | 2.41e-02 |
| Interleukin-15 signaling | 14 | 1.22e-01 | 2.38e-01 | 1.97e-01 |
| Sphingolipid metabolism | 78 | 2.72e-04 | 2.38e-01 | 1.35e-03 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 54 | 2.55e-03 | 2.37e-01 | 8.78e-03 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 54 | 2.55e-03 | 2.37e-01 | 8.78e-03 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 54 | 2.55e-03 | 2.37e-01 | 8.78e-03 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 54 | 2.55e-03 | 2.37e-01 | 8.78e-03 |
| Signaling by NOTCH1 in Cancer | 54 | 2.55e-03 | 2.37e-01 | 8.78e-03 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 18 | 8.14e-02 | 2.37e-01 | 1.45e-01 |
| Signaling by Hippo | 18 | 8.17e-02 | 2.37e-01 | 1.45e-01 |
| Activation of gene expression by SREBF (SREBP) | 42 | 7.92e-03 | 2.37e-01 | 2.22e-02 |
| Plasma lipoprotein assembly | 10 | 1.97e-01 | 2.36e-01 | 2.96e-01 |
| Extra-nuclear estrogen signaling | 66 | 9.28e-04 | 2.36e-01 | 3.79e-03 |
| Glycerophospholipid biosynthesis | 106 | 2.89e-05 | 2.35e-01 | 2.02e-04 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 72 | 5.71e-04 | 2.35e-01 | 2.57e-03 |
| CDK-mediated phosphorylation and removal of Cdc6 | 72 | 5.83e-04 | 2.34e-01 | 2.60e-03 |
| Acyl chain remodelling of PC | 19 | 7.71e-02 | 2.34e-01 | 1.38e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 80 | 2.96e-04 | 2.34e-01 | 1.46e-03 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 73 | 5.49e-04 | 2.34e-01 | 2.48e-03 |
| Keratinization | 33 | 2.01e-02 | 2.34e-01 | 4.62e-02 |
| Depolymerisation of the Nuclear Lamina | 15 | 1.19e-01 | 2.32e-01 | 1.93e-01 |
| mRNA decay by 3’ to 5’ exoribonuclease | 16 | 1.07e-01 | -2.32e-01 | 1.79e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 76 | 4.70e-04 | 2.32e-01 | 2.18e-03 |
| RIPK1-mediated regulated necrosis | 29 | 3.09e-02 | 2.32e-01 | 6.55e-02 |
| Regulated Necrosis | 29 | 3.09e-02 | 2.32e-01 | 6.55e-02 |
| Regulation of necroptotic cell death | 29 | 3.09e-02 | 2.32e-01 | 6.55e-02 |
| HDR through Homologous Recombination (HRR) | 66 | 1.15e-03 | -2.31e-01 | 4.56e-03 |
| COPI-dependent Golgi-to-ER retrograde traffic | 78 | 4.28e-04 | 2.31e-01 | 2.01e-03 |
| RA biosynthesis pathway | 13 | 1.50e-01 | -2.30e-01 | 2.33e-01 |
| Chaperonin-mediated protein folding | 84 | 2.68e-04 | 2.30e-01 | 1.34e-03 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 5.83e-04 | 2.30e-01 | 2.60e-03 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 28 | 3.58e-02 | 2.29e-01 | 7.37e-02 |
| Intra-Golgi traffic | 43 | 9.48e-03 | 2.29e-01 | 2.52e-02 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 9.62e-03 | -2.28e-01 | 2.55e-02 |
| Phase 0 - rapid depolarisation | 22 | 6.53e-02 | -2.27e-01 | 1.21e-01 |
| Oncogene Induced Senescence | 33 | 2.40e-02 | 2.27e-01 | 5.35e-02 |
| Beta-catenin independent WNT signaling | 137 | 4.52e-06 | 2.27e-01 | 4.17e-05 |
| Diseases of signal transduction by growth factor receptors and second messengers | 342 | 6.05e-13 | 2.26e-01 | 2.67e-11 |
| Selenoamino acid metabolism | 114 | 2.96e-05 | -2.26e-01 | 2.06e-04 |
| NOD1/2 Signaling Pathway | 32 | 2.68e-02 | 2.26e-01 | 5.86e-02 |
| Tryptophan catabolism | 12 | 1.75e-01 | 2.26e-01 | 2.66e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 1.44e-01 | 2.26e-01 | 2.26e-01 |
| UCH proteinases | 87 | 2.83e-04 | 2.25e-01 | 1.40e-03 |
| ABC-family proteins mediated transport | 94 | 1.66e-04 | 2.25e-01 | 8.84e-04 |
| p53-Dependent G1 DNA Damage Response | 64 | 1.89e-03 | 2.25e-01 | 6.83e-03 |
| p53-Dependent G1/S DNA damage checkpoint | 64 | 1.89e-03 | 2.25e-01 | 6.83e-03 |
| Sphingolipid de novo biosynthesis | 42 | 1.19e-02 | 2.24e-01 | 2.97e-02 |
| Plasma lipoprotein remodeling | 18 | 9.94e-02 | 2.24e-01 | 1.68e-01 |
| Signaling by NOTCH3 | 43 | 1.11e-02 | 2.24e-01 | 2.83e-02 |
| Costimulation by the CD28 family | 74 | 8.86e-04 | -2.23e-01 | 3.70e-03 |
| Degradation of the extracellular matrix | 78 | 6.48e-04 | 2.23e-01 | 2.86e-03 |
| Influenza Viral RNA Transcription and Replication | 135 | 7.53e-06 | -2.23e-01 | 6.43e-05 |
| TP53 Regulates Metabolic Genes | 85 | 3.76e-04 | 2.23e-01 | 1.80e-03 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 5.39e-02 | -2.23e-01 | 1.04e-01 |
| G1/S DNA Damage Checkpoints | 66 | 1.79e-03 | 2.22e-01 | 6.56e-03 |
| Estrogen-dependent gene expression | 99 | 1.33e-04 | 2.22e-01 | 7.22e-04 |
| EPH-ephrin mediated repulsion of cells | 40 | 1.52e-02 | 2.22e-01 | 3.67e-02 |
| Regulation of RUNX2 expression and activity | 67 | 1.71e-03 | 2.22e-01 | 6.33e-03 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 1.46e-04 | -2.20e-01 | 7.84e-04 |
| Selective autophagy | 58 | 3.80e-03 | 2.20e-01 | 1.22e-02 |
| Signaling by ERBB2 in Cancer | 21 | 8.27e-02 | 2.19e-01 | 1.46e-01 |
| Adenylate cyclase inhibitory pathway | 11 | 2.10e-01 | 2.19e-01 | 3.11e-01 |
| Downregulation of ERBB2 signaling | 24 | 6.39e-02 | 2.18e-01 | 1.18e-01 |
| NRIF signals cell death from the nucleus | 15 | 1.45e-01 | 2.18e-01 | 2.27e-01 |
| Chaperone Mediated Autophagy | 20 | 9.61e-02 | 2.15e-01 | 1.64e-01 |
| Removal of the Flap Intermediate from the C-strand | 17 | 1.25e-01 | -2.15e-01 | 2.01e-01 |
| Signaling by Nuclear Receptors | 217 | 5.11e-08 | 2.15e-01 | 9.42e-07 |
| Signaling by WNT | 254 | 4.05e-09 | 2.14e-01 | 9.22e-08 |
| PTEN Regulation | 139 | 1.30e-05 | 2.14e-01 | 1.01e-04 |
| Negative regulation of FGFR2 signaling | 23 | 7.66e-02 | 2.13e-01 | 1.38e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 46 | 1.26e-02 | 2.13e-01 | 3.13e-02 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 55 | 6.53e-03 | 2.12e-01 | 1.89e-02 |
| Interleukin-12 family signaling | 53 | 7.67e-03 | 2.12e-01 | 2.16e-02 |
| SUMOylation of SUMOylation proteins | 35 | 3.02e-02 | -2.12e-01 | 6.46e-02 |
| Interleukin-12 signaling | 44 | 1.54e-02 | 2.11e-01 | 3.72e-02 |
| Sialic acid metabolism | 28 | 5.34e-02 | 2.11e-01 | 1.03e-01 |
| Purine salvage | 12 | 2.06e-01 | 2.11e-01 | 3.08e-01 |
| Retinoid metabolism and transport | 24 | 7.37e-02 | 2.11e-01 | 1.34e-01 |
| Signaling by Rho GTPases | 367 | 4.57e-12 | 2.10e-01 | 1.84e-10 |
| TCF dependent signaling in response to WNT | 166 | 3.21e-06 | 2.09e-01 | 3.27e-05 |
| NOTCH3 Intracellular Domain Regulates Transcription | 21 | 9.74e-02 | 2.09e-01 | 1.65e-01 |
| Attenuation phase | 23 | 8.28e-02 | 2.09e-01 | 1.46e-01 |
| Integrin cell surface interactions | 52 | 9.18e-03 | 2.09e-01 | 2.47e-02 |
| Transcriptional Regulation by E2F6 | 34 | 3.52e-02 | -2.09e-01 | 7.27e-02 |
| Striated Muscle Contraction | 24 | 7.76e-02 | 2.08e-01 | 1.39e-01 |
| Metabolism of fat-soluble vitamins | 28 | 5.67e-02 | 2.08e-01 | 1.08e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 2.32e-01 | 2.08e-01 | 3.37e-01 |
| Inwardly rectifying K+ channels | 24 | 7.79e-02 | 2.08e-01 | 1.40e-01 |
| Protein folding | 90 | 6.57e-04 | 2.08e-01 | 2.90e-03 |
| MHC class II antigen presentation | 101 | 3.09e-04 | 2.08e-01 | 1.51e-03 |
| Interleukin-6 family signaling | 18 | 1.30e-01 | 2.06e-01 | 2.08e-01 |
| Termination of translesion DNA synthesis | 32 | 4.40e-02 | -2.06e-01 | 8.81e-02 |
| Formation of a pool of free 40S subunits | 100 | 3.77e-04 | -2.06e-01 | 1.80e-03 |
| Assembly of active LPL and LIPC lipase complexes | 10 | 2.60e-01 | 2.06e-01 | 3.68e-01 |
| RUNX3 regulates NOTCH signaling | 14 | 1.85e-01 | 2.05e-01 | 2.81e-01 |
| ABC transporters in lipid homeostasis | 14 | 1.86e-01 | -2.04e-01 | 2.81e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 7.71e-02 | 2.04e-01 | 1.38e-01 |
| p75 NTR receptor-mediated signalling | 89 | 9.07e-04 | 2.03e-01 | 3.76e-03 |
| Insulin processing | 21 | 1.09e-01 | 2.02e-01 | 1.81e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.19e-02 | 2.02e-01 | 2.97e-02 |
| Elastic fibre formation | 32 | 4.85e-02 | 2.01e-01 | 9.53e-02 |
| Transcriptional regulation by RUNX3 | 90 | 1.01e-03 | 2.01e-01 | 4.08e-03 |
| SUMOylation of intracellular receptors | 26 | 7.68e-02 | 2.00e-01 | 1.38e-01 |
| SARS-CoV Infections | 140 | 4.53e-05 | 2.00e-01 | 2.99e-04 |
| CaM pathway | 27 | 7.26e-02 | 2.00e-01 | 1.32e-01 |
| Calmodulin induced events | 27 | 7.26e-02 | 2.00e-01 | 1.32e-01 |
| Biosynthesis of DHA-derived SPMs | 14 | 1.97e-01 | 1.99e-01 | 2.97e-01 |
| Signaling by FGFR1 | 38 | 3.40e-02 | 1.99e-01 | 7.08e-02 |
| RNA Polymerase I Transcription Initiation | 44 | 2.27e-02 | -1.98e-01 | 5.12e-02 |
| RET signaling | 32 | 5.21e-02 | 1.98e-01 | 1.02e-01 |
| Immune System | 1893 | 3.24e-46 | 1.98e-01 | 1.48e-43 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 1.60e-01 | 1.97e-01 | 2.46e-01 |
| Regulation of TP53 Activity through Acetylation | 29 | 6.76e-02 | -1.96e-01 | 1.24e-01 |
| Cohesin Loading onto Chromatin | 10 | 2.84e-01 | 1.96e-01 | 3.93e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 12 | 2.42e-01 | -1.95e-01 | 3.47e-01 |
| Signaling by TGF-beta Receptor Complex | 72 | 4.29e-03 | 1.95e-01 | 1.35e-02 |
| BBSome-mediated cargo-targeting to cilium | 22 | 1.14e-01 | -1.94e-01 | 1.87e-01 |
| DAP12 interactions | 39 | 3.59e-02 | 1.94e-01 | 7.38e-02 |
| Signaling by FGFR1 in disease | 30 | 6.60e-02 | 1.94e-01 | 1.22e-01 |
| NR1H2 and NR1H3-mediated signaling | 39 | 3.61e-02 | 1.94e-01 | 7.41e-02 |
| Downregulation of TGF-beta receptor signaling | 26 | 8.73e-02 | 1.94e-01 | 1.52e-01 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 3.56e-04 | -1.94e-01 | 1.71e-03 |
| Nonsense-Mediated Decay (NMD) | 114 | 3.56e-04 | -1.94e-01 | 1.71e-03 |
| Diseases associated with O-glycosylation of proteins | 48 | 2.04e-02 | -1.93e-01 | 4.66e-02 |
| Negative regulation of MAPK pathway | 42 | 3.02e-02 | 1.93e-01 | 6.46e-02 |
| Regulation of APC/C activators between G1/S and early anaphase | 80 | 2.83e-03 | 1.93e-01 | 9.54e-03 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 1.26e-01 | 1.93e-01 | 2.02e-01 |
| Cellular Senescence | 144 | 6.80e-05 | 1.92e-01 | 4.19e-04 |
| Arachidonic acid metabolism | 43 | 2.93e-02 | 1.92e-01 | 6.31e-02 |
| PRC2 methylates histones and DNA | 29 | 7.36e-02 | 1.92e-01 | 1.33e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 14 | 2.14e-01 | -1.92e-01 | 3.17e-01 |
| Ion channel transport | 135 | 1.22e-04 | 1.92e-01 | 6.84e-04 |
| Metabolism of cofactors | 19 | 1.49e-01 | 1.91e-01 | 2.32e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 17 | 1.72e-01 | 1.91e-01 | 2.62e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 1.39e-01 | 1.91e-01 | 2.20e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 44 | 2.85e-02 | 1.91e-01 | 6.17e-02 |
| Metabolism of amine-derived hormones | 10 | 2.99e-01 | -1.90e-01 | 4.09e-01 |
| Transport of small molecules | 561 | 1.57e-14 | 1.90e-01 | 1.07e-12 |
| Activation of HOX genes during differentiation | 69 | 6.52e-03 | 1.89e-01 | 1.89e-02 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 69 | 6.52e-03 | 1.89e-01 | 1.89e-02 |
| Metabolism of steroids | 120 | 3.42e-04 | 1.89e-01 | 1.66e-03 |
| FRS-mediated FGFR3 signaling | 11 | 2.78e-01 | 1.89e-01 | 3.88e-01 |
| RNA Polymerase III Chain Elongation | 18 | 1.66e-01 | -1.89e-01 | 2.53e-01 |
| PINK1-PRKN Mediated Mitophagy | 21 | 1.35e-01 | 1.88e-01 | 2.15e-01 |
| Acyl chain remodelling of PE | 20 | 1.45e-01 | 1.88e-01 | 2.28e-01 |
| PKA-mediated phosphorylation of CREB | 17 | 1.80e-01 | 1.88e-01 | 2.74e-01 |
| Triglyceride metabolism | 25 | 1.05e-01 | 1.87e-01 | 1.75e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 33 | 6.33e-02 | 1.87e-01 | 1.18e-01 |
| PIP3 activates AKT signaling | 241 | 6.02e-07 | 1.87e-01 | 8.47e-06 |
| Phospholipid metabolism | 185 | 1.23e-05 | 1.86e-01 | 9.85e-05 |
| CD209 (DC-SIGN) signaling | 20 | 1.50e-01 | 1.86e-01 | 2.33e-01 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 5.36e-02 | -1.86e-01 | 1.03e-01 |
| Signaling by ERBB2 KD Mutants | 20 | 1.50e-01 | 1.86e-01 | 2.33e-01 |
| Phase 2 - plateau phase | 11 | 2.86e-01 | -1.86e-01 | 3.95e-01 |
| Cytosolic iron-sulfur cluster assembly | 13 | 2.46e-01 | -1.86e-01 | 3.53e-01 |
| Transcriptional regulation by RUNX2 | 103 | 1.14e-03 | 1.86e-01 | 4.52e-03 |
| Extracellular matrix organization | 219 | 2.25e-06 | 1.85e-01 | 2.48e-05 |
| Nitric oxide stimulates guanylate cyclase | 15 | 2.14e-01 | 1.85e-01 | 3.17e-01 |
| Mitophagy | 28 | 8.99e-02 | 1.85e-01 | 1.56e-01 |
| Regulation of IFNA signaling | 12 | 2.67e-01 | 1.85e-01 | 3.76e-01 |
| Antiviral mechanism by IFN-stimulated genes | 80 | 4.28e-03 | -1.85e-01 | 1.35e-02 |
| Collagen formation | 66 | 9.52e-03 | 1.85e-01 | 2.53e-02 |
| Regulation of localization of FOXO transcription factors | 12 | 2.71e-01 | 1.84e-01 | 3.80e-01 |
| Peroxisomal protein import | 57 | 1.71e-02 | 1.83e-01 | 4.04e-02 |
| Metabolism of lipids | 626 | 6.70e-15 | 1.82e-01 | 4.81e-13 |
| Activation of kainate receptors upon glutamate binding | 26 | 1.08e-01 | 1.82e-01 | 1.79e-01 |
| Assembly of the pre-replicative complex | 67 | 9.99e-03 | 1.82e-01 | 2.63e-02 |
| Stimuli-sensing channels | 74 | 6.87e-03 | 1.82e-01 | 1.97e-02 |
| Disorders of Developmental Biology | 12 | 2.76e-01 | 1.82e-01 | 3.86e-01 |
| Disorders of Nervous System Development | 12 | 2.76e-01 | 1.82e-01 | 3.86e-01 |
| Loss of function of MECP2 in Rett syndrome | 12 | 2.76e-01 | 1.82e-01 | 3.86e-01 |
| Pervasive developmental disorders | 12 | 2.76e-01 | 1.82e-01 | 3.86e-01 |
| Signaling by TGFB family members | 91 | 2.84e-03 | 1.81e-01 | 9.57e-03 |
| APC/C-mediated degradation of cell cycle proteins | 87 | 3.52e-03 | 1.81e-01 | 1.15e-02 |
| Regulation of mitotic cell cycle | 87 | 3.52e-03 | 1.81e-01 | 1.15e-02 |
| SUMOylation of RNA binding proteins | 47 | 3.20e-02 | -1.81e-01 | 6.74e-02 |
| Synthesis of PE | 12 | 2.79e-01 | -1.81e-01 | 3.88e-01 |
| Intracellular signaling by second messengers | 273 | 3.32e-07 | 1.79e-01 | 4.99e-06 |
| Influenza Infection | 154 | 1.22e-04 | -1.79e-01 | 6.84e-04 |
| Ub-specific processing proteases | 171 | 5.65e-05 | 1.78e-01 | 3.57e-04 |
| NCAM1 interactions | 23 | 1.39e-01 | -1.78e-01 | 2.19e-01 |
| Factors involved in megakaryocyte development and platelet production | 117 | 8.93e-04 | 1.78e-01 | 3.71e-03 |
| SUMOylation of ubiquitinylation proteins | 39 | 5.48e-02 | -1.78e-01 | 1.05e-01 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 3.17e-02 | 1.77e-01 | 6.69e-02 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 2.87e-01 | 1.77e-01 | 3.97e-01 |
| Glutathione conjugation | 26 | 1.18e-01 | 1.77e-01 | 1.92e-01 |
| Resolution of D-Loop Structures | 33 | 7.85e-02 | -1.77e-01 | 1.40e-01 |
| Acyl chain remodelling of PG | 11 | 3.12e-01 | 1.76e-01 | 4.23e-01 |
| Cyclin E associated events during G1/S transition | 83 | 5.53e-03 | 1.76e-01 | 1.65e-02 |
| Peptide hormone metabolism | 50 | 3.13e-02 | 1.76e-01 | 6.61e-02 |
| Cell junction organization | 60 | 1.85e-02 | 1.76e-01 | 4.28e-02 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 17 | 2.11e-01 | -1.75e-01 | 3.13e-01 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 1.56e-01 | 1.75e-01 | 2.41e-01 |
| Apoptotic cleavage of cellular proteins | 34 | 7.85e-02 | 1.74e-01 | 1.40e-01 |
| B-WICH complex positively regulates rRNA expression | 44 | 4.55e-02 | 1.74e-01 | 9.04e-02 |
| Circadian Clock | 67 | 1.37e-02 | 1.74e-01 | 3.37e-02 |
| Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 3.41e-01 | 1.74e-01 | 4.51e-01 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 8.89e-02 | -1.74e-01 | 1.54e-01 |
| Peroxisomal lipid metabolism | 27 | 1.19e-01 | 1.74e-01 | 1.92e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 80 | 7.44e-03 | 1.73e-01 | 2.10e-02 |
| Meiotic synapsis | 45 | 4.48e-02 | 1.73e-01 | 8.95e-02 |
| Deubiquitination | 242 | 3.70e-06 | 1.73e-01 | 3.59e-05 |
| Class I MHC mediated antigen processing & presentation | 350 | 2.99e-08 | 1.72e-01 | 5.84e-07 |
| Regulation of PTEN gene transcription | 59 | 2.23e-02 | 1.72e-01 | 5.03e-02 |
| Signaling by Hedgehog | 121 | 1.10e-03 | 1.72e-01 | 4.41e-03 |
| Unfolded Protein Response (UPR) | 87 | 5.84e-03 | 1.71e-01 | 1.72e-02 |
| RNA Polymerase III Transcription Initiation | 36 | 7.66e-02 | -1.71e-01 | 1.38e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 124 | 1.06e-03 | 1.70e-01 | 4.26e-03 |
| HS-GAG biosynthesis | 20 | 1.88e-01 | 1.70e-01 | 2.85e-01 |
| CD28 dependent Vav1 pathway | 12 | 3.08e-01 | 1.70e-01 | 4.19e-01 |
| Signaling by PDGFR in disease | 19 | 2.02e-01 | 1.69e-01 | 3.03e-01 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 1.10e-01 | 1.69e-01 | 1.81e-01 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 1.10e-01 | 1.69e-01 | 1.81e-01 |
| HCMV Late Events | 69 | 1.53e-02 | 1.69e-01 | 3.70e-02 |
| Maturation of nucleoprotein | 10 | 3.55e-01 | -1.69e-01 | 4.64e-01 |
| MAPK1/MAPK3 signaling | 236 | 8.18e-06 | 1.69e-01 | 6.90e-05 |
| Signaling by ERBB2 | 44 | 5.38e-02 | 1.68e-01 | 1.04e-01 |
| G alpha (12/13) signalling events | 69 | 1.67e-02 | 1.67e-01 | 3.98e-02 |
| Mitochondrial biogenesis | 88 | 7.05e-03 | 1.66e-01 | 2.02e-02 |
| MAPK family signaling cascades | 270 | 2.63e-06 | 1.66e-01 | 2.72e-05 |
| VEGFR2 mediated cell proliferation | 18 | 2.23e-01 | 1.66e-01 | 3.26e-01 |
| Other semaphorin interactions | 16 | 2.52e-01 | 1.65e-01 | 3.59e-01 |
| Carboxyterminal post-translational modifications of tubulin | 27 | 1.37e-01 | 1.65e-01 | 2.18e-01 |
| Defects in cobalamin (B12) metabolism | 13 | 3.03e-01 | -1.65e-01 | 4.14e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 1.19e-01 | -1.65e-01 | 1.92e-01 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 2.27e-01 | 1.64e-01 | 3.32e-01 |
| Dual Incision in GG-NER | 41 | 6.86e-02 | -1.64e-01 | 1.26e-01 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 3.45e-01 | 1.64e-01 | 4.55e-01 |
| Glycosaminoglycan metabolism | 94 | 5.91e-03 | 1.64e-01 | 1.74e-02 |
| NoRC negatively regulates rRNA expression | 59 | 2.92e-02 | 1.64e-01 | 6.31e-02 |
| RNA Polymerase I Promoter Escape | 44 | 6.00e-02 | 1.64e-01 | 1.13e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 20 | 2.05e-01 | 1.64e-01 | 3.07e-01 |
| Trafficking of AMPA receptors | 20 | 2.05e-01 | 1.64e-01 | 3.07e-01 |
| Insulin receptor signalling cascade | 39 | 7.68e-02 | 1.64e-01 | 1.38e-01 |
| Incretin synthesis, secretion, and inactivation | 10 | 3.71e-01 | 1.63e-01 | 4.78e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 10 | 3.71e-01 | 1.63e-01 | 4.78e-01 |
| Metabolism of carbohydrates | 244 | 1.10e-05 | 1.63e-01 | 8.84e-05 |
| Rho GTPase cycle | 126 | 1.57e-03 | 1.63e-01 | 5.91e-03 |
| Downstream signal transduction | 27 | 1.42e-01 | 1.63e-01 | 2.24e-01 |
| Activation of RAC1 | 11 | 3.49e-01 | 1.63e-01 | 4.59e-01 |
| Intrinsic Pathway for Apoptosis | 53 | 4.03e-02 | 1.63e-01 | 8.14e-02 |
| Regulation of actin dynamics for phagocytic cup formation | 123 | 1.85e-03 | 1.62e-01 | 6.78e-03 |
| Dectin-2 family | 19 | 2.22e-01 | 1.62e-01 | 3.26e-01 |
| FLT3 Signaling | 245 | 1.28e-05 | 1.62e-01 | 1.00e-04 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 1.55e-01 | 1.61e-01 | 2.40e-01 |
| rRNA processing in the mitochondrion | 29 | 1.34e-01 | -1.61e-01 | 2.14e-01 |
| SUMOylation of DNA damage response and repair proteins | 77 | 1.48e-02 | -1.61e-01 | 3.62e-02 |
| Aflatoxin activation and detoxification | 14 | 2.99e-01 | 1.60e-01 | 4.09e-01 |
| Neddylation | 219 | 4.38e-05 | 1.60e-01 | 2.92e-04 |
| HIV elongation arrest and recovery | 32 | 1.18e-01 | 1.60e-01 | 1.92e-01 |
| Pausing and recovery of HIV elongation | 32 | 1.18e-01 | 1.60e-01 | 1.92e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 85 | 1.09e-02 | 1.60e-01 | 2.79e-02 |
| FRS-mediated FGFR4 signaling | 12 | 3.40e-01 | 1.59e-01 | 4.51e-01 |
| RAF/MAP kinase cascade | 231 | 3.18e-05 | 1.59e-01 | 2.20e-04 |
| Bile acid and bile salt metabolism | 28 | 1.49e-01 | 1.58e-01 | 2.32e-01 |
| Hedgehog ‘off’ state | 93 | 8.83e-03 | 1.57e-01 | 2.41e-02 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 1.92e-01 | 1.57e-01 | 2.90e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 17 | 2.65e-01 | -1.56e-01 | 3.75e-01 |
| Metabolic disorders of biological oxidation enzymes | 26 | 1.68e-01 | 1.56e-01 | 2.57e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 2.30e-02 | -1.55e-01 | 5.17e-02 |
| Downregulation of ERBB2:ERBB3 signaling | 12 | 3.53e-01 | 1.55e-01 | 4.62e-01 |
| Deadenylation of mRNA | 22 | 2.09e-01 | 1.55e-01 | 3.11e-01 |
| Interferon Signaling | 177 | 3.85e-04 | -1.55e-01 | 1.82e-03 |
| Signaling by ERBB2 ECD mutants | 15 | 3.03e-01 | 1.54e-01 | 4.13e-01 |
| Degradation of cysteine and homocysteine | 12 | 3.57e-01 | 1.54e-01 | 4.65e-01 |
| Potential therapeutics for SARS | 78 | 1.94e-02 | 1.53e-01 | 4.47e-02 |
| Post-translational protein modification | 1193 | 6.81e-19 | 1.52e-01 | 7.16e-17 |
| Fatty acid metabolism | 153 | 1.16e-03 | 1.52e-01 | 4.58e-03 |
| Signal Transduction | 1894 | 7.04e-28 | 1.52e-01 | 1.60e-25 |
| ISG15 antiviral mechanism | 72 | 2.60e-02 | -1.52e-01 | 5.73e-02 |
| Formation of RNA Pol II elongation complex | 57 | 4.80e-02 | 1.51e-01 | 9.42e-02 |
| RNA Polymerase II Transcription Elongation | 57 | 4.80e-02 | 1.51e-01 | 9.42e-02 |
| Fatty acyl-CoA biosynthesis | 35 | 1.21e-01 | 1.51e-01 | 1.95e-01 |
| Blood group systems biosynthesis | 17 | 2.81e-01 | 1.51e-01 | 3.90e-01 |
| TNFR2 non-canonical NF-kB pathway | 96 | 1.06e-02 | 1.51e-01 | 2.74e-02 |
| HCMV Infection | 96 | 1.07e-02 | 1.51e-01 | 2.75e-02 |
| Chemokine receptors bind chemokines | 39 | 1.03e-01 | -1.51e-01 | 1.73e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 4.10e-01 | -1.51e-01 | 5.20e-01 |
| Leishmania infection | 245 | 5.06e-05 | 1.50e-01 | 3.26e-04 |
| Disorders of transmembrane transporters | 148 | 1.67e-03 | 1.50e-01 | 6.23e-03 |
| Signaling by NTRK2 (TRKB) | 20 | 2.47e-01 | 1.50e-01 | 3.53e-01 |
| Transcriptional regulation by RUNX1 | 185 | 4.54e-04 | 1.49e-01 | 2.12e-03 |
| Early Phase of HIV Life Cycle | 14 | 3.34e-01 | -1.49e-01 | 4.46e-01 |
| Transmission across Chemical Synapses | 172 | 7.60e-04 | 1.49e-01 | 3.26e-03 |
| Repression of WNT target genes | 14 | 3.36e-01 | -1.48e-01 | 4.47e-01 |
| Transport of vitamins, nucleosides, and related molecules | 33 | 1.41e-01 | 1.48e-01 | 2.22e-01 |
| NOTCH2 intracellular domain regulates transcription | 11 | 3.95e-01 | 1.48e-01 | 5.07e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 17 | 2.93e-01 | -1.47e-01 | 4.03e-01 |
| Miscellaneous transport and binding events | 20 | 2.54e-01 | 1.47e-01 | 3.61e-01 |
| Death Receptor Signalling | 132 | 3.50e-03 | 1.47e-01 | 1.15e-02 |
| Cell death signalling via NRAGE, NRIF and NADE | 70 | 3.34e-02 | 1.47e-01 | 6.97e-02 |
| Transcriptional Regulation by MECP2 | 47 | 8.13e-02 | 1.47e-01 | 1.45e-01 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 147 | 2.11e-03 | 1.47e-01 | 7.48e-03 |
| MET activates PTK2 signaling | 15 | 3.25e-01 | 1.47e-01 | 4.38e-01 |
| Cell-Cell communication | 89 | 1.71e-02 | 1.46e-01 | 4.04e-02 |
| RAF-independent MAPK1/3 activation | 21 | 2.47e-01 | 1.46e-01 | 3.53e-01 |
| Cellular responses to external stimuli | 506 | 1.91e-08 | 1.46e-01 | 3.89e-07 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 8.23e-03 | -1.45e-01 | 2.28e-02 |
| tRNA processing in the mitochondrion | 32 | 1.55e-01 | -1.45e-01 | 2.40e-01 |
| Synthesis of bile acids and bile salts | 24 | 2.21e-01 | 1.44e-01 | 3.24e-01 |
| Interferon gamma signaling | 83 | 2.32e-02 | -1.44e-01 | 5.21e-02 |
| Adrenaline,noradrenaline inhibits insulin secretion | 24 | 2.22e-01 | 1.44e-01 | 3.26e-01 |
| SUMOylation of DNA replication proteins | 46 | 9.14e-02 | -1.44e-01 | 1.58e-01 |
| FRS-mediated FGFR1 signaling | 14 | 3.52e-01 | 1.44e-01 | 4.61e-01 |
| Vitamin B5 (pantothenate) metabolism | 17 | 3.05e-01 | 1.44e-01 | 4.15e-01 |
| Signaling by FGFR2 IIIa TM | 18 | 2.95e-01 | 1.43e-01 | 4.05e-01 |
| HS-GAG degradation | 16 | 3.25e-01 | 1.42e-01 | 4.38e-01 |
| Cellular responses to stress | 500 | 5.60e-08 | 1.42e-01 | 9.82e-07 |
| HIV Transcription Initiation | 45 | 9.99e-02 | 1.42e-01 | 1.68e-01 |
| RNA Polymerase II HIV Promoter Escape | 45 | 9.99e-02 | 1.42e-01 | 1.68e-01 |
| RNA Polymerase II Promoter Escape | 45 | 9.99e-02 | 1.42e-01 | 1.68e-01 |
| RNA Polymerase II Transcription Initiation | 45 | 9.99e-02 | 1.42e-01 | 1.68e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 9.99e-02 | 1.42e-01 | 1.68e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 9.99e-02 | 1.42e-01 | 1.68e-01 |
| Metabolism of folate and pterines | 16 | 3.26e-01 | 1.42e-01 | 4.39e-01 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 1.05e-02 | -1.41e-01 | 2.73e-02 |
| Signaling by Activin | 10 | 4.40e-01 | -1.41e-01 | 5.49e-01 |
| SUMOylation of chromatin organization proteins | 57 | 6.56e-02 | -1.41e-01 | 1.21e-01 |
| Collagen biosynthesis and modifying enzymes | 48 | 9.20e-02 | 1.41e-01 | 1.59e-01 |
| FCGR activation | 76 | 3.45e-02 | -1.40e-01 | 7.14e-02 |
| Negative regulation of the PI3K/AKT network | 87 | 2.39e-02 | 1.40e-01 | 5.34e-02 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 2.08e-01 | 1.40e-01 | 3.10e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 2.08e-01 | 1.40e-01 | 3.10e-01 |
| Polo-like kinase mediated events | 16 | 3.33e-01 | 1.40e-01 | 4.45e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 25 | 2.27e-01 | 1.40e-01 | 3.31e-01 |
| Muscle contraction | 136 | 4.93e-03 | 1.40e-01 | 1.50e-02 |
| Metabolism | 1772 | 1.65e-22 | 1.40e-01 | 2.81e-20 |
| Translation of structural proteins | 28 | 2.02e-01 | 1.39e-01 | 3.03e-01 |
| Assembly of collagen fibrils and other multimeric structures | 42 | 1.20e-01 | 1.39e-01 | 1.93e-01 |
| Signaling by PDGF | 44 | 1.12e-01 | 1.39e-01 | 1.83e-01 |
| FOXO-mediated transcription | 59 | 6.72e-02 | 1.38e-01 | 1.24e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 12 | 4.09e-01 | -1.38e-01 | 5.20e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 43 | 1.20e-01 | 1.37e-01 | 1.94e-01 |
| Folding of actin by CCT/TriC | 10 | 4.53e-01 | 1.37e-01 | 5.63e-01 |
| FCGR3A-mediated phagocytosis | 121 | 9.35e-03 | 1.37e-01 | 2.50e-02 |
| Leishmania phagocytosis | 121 | 9.35e-03 | 1.37e-01 | 2.50e-02 |
| Parasite infection | 121 | 9.35e-03 | 1.37e-01 | 2.50e-02 |
| Regulation of MECP2 expression and activity | 28 | 2.10e-01 | 1.37e-01 | 3.12e-01 |
| Signaling by FGFR in disease | 50 | 9.53e-02 | 1.36e-01 | 1.63e-01 |
| Synthesis of PIPs at the plasma membrane | 52 | 8.98e-02 | 1.36e-01 | 1.56e-01 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 4.57e-01 | 1.36e-01 | 5.66e-01 |
| Downstream signaling of activated FGFR3 | 16 | 3.48e-01 | 1.35e-01 | 4.59e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 3.56e-02 | -1.35e-01 | 7.34e-02 |
| Phase 4 - resting membrane potential | 10 | 4.63e-01 | 1.34e-01 | 5.72e-01 |
| Metal ion SLC transporters | 21 | 2.88e-01 | 1.34e-01 | 3.98e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 182 | 1.89e-03 | -1.34e-01 | 6.83e-03 |
| SUMOylation of transcription factors | 16 | 3.57e-01 | 1.33e-01 | 4.65e-01 |
| Developmental Biology | 732 | 1.07e-09 | 1.32e-01 | 2.75e-08 |
| SRP-dependent cotranslational protein targeting to membrane | 111 | 1.62e-02 | -1.32e-01 | 3.89e-02 |
| RNA Polymerase II Pre-transcription Events | 78 | 4.41e-02 | 1.32e-01 | 8.81e-02 |
| Zinc transporters | 14 | 3.93e-01 | 1.32e-01 | 5.05e-01 |
| Orc1 removal from chromatin | 70 | 5.76e-02 | 1.31e-01 | 1.10e-01 |
| Fc epsilon receptor (FCERI) signaling | 191 | 1.77e-03 | 1.31e-01 | 6.51e-03 |
| Classical antibody-mediated complement activation | 69 | 5.97e-02 | -1.31e-01 | 1.13e-01 |
| O-linked glycosylation of mucins | 47 | 1.21e-01 | 1.31e-01 | 1.95e-01 |
| CD22 mediated BCR regulation | 59 | 8.26e-02 | -1.31e-01 | 1.46e-01 |
| Metabolism of proteins | 1718 | 2.21e-19 | 1.31e-01 | 2.52e-17 |
| Protein methylation | 15 | 3.83e-01 | 1.30e-01 | 4.93e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 10 | 4.76e-01 | 1.30e-01 | 5.85e-01 |
| Cap-dependent Translation Initiation | 118 | 1.50e-02 | -1.30e-01 | 3.63e-02 |
| Eukaryotic Translation Initiation | 118 | 1.50e-02 | -1.30e-01 | 3.63e-02 |
| Synthesis of substrates in N-glycan biosythesis | 58 | 8.82e-02 | 1.29e-01 | 1.53e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 13 | 4.21e-01 | 1.29e-01 | 5.34e-01 |
| Long-term potentiation | 14 | 4.04e-01 | -1.29e-01 | 5.16e-01 |
| RAS processing | 19 | 3.32e-01 | 1.28e-01 | 4.45e-01 |
| HIV Infection | 225 | 9.21e-04 | 1.28e-01 | 3.79e-03 |
| Viral Messenger RNA Synthesis | 44 | 1.42e-01 | -1.28e-01 | 2.24e-01 |
| Cytosolic tRNA aminoacylation | 24 | 2.78e-01 | -1.28e-01 | 3.88e-01 |
| Disease | 1355 | 2.72e-15 | 1.28e-01 | 2.18e-13 |
| Amino acid transport across the plasma membrane | 24 | 2.81e-01 | 1.27e-01 | 3.90e-01 |
| Transcriptional regulation of pluripotent stem cells | 20 | 3.26e-01 | 1.27e-01 | 4.39e-01 |
| Formation of the Early Elongation Complex | 33 | 2.09e-01 | 1.26e-01 | 3.11e-01 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 2.09e-01 | 1.26e-01 | 3.11e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 2.48e-01 | -1.26e-01 | 3.54e-01 |
| Translesion Synthesis by POLH | 18 | 3.56e-01 | -1.26e-01 | 4.64e-01 |
| Cytosolic sulfonation of small molecules | 18 | 3.58e-01 | 1.25e-01 | 4.65e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 2.80e-01 | 1.25e-01 | 3.89e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 20 | 3.35e-01 | 1.25e-01 | 4.47e-01 |
| Telomere Extension By Telomerase | 23 | 3.01e-01 | -1.24e-01 | 4.12e-01 |
| Negative epigenetic regulation of rRNA expression | 62 | 9.09e-02 | 1.24e-01 | 1.57e-01 |
| Ephrin signaling | 18 | 3.62e-01 | 1.24e-01 | 4.70e-01 |
| RUNX3 regulates p14-ARF | 10 | 4.97e-01 | 1.24e-01 | 6.04e-01 |
| HSF1-dependent transactivation | 29 | 2.49e-01 | 1.24e-01 | 3.54e-01 |
| Regulation of beta-cell development | 19 | 3.52e-01 | 1.23e-01 | 4.61e-01 |
| Cell surface interactions at the vascular wall | 174 | 5.36e-03 | 1.22e-01 | 1.61e-02 |
| Meiotic recombination | 38 | 1.94e-01 | 1.22e-01 | 2.92e-01 |
| Class I peroxisomal membrane protein import | 20 | 3.49e-01 | -1.21e-01 | 4.59e-01 |
| Infectious disease | 777 | 1.03e-08 | 1.21e-01 | 2.18e-07 |
| E2F mediated regulation of DNA replication | 22 | 3.32e-01 | -1.20e-01 | 4.45e-01 |
| Potassium Channels | 64 | 9.86e-02 | 1.19e-01 | 1.67e-01 |
| Axon guidance | 457 | 1.28e-05 | 1.19e-01 | 1.00e-04 |
| Creation of C4 and C2 activators | 71 | 8.33e-02 | -1.19e-01 | 1.47e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 3.70e-01 | -1.19e-01 | 4.78e-01 |
| DAG and IP3 signaling | 33 | 2.39e-01 | 1.18e-01 | 3.44e-01 |
| SHC-mediated cascade:FGFR4 | 10 | 5.17e-01 | 1.18e-01 | 6.25e-01 |
| Mitotic Prophase | 98 | 4.33e-02 | 1.18e-01 | 8.69e-02 |
| Protein localization | 157 | 1.07e-02 | 1.18e-01 | 2.75e-02 |
| Platelet calcium homeostasis | 22 | 3.38e-01 | 1.18e-01 | 4.50e-01 |
| RNA Polymerase I Transcription Termination | 27 | 2.90e-01 | -1.18e-01 | 4.00e-01 |
| Downstream signaling of activated FGFR4 | 17 | 4.02e-01 | 1.17e-01 | 5.14e-01 |
| Keratan sulfate/keratin metabolism | 27 | 2.91e-01 | 1.17e-01 | 4.01e-01 |
| Signaling by NOTCH2 | 30 | 2.68e-01 | 1.17e-01 | 3.76e-01 |
| Neuronal System | 259 | 1.19e-03 | 1.17e-01 | 4.67e-03 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 37 | 2.18e-01 | 1.17e-01 | 3.22e-01 |
| ECM proteoglycans | 35 | 2.32e-01 | 1.17e-01 | 3.37e-01 |
| Nuclear Envelope (NE) Reassembly | 69 | 9.41e-02 | 1.17e-01 | 1.62e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 5.27e-01 | 1.16e-01 | 6.35e-01 |
| Mitotic Anaphase | 224 | 3.35e-03 | 1.14e-01 | 1.11e-02 |
| MECP2 regulates neuronal receptors and channels | 13 | 4.78e-01 | 1.14e-01 | 5.87e-01 |
| VEGFR2 mediated vascular permeability | 27 | 3.08e-01 | 1.13e-01 | 4.19e-01 |
| Nervous system development | 476 | 2.40e-05 | 1.13e-01 | 1.75e-04 |
| Antigen processing: Ubiquitination & Proteasome degradation | 289 | 1.01e-03 | 1.12e-01 | 4.10e-03 |
| Non-integrin membrane-ECM interactions | 37 | 2.38e-01 | 1.12e-01 | 3.43e-01 |
| Initial triggering of complement | 78 | 8.68e-02 | -1.12e-01 | 1.51e-01 |
| Molecules associated with elastic fibres | 22 | 3.63e-01 | 1.12e-01 | 4.71e-01 |
| RNA polymerase II transcribes snRNA genes | 72 | 1.01e-01 | 1.12e-01 | 1.69e-01 |
| Formation of TC-NER Pre-Incision Complex | 53 | 1.61e-01 | 1.11e-01 | 2.47e-01 |
| PI Metabolism | 80 | 8.53e-02 | 1.11e-01 | 1.50e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 4.56e-01 | 1.11e-01 | 5.66e-01 |
| Interleukin-20 family signaling | 17 | 4.30e-01 | 1.11e-01 | 5.41e-01 |
| Ca2+ pathway | 57 | 1.50e-01 | 1.10e-01 | 2.33e-01 |
| Phase I - Functionalization of compounds | 65 | 1.24e-01 | 1.10e-01 | 1.99e-01 |
| Metabolism of nucleotides | 86 | 7.90e-02 | 1.10e-01 | 1.41e-01 |
| Mitotic Metaphase and Anaphase | 225 | 4.82e-03 | 1.09e-01 | 1.48e-02 |
| Adherens junctions interactions | 19 | 4.11e-01 | 1.09e-01 | 5.22e-01 |
| Glucose metabolism | 84 | 8.62e-02 | 1.08e-01 | 1.51e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 15 | 4.70e-01 | -1.08e-01 | 5.79e-01 |
| Assembly and cell surface presentation of NMDA receptors | 18 | 4.29e-01 | -1.08e-01 | 5.41e-01 |
| SHC-mediated cascade:FGFR1 | 12 | 5.19e-01 | 1.07e-01 | 6.27e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 2.54e-01 | -1.07e-01 | 3.61e-01 |
| Cytokine Signaling in Immune system | 736 | 8.01e-07 | 1.07e-01 | 1.03e-05 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 2.32e-01 | 1.07e-01 | 3.37e-01 |
| HIV Transcription Elongation | 42 | 2.32e-01 | 1.07e-01 | 3.37e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 2.32e-01 | 1.07e-01 | 3.37e-01 |
| Chromosome Maintenance | 105 | 5.92e-02 | -1.07e-01 | 1.12e-01 |
| Glycolysis | 67 | 1.32e-01 | 1.06e-01 | 2.10e-01 |
| Phase II - Conjugation of compounds | 67 | 1.34e-01 | 1.06e-01 | 2.13e-01 |
| Role of phospholipids in phagocytosis | 88 | 8.64e-02 | -1.06e-01 | 1.51e-01 |
| G alpha (i) signalling events | 245 | 4.53e-03 | 1.05e-01 | 1.41e-02 |
| The phototransduction cascade | 26 | 3.54e-01 | -1.05e-01 | 4.63e-01 |
| PI-3K cascade:FGFR4 | 10 | 5.65e-01 | 1.05e-01 | 6.67e-01 |
| Activation of NMDA receptors and postsynaptic events | 58 | 1.69e-01 | 1.04e-01 | 2.58e-01 |
| Cellular hexose transport | 15 | 4.86e-01 | -1.04e-01 | 5.94e-01 |
| FCERI mediated NF-kB activation | 138 | 3.53e-02 | 1.04e-01 | 7.29e-02 |
| Signaling by FGFR2 | 60 | 1.65e-01 | 1.04e-01 | 2.53e-01 |
| PI3K/AKT Signaling in Cancer | 81 | 1.08e-01 | 1.03e-01 | 1.79e-01 |
| RUNX2 regulates osteoblast differentiation | 19 | 4.36e-01 | -1.03e-01 | 5.45e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 2.38e-01 | 1.03e-01 | 3.43e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 11 | 5.55e-01 | -1.03e-01 | 6.60e-01 |
| Generic Transcription Pathway | 1085 | 1.09e-08 | -1.03e-01 | 2.25e-07 |
| Mitochondrial calcium ion transport | 22 | 4.05e-01 | 1.03e-01 | 5.16e-01 |
| Regulation of TP53 Activity | 152 | 2.96e-02 | -1.02e-01 | 6.37e-02 |
| SLC-mediated transmembrane transport | 180 | 1.84e-02 | 1.02e-01 | 4.27e-02 |
| Gene expression (Transcription) | 1332 | 5.27e-10 | -1.01e-01 | 1.39e-08 |
| DNA Double-Strand Break Repair | 135 | 4.22e-02 | -1.01e-01 | 8.50e-02 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 5.47e-01 | 1.01e-01 | 6.53e-01 |
| Interleukin receptor SHC signaling | 23 | 4.04e-01 | 1.00e-01 | 5.16e-01 |
| Transcriptional activation of mitochondrial biogenesis | 51 | 2.20e-01 | 9.92e-02 | 3.24e-01 |
| Post NMDA receptor activation events | 48 | 2.36e-01 | 9.88e-02 | 3.41e-01 |
| Interconversion of nucleotide di- and triphosphates | 27 | 3.75e-01 | 9.87e-02 | 4.83e-01 |
| Cilium Assembly | 180 | 2.26e-02 | -9.85e-02 | 5.10e-02 |
| Switching of origins to a post-replicative state | 90 | 1.07e-01 | 9.84e-02 | 1.78e-01 |
| Condensation of Prometaphase Chromosomes | 11 | 5.73e-01 | 9.81e-02 | 6.76e-01 |
| Biological oxidations | 137 | 4.75e-02 | 9.81e-02 | 9.39e-02 |
| Regulation of KIT signaling | 15 | 5.12e-01 | 9.79e-02 | 6.20e-01 |
| Glutamate and glutamine metabolism | 12 | 5.61e-01 | -9.69e-02 | 6.65e-01 |
| Nicotinamide salvaging | 14 | 5.31e-01 | -9.67e-02 | 6.38e-01 |
| PI-3K cascade:FGFR1 | 12 | 5.63e-01 | 9.63e-02 | 6.66e-01 |
| Endosomal/Vacuolar pathway | 12 | 5.63e-01 | -9.63e-02 | 6.66e-01 |
| Downstream signaling of activated FGFR1 | 20 | 4.62e-01 | 9.49e-02 | 5.72e-01 |
| IGF1R signaling cascade | 36 | 3.24e-01 | 9.49e-02 | 4.38e-01 |
| N-Glycan antennae elongation | 13 | 5.54e-01 | -9.48e-02 | 6.60e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 73 | 1.62e-01 | 9.47e-02 | 2.49e-01 |
| Cytochrome P450 - arranged by substrate type | 36 | 3.28e-01 | 9.43e-02 | 4.40e-01 |
| Diseases associated with glycosaminoglycan metabolism | 26 | 4.08e-01 | 9.38e-02 | 5.19e-01 |
| Separation of Sister Chromatids | 168 | 3.62e-02 | 9.36e-02 | 7.41e-02 |
| Interleukin-2 family signaling | 38 | 3.19e-01 | 9.35e-02 | 4.31e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 46 | 2.74e-01 | 9.31e-02 | 3.85e-01 |
| Positive epigenetic regulation of rRNA expression | 59 | 2.16e-01 | 9.31e-02 | 3.19e-01 |
| Cholesterol biosynthesis | 24 | 4.30e-01 | 9.30e-02 | 5.41e-01 |
| HSF1 activation | 26 | 4.12e-01 | 9.30e-02 | 5.23e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 23 | 4.43e-01 | 9.25e-02 | 5.52e-01 |
| G alpha (q) signalling events | 134 | 6.48e-02 | 9.24e-02 | 1.20e-01 |
| Signaling by FGFR | 69 | 1.85e-01 | 9.23e-02 | 2.81e-01 |
| Regulation of TP53 Activity through Phosphorylation | 88 | 1.35e-01 | -9.21e-02 | 2.15e-01 |
| Nuclear Envelope Breakdown | 53 | 2.46e-01 | -9.20e-02 | 3.53e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 22 | 4.56e-01 | 9.17e-02 | 5.66e-01 |
| mRNA Capping | 29 | 3.97e-01 | 9.08e-02 | 5.09e-01 |
| DNA Damage Bypass | 47 | 2.82e-01 | -9.07e-02 | 3.91e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 41 | 3.15e-01 | -9.06e-02 | 4.27e-01 |
| RNA Polymerase III Transcription | 41 | 3.15e-01 | -9.06e-02 | 4.27e-01 |
| Acyl chain remodelling of PS | 14 | 5.59e-01 | 9.02e-02 | 6.63e-01 |
| Mitotic G2-G2/M phases | 182 | 3.62e-02 | 9.00e-02 | 7.41e-02 |
| STING mediated induction of host immune responses | 15 | 5.48e-01 | 8.96e-02 | 6.53e-01 |
| Homology Directed Repair | 110 | 1.07e-01 | -8.89e-02 | 1.79e-01 |
| M Phase | 360 | 3.81e-03 | 8.88e-02 | 1.22e-02 |
| Lysine catabolism | 11 | 6.10e-01 | 8.87e-02 | 7.09e-01 |
| Metabolism of RNA | 688 | 7.82e-05 | -8.83e-02 | 4.70e-04 |
| Purine catabolism | 16 | 5.42e-01 | 8.80e-02 | 6.48e-01 |
| RNA Polymerase II Transcription | 1204 | 4.09e-07 | -8.67e-02 | 5.95e-06 |
| NCAM signaling for neurite out-growth | 43 | 3.26e-01 | -8.66e-02 | 4.39e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 3.69e-01 | 8.65e-02 | 4.78e-01 |
| Nonhomologous End-Joining (NHEJ) | 42 | 3.36e-01 | 8.58e-02 | 4.47e-01 |
| Inositol phosphate metabolism | 42 | 3.38e-01 | 8.54e-02 | 4.50e-01 |
| Signaling by the B Cell Receptor (BCR) | 163 | 6.05e-02 | 8.52e-02 | 1.13e-01 |
| Peptide ligand-binding receptors | 97 | 1.47e-01 | 8.52e-02 | 2.30e-01 |
| Transcription of the HIV genome | 67 | 2.28e-01 | 8.51e-02 | 3.33e-01 |
| Activation of BH3-only proteins | 30 | 4.22e-01 | 8.48e-02 | 5.34e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 4.76e-01 | 8.40e-02 | 5.85e-01 |
| Processing of Intronless Pre-mRNAs | 19 | 5.28e-01 | -8.37e-02 | 6.35e-01 |
| Nephrin family interactions | 18 | 5.40e-01 | -8.33e-02 | 6.46e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 4.90e-01 | 8.31e-02 | 5.96e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 6.04e-01 | 8.31e-02 | 7.03e-01 |
| Signaling by WNT in cancer | 30 | 4.31e-01 | 8.30e-02 | 5.41e-01 |
| Prolactin receptor signaling | 11 | 6.33e-01 | 8.30e-02 | 7.28e-01 |
| IRS-related events triggered by IGF1R | 35 | 3.95e-01 | 8.30e-02 | 5.07e-01 |
| G2/M Transition | 180 | 5.50e-02 | 8.29e-02 | 1.05e-01 |
| Fertilization | 12 | 6.19e-01 | 8.29e-02 | 7.15e-01 |
| G1/S-Specific Transcription | 29 | 4.40e-01 | -8.28e-02 | 5.49e-01 |
| Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 10 | 6.50e-01 | -8.28e-02 | 7.45e-01 |
| NRAGE signals death through JNK | 53 | 3.03e-01 | 8.19e-02 | 4.13e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 5.60e-01 | -8.16e-02 | 6.64e-01 |
| DNA Repair | 289 | 1.71e-02 | -8.15e-02 | 4.04e-02 |
| Elevation of cytosolic Ca2+ levels | 13 | 6.11e-01 | 8.15e-02 | 7.09e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex | 51 | 3.16e-01 | -8.11e-02 | 4.28e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 6.43e-01 | -8.08e-02 | 7.38e-01 |
| Host Interactions of HIV factors | 130 | 1.12e-01 | 8.07e-02 | 1.83e-01 |
| TNFs bind their physiological receptors | 25 | 4.86e-01 | -8.06e-02 | 5.94e-01 |
| DNA Double Strand Break Response | 47 | 3.40e-01 | 8.05e-02 | 4.50e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 38 | 3.91e-01 | 8.04e-02 | 5.03e-01 |
| Regulation of HSF1-mediated heat shock response | 79 | 2.22e-01 | -7.94e-02 | 3.26e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 5.71e-01 | -7.93e-02 | 6.74e-01 |
| PKMTs methylate histone lysines | 45 | 3.58e-01 | -7.92e-02 | 4.65e-01 |
| Olfactory Signaling Pathway | 60 | 2.89e-01 | 7.91e-02 | 3.99e-01 |
| GPCR downstream signalling | 500 | 2.69e-03 | 7.84e-02 | 9.22e-03 |
| Interleukin-7 signaling | 21 | 5.38e-01 | 7.76e-02 | 6.44e-01 |
| Signaling by GPCR | 545 | 2.12e-03 | 7.69e-02 | 7.51e-03 |
| Sema3A PAK dependent Axon repulsion | 16 | 5.96e-01 | 7.66e-02 | 6.95e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 73 | 2.62e-01 | 7.60e-02 | 3.71e-01 |
| Recruitment of NuMA to mitotic centrosomes | 79 | 2.44e-01 | -7.58e-02 | 3.50e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 17 | 5.89e-01 | -7.56e-02 | 6.91e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 25 | 5.13e-01 | 7.56e-02 | 6.21e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 12 | 6.52e-01 | 7.51e-02 | 7.47e-01 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 6.66e-01 | -7.51e-02 | 7.56e-01 |
| Transcriptional regulation by small RNAs | 63 | 3.04e-01 | 7.49e-02 | 4.14e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 6.55e-01 | 7.46e-02 | 7.49e-01 |
| FCERI mediated Ca+2 mobilization | 89 | 2.26e-01 | -7.42e-02 | 3.31e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 25 | 5.22e-01 | -7.40e-02 | 6.29e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 37 | 4.36e-01 | 7.39e-02 | 5.45e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 5.78e-01 | -7.36e-02 | 6.81e-01 |
| Signaling by NTRK3 (TRKC) | 16 | 6.13e-01 | 7.29e-02 | 7.10e-01 |
| Neurotransmitter release cycle | 39 | 4.31e-01 | 7.29e-02 | 5.41e-01 |
| Cell-cell junction organization | 39 | 4.31e-01 | 7.29e-02 | 5.41e-01 |
| TCR signaling | 122 | 1.65e-01 | 7.28e-02 | 2.52e-01 |
| TRP channels | 19 | 5.83e-01 | -7.28e-02 | 6.85e-01 |
| Regulation of RUNX1 Expression and Activity | 18 | 5.97e-01 | -7.20e-02 | 6.96e-01 |
| Adaptive Immune System | 757 | 7.74e-04 | 7.18e-02 | 3.30e-03 |
| Centrosome maturation | 80 | 2.68e-01 | -7.17e-02 | 3.76e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 80 | 2.68e-01 | -7.17e-02 | 3.76e-01 |
| Ovarian tumor domain proteases | 37 | 4.53e-01 | 7.13e-02 | 5.63e-01 |
| Downstream TCR signaling | 101 | 2.16e-01 | 7.12e-02 | 3.19e-01 |
| MicroRNA (miRNA) biogenesis | 24 | 5.54e-01 | 6.97e-02 | 6.60e-01 |
| FCGR3A-mediated IL10 synthesis | 99 | 2.34e-01 | -6.92e-02 | 3.39e-01 |
| RNA Polymerase I Promoter Clearance | 63 | 3.43e-01 | 6.91e-02 | 4.52e-01 |
| RNA Polymerase I Transcription | 63 | 3.43e-01 | 6.91e-02 | 4.52e-01 |
| Anchoring of the basal body to the plasma membrane | 96 | 2.48e-01 | -6.82e-02 | 3.54e-01 |
| Cellular response to heat stress | 93 | 2.59e-01 | -6.78e-02 | 3.67e-01 |
| Establishment of Sister Chromatid Cohesion | 11 | 6.97e-01 | 6.78e-02 | 7.86e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 63 | 3.59e-01 | 6.68e-02 | 4.66e-01 |
| G alpha (s) signalling events | 143 | 1.69e-01 | 6.66e-02 | 2.58e-01 |
| Cyclin D associated events in G1 | 47 | 4.33e-01 | 6.61e-02 | 5.43e-01 |
| G1 Phase | 47 | 4.33e-01 | 6.61e-02 | 5.43e-01 |
| Signaling by FGFR4 in disease | 11 | 7.05e-01 | 6.59e-02 | 7.93e-01 |
| TRAF6 mediated IRF7 activation | 15 | 6.59e-01 | 6.59e-02 | 7.52e-01 |
| IRS-mediated signalling | 34 | 5.09e-01 | 6.55e-02 | 6.16e-01 |
| Scavenging of heme from plasma | 71 | 3.41e-01 | -6.53e-02 | 4.51e-01 |
| Pregnenolone biosynthesis | 10 | 7.23e-01 | 6.47e-02 | 8.06e-01 |
| SUMOylation of transcription cofactors | 44 | 4.59e-01 | 6.45e-02 | 5.68e-01 |
| WNT ligand biogenesis and trafficking | 21 | 6.10e-01 | 6.42e-02 | 7.09e-01 |
| FGFR2 alternative splicing | 25 | 5.82e-01 | 6.37e-02 | 6.84e-01 |
| Interleukin-37 signaling | 19 | 6.31e-01 | 6.36e-02 | 7.26e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 104 | 2.63e-01 | -6.36e-02 | 3.71e-01 |
| Xenobiotics | 12 | 7.03e-01 | -6.35e-02 | 7.91e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 43 | 4.72e-01 | 6.34e-02 | 5.81e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 11 | 7.16e-01 | -6.33e-02 | 8.01e-01 |
| Base Excision Repair | 58 | 4.05e-01 | -6.32e-02 | 5.16e-01 |
| Basigin interactions | 23 | 6.01e-01 | 6.31e-02 | 7.00e-01 |
| Late Phase of HIV Life Cycle | 131 | 2.13e-01 | 6.30e-02 | 3.16e-01 |
| Processing and activation of SUMO | 10 | 7.35e-01 | 6.17e-02 | 8.15e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 7.13e-01 | -6.13e-02 | 7.99e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 57 | 4.25e-01 | 6.11e-02 | 5.37e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 54 | 4.44e-01 | 6.02e-02 | 5.53e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 48 | 4.74e-01 | 5.97e-02 | 5.83e-01 |
| Regulation of TNFR1 signaling | 34 | 5.47e-01 | -5.97e-02 | 6.53e-01 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 5.92e-01 | 5.96e-02 | 6.93e-01 |
| Receptor-type tyrosine-protein phosphatases | 12 | 7.24e-01 | 5.89e-02 | 8.06e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 84 | 3.51e-01 | -5.89e-02 | 4.61e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 18 | 6.67e-01 | 5.87e-02 | 7.56e-01 |
| Transcriptional Regulation by VENTX | 38 | 5.38e-01 | -5.77e-02 | 6.44e-01 |
| Diseases associated with N-glycosylation of proteins | 17 | 6.85e-01 | 5.69e-02 | 7.75e-01 |
| PI3K Cascade | 30 | 5.90e-01 | 5.69e-02 | 6.91e-01 |
| Regulation of PTEN mRNA translation | 13 | 7.23e-01 | -5.67e-02 | 8.06e-01 |
| PERK regulates gene expression | 31 | 5.86e-01 | 5.66e-02 | 6.87e-01 |
| Branched-chain amino acid catabolism | 21 | 6.58e-01 | -5.57e-02 | 7.52e-01 |
| G2/M Checkpoints | 140 | 2.68e-01 | 5.42e-02 | 3.77e-01 |
| Translation | 295 | 1.10e-01 | -5.41e-02 | 1.81e-01 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 80 | 4.08e-01 | 5.35e-02 | 5.19e-01 |
| Other interleukin signaling | 18 | 6.95e-01 | 5.34e-02 | 7.84e-01 |
| PI-3K cascade:FGFR2 | 12 | 7.50e-01 | -5.32e-02 | 8.26e-01 |
| SUMOylation | 166 | 2.45e-01 | -5.23e-02 | 3.52e-01 |
| Synthesis of PIPs at the Golgi membrane | 16 | 7.21e-01 | 5.16e-02 | 8.05e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 34 | 6.03e-01 | 5.15e-02 | 7.02e-01 |
| Processing of SMDT1 | 15 | 7.30e-01 | 5.14e-02 | 8.12e-01 |
| Eicosanoid ligand-binding receptors | 13 | 7.48e-01 | -5.14e-02 | 8.26e-01 |
| O-linked glycosylation | 83 | 4.27e-01 | -5.05e-02 | 5.39e-01 |
| CD28 co-stimulation | 33 | 6.17e-01 | -5.03e-02 | 7.13e-01 |
| Cargo trafficking to the periciliary membrane | 47 | 5.63e-01 | 4.88e-02 | 6.66e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 74 | 4.69e-01 | -4.87e-02 | 5.79e-01 |
| Signaling by NODAL | 13 | 7.62e-01 | -4.86e-02 | 8.34e-01 |
| Loss of Nlp from mitotic centrosomes | 68 | 4.90e-01 | -4.84e-02 | 5.96e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 68 | 4.90e-01 | -4.84e-02 | 5.96e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 37 | 6.11e-01 | 4.83e-02 | 7.09e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 7.63e-01 | 4.82e-02 | 8.36e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 5.20e-01 | -4.76e-02 | 6.27e-01 |
| Processing of Capped Intronless Pre-mRNA | 28 | 6.63e-01 | -4.76e-02 | 7.55e-01 |
| mRNA Splicing - Minor Pathway | 52 | 5.56e-01 | 4.72e-02 | 6.61e-01 |
| Neurexins and neuroligins | 37 | 6.21e-01 | -4.70e-02 | 7.16e-01 |
| Chromatin modifying enzymes | 218 | 2.34e-01 | 4.67e-02 | 3.39e-01 |
| Chromatin organization | 218 | 2.34e-01 | 4.67e-02 | 3.39e-01 |
| HIV Life Cycle | 144 | 3.39e-01 | 4.61e-02 | 4.50e-01 |
| Phosphorylation of the APC/C | 20 | 7.21e-01 | 4.61e-02 | 8.05e-01 |
| Mitotic Prometaphase | 184 | 2.83e-01 | -4.59e-02 | 3.92e-01 |
| Telomere Maintenance | 80 | 4.88e-01 | -4.48e-02 | 5.96e-01 |
| Ion transport by P-type ATPases | 43 | 6.12e-01 | 4.47e-02 | 7.09e-01 |
| SUMO E3 ligases SUMOylate target proteins | 160 | 3.33e-01 | -4.44e-02 | 4.45e-01 |
| Reproduction | 80 | 4.93e-01 | 4.43e-02 | 5.99e-01 |
| Glucagon-type ligand receptors | 20 | 7.32e-01 | 4.42e-02 | 8.12e-01 |
| DNA Replication Pre-Initiation | 83 | 4.87e-01 | 4.42e-02 | 5.94e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 4.86e-01 | -4.40e-02 | 5.94e-01 |
| Signaling by FGFR2 in disease | 32 | 6.67e-01 | 4.39e-02 | 7.56e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 11 | 8.02e-01 | -4.37e-02 | 8.66e-01 |
| Netrin-1 signaling | 40 | 6.38e-01 | 4.30e-02 | 7.33e-01 |
| RNA Polymerase III Transcription Termination | 23 | 7.25e-01 | -4.24e-02 | 8.06e-01 |
| DAP12 signaling | 28 | 6.98e-01 | 4.23e-02 | 7.87e-01 |
| Regulation of expression of SLITs and ROBOs | 161 | 3.55e-01 | -4.22e-02 | 4.64e-01 |
| SHC-mediated cascade:FGFR2 | 12 | 8.01e-01 | -4.21e-02 | 8.66e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 7.45e-01 | -4.20e-02 | 8.24e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 8.02e-01 | 4.18e-02 | 8.66e-01 |
| Transcriptional Regulation by TP53 | 352 | 1.82e-01 | 4.14e-02 | 2.77e-01 |
| Diseases of metabolism | 190 | 3.27e-01 | 4.12e-02 | 4.39e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 14 | 7.92e-01 | 4.07e-02 | 8.61e-01 |
| Signaling by KIT in disease | 20 | 7.56e-01 | -4.01e-02 | 8.30e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 7.56e-01 | -4.01e-02 | 8.30e-01 |
| Glutamate Neurotransmitter Release Cycle | 20 | 7.57e-01 | -4.00e-02 | 8.30e-01 |
| IL-6-type cytokine receptor ligand interactions | 12 | 8.11e-01 | 3.98e-02 | 8.74e-01 |
| Lewis blood group biosynthesis | 13 | 8.04e-01 | 3.97e-02 | 8.68e-01 |
| CDC6 association with the ORC:origin complex | 11 | 8.20e-01 | -3.95e-02 | 8.82e-01 |
| Formation of Incision Complex in GG-NER | 43 | 6.56e-01 | 3.93e-02 | 7.50e-01 |
| SUMOylation of DNA methylation proteins | 16 | 7.86e-01 | -3.91e-02 | 8.57e-01 |
| Sulfur amino acid metabolism | 22 | 7.53e-01 | 3.88e-02 | 8.28e-01 |
| Interleukin-2 signaling | 11 | 8.25e-01 | 3.84e-02 | 8.87e-01 |
| Meiosis | 68 | 5.93e-01 | 3.75e-02 | 6.93e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 91 | 5.38e-01 | -3.74e-02 | 6.44e-01 |
| Amplification of signal from the kinetochores | 91 | 5.38e-01 | -3.74e-02 | 6.44e-01 |
| mRNA 3’-end processing | 56 | 6.29e-01 | -3.73e-02 | 7.25e-01 |
| TNFR1-induced NFkappaB signaling pathway | 25 | 7.50e-01 | -3.68e-02 | 8.26e-01 |
| Cytosolic sensors of pathogen-associated DNA | 62 | 6.19e-01 | 3.65e-02 | 7.15e-01 |
| Termination of O-glycan biosynthesis | 16 | 8.02e-01 | 3.63e-02 | 8.66e-01 |
| Mitochondrial protein import | 64 | 6.19e-01 | 3.59e-02 | 7.15e-01 |
| Deactivation of the beta-catenin transactivating complex | 36 | 7.10e-01 | 3.58e-02 | 7.96e-01 |
| Synthesis of DNA | 119 | 5.06e-01 | -3.53e-02 | 6.14e-01 |
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 8.40e-01 | -3.52e-02 | 8.97e-01 |
| S Phase | 161 | 4.47e-01 | -3.48e-02 | 5.56e-01 |
| Class A/1 (Rhodopsin-like receptors) | 169 | 4.36e-01 | 3.47e-02 | 5.45e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 8.42e-01 | 3.47e-02 | 8.99e-01 |
| Metabolism of water-soluble vitamins and cofactors | 110 | 5.37e-01 | -3.41e-02 | 6.44e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 238 | 3.66e-01 | -3.40e-02 | 4.73e-01 |
| Mitotic G1 phase and G1/S transition | 148 | 4.86e-01 | 3.32e-02 | 5.94e-01 |
| Metabolism of vitamins and cofactors | 156 | 4.76e-01 | 3.31e-02 | 5.85e-01 |
| Vitamin D (calciferol) metabolism | 10 | 8.57e-01 | 3.29e-02 | 9.04e-01 |
| IRF3-mediated induction of type I IFN | 12 | 8.44e-01 | -3.29e-02 | 8.99e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 24 | 7.81e-01 | 3.28e-02 | 8.53e-01 |
| Visual phototransduction | 60 | 6.65e-01 | 3.23e-02 | 7.56e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 14 | 8.38e-01 | -3.16e-02 | 8.96e-01 |
| Nucleotide-like (purinergic) receptors | 13 | 8.44e-01 | 3.15e-02 | 8.99e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 7.45e-01 | -3.13e-02 | 8.24e-01 |
| Diseases of mitotic cell cycle | 36 | 7.45e-01 | -3.13e-02 | 8.24e-01 |
| Mitotic Spindle Checkpoint | 108 | 5.80e-01 | -3.08e-02 | 6.82e-01 |
| Processing of DNA double-strand break ends | 71 | 6.59e-01 | -3.03e-02 | 7.52e-01 |
| TNF signaling | 43 | 7.31e-01 | 3.03e-02 | 8.12e-01 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 8.45e-01 | -3.02e-02 | 9.00e-01 |
| Signaling by Retinoic Acid | 31 | 7.73e-01 | 3.00e-02 | 8.45e-01 |
| GABA synthesis, release, reuptake and degradation | 13 | 8.52e-01 | -2.98e-02 | 9.01e-01 |
| Voltage gated Potassium channels | 25 | 7.97e-01 | 2.97e-02 | 8.65e-01 |
| AURKA Activation by TPX2 | 71 | 6.66e-01 | -2.96e-02 | 7.56e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 8.34e-01 | -2.94e-02 | 8.93e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 8.34e-01 | -2.94e-02 | 8.93e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 8.54e-01 | 2.85e-02 | 9.01e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 8.54e-01 | 2.85e-02 | 9.01e-01 |
| G2/M DNA damage checkpoint | 68 | 6.86e-01 | -2.84e-02 | 7.75e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 6.95e-01 | -2.84e-02 | 7.84e-01 |
| RNA Polymerase II Transcription Termination | 65 | 6.95e-01 | -2.81e-02 | 7.84e-01 |
| Serotonin Neurotransmitter Release Cycle | 15 | 8.50e-01 | 2.81e-02 | 9.01e-01 |
| Activation of SMO | 13 | 8.65e-01 | 2.73e-02 | 9.10e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 36 | 7.77e-01 | 2.73e-02 | 8.49e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 8.32e-01 | -2.68e-02 | 8.92e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 8.32e-01 | -2.68e-02 | 8.92e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 8.58e-01 | -2.59e-02 | 9.04e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 21 | 8.40e-01 | -2.54e-02 | 8.97e-01 |
| Epigenetic regulation of gene expression | 100 | 6.61e-01 | 2.54e-02 | 7.53e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 8.37e-01 | 2.34e-02 | 8.96e-01 |
| Ribosomal scanning and start codon recognition | 58 | 7.59e-01 | -2.33e-02 | 8.32e-01 |
| Interaction between L1 and Ankyrins | 22 | 8.50e-01 | 2.33e-02 | 9.01e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 40 | 8.00e-01 | 2.32e-02 | 8.66e-01 |
| Nucleosome assembly | 40 | 8.00e-01 | 2.32e-02 | 8.66e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 8.69e-01 | -2.32e-02 | 9.13e-01 |
| FGFR2 mutant receptor activation | 22 | 8.51e-01 | 2.31e-02 | 9.01e-01 |
| Interleukin-35 Signalling | 12 | 8.91e-01 | -2.29e-02 | 9.32e-01 |
| DNA Replication | 126 | 6.64e-01 | -2.24e-02 | 7.55e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors | 93 | 7.09e-01 | 2.24e-02 | 7.96e-01 |
| Regulation of Complement cascade | 95 | 7.15e-01 | -2.17e-02 | 8.00e-01 |
| Complement cascade | 99 | 7.15e-01 | -2.12e-02 | 8.00e-01 |
| Class B/2 (Secretin family receptors) | 56 | 7.84e-01 | 2.11e-02 | 8.56e-01 |
| Methylation | 12 | 8.99e-01 | -2.11e-02 | 9.38e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 22 | 8.65e-01 | 2.10e-02 | 9.10e-01 |
| G0 and Early G1 | 27 | 8.52e-01 | 2.08e-02 | 9.01e-01 |
| Cell Cycle, Mitotic | 502 | 4.26e-01 | 2.07e-02 | 5.38e-01 |
| GPCR ligand binding | 235 | 5.92e-01 | 2.03e-02 | 6.93e-01 |
| RHO GTPases Activate Formins | 117 | 7.09e-01 | 2.00e-02 | 7.96e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 8.98e-01 | 1.99e-02 | 9.37e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 11 | 9.10e-01 | -1.97e-02 | 9.43e-01 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 8.99e-01 | 1.96e-02 | 9.38e-01 |
| Synthesis of PA | 32 | 8.50e-01 | 1.94e-02 | 9.01e-01 |
| Signaling by BMP | 21 | 8.81e-01 | -1.89e-02 | 9.23e-01 |
| EML4 and NUDC in mitotic spindle formation | 95 | 7.52e-01 | -1.87e-02 | 8.28e-01 |
| RUNX2 regulates bone development | 24 | 8.75e-01 | -1.85e-02 | 9.19e-01 |
| Signaling by FGFR3 in disease | 13 | 9.08e-01 | 1.84e-02 | 9.43e-01 |
| Signaling by FGFR3 point mutants in cancer | 13 | 9.08e-01 | 1.84e-02 | 9.43e-01 |
| Translation initiation complex formation | 58 | 8.09e-01 | -1.83e-02 | 8.73e-01 |
| HCMV Early Events | 74 | 7.91e-01 | 1.78e-02 | 8.61e-01 |
| Dual incision in TC-NER | 65 | 8.15e-01 | -1.67e-02 | 8.78e-01 |
| Cell Cycle Checkpoints | 260 | 6.48e-01 | 1.65e-02 | 7.43e-01 |
| Downstream signaling of activated FGFR2 | 19 | 9.03e-01 | 1.62e-02 | 9.41e-01 |
| HATs acetylate histones | 93 | 7.88e-01 | -1.61e-02 | 8.58e-01 |
| AKT phosphorylates targets in the nucleus | 10 | 9.31e-01 | -1.58e-02 | 9.54e-01 |
| FCERI mediated MAPK activation | 90 | 7.97e-01 | 1.57e-02 | 8.65e-01 |
| CRMPs in Sema3A signaling | 14 | 9.19e-01 | -1.56e-02 | 9.50e-01 |
| FRS-mediated FGFR2 signaling | 14 | 9.20e-01 | 1.56e-02 | 9.50e-01 |
| Lysosphingolipid and LPA receptors | 11 | 9.30e-01 | -1.52e-02 | 9.54e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 9.08e-01 | -1.50e-02 | 9.43e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 9.08e-01 | 1.49e-02 | 9.43e-01 |
| Keratan sulfate biosynthesis | 22 | 9.04e-01 | -1.49e-02 | 9.41e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 34 | 8.90e-01 | -1.37e-02 | 9.32e-01 |
| Regulation of TP53 Expression and Degradation | 36 | 8.93e-01 | -1.30e-02 | 9.33e-01 |
| CTLA4 inhibitory signaling | 21 | 9.19e-01 | -1.29e-02 | 9.50e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 10 | 9.44e-01 | 1.29e-02 | 9.62e-01 |
| Defective EXT2 causes exostoses 2 | 10 | 9.44e-01 | 1.29e-02 | 9.62e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 9.26e-01 | 1.23e-02 | 9.53e-01 |
| FOXO-mediated transcription of cell cycle genes | 15 | 9.36e-01 | 1.19e-02 | 9.58e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 86 | 8.52e-01 | -1.16e-02 | 9.01e-01 |
| Dopamine Neurotransmitter Release Cycle | 20 | 9.29e-01 | 1.15e-02 | 9.53e-01 |
| Nicotinate metabolism | 25 | 9.21e-01 | -1.15e-02 | 9.50e-01 |
| Organelle biogenesis and maintenance | 268 | 7.48e-01 | -1.14e-02 | 8.26e-01 |
| Diseases of glycosylation | 108 | 8.47e-01 | -1.07e-02 | 9.01e-01 |
| Signaling by ROBO receptors | 201 | 7.93e-01 | -1.07e-02 | 8.62e-01 |
| Mitochondrial translation termination | 91 | 8.68e-01 | -1.01e-02 | 9.13e-01 |
| CASP8 activity is inhibited | 11 | 9.55e-01 | -9.91e-03 | 9.67e-01 |
| Dimerization of procaspase-8 | 11 | 9.55e-01 | -9.91e-03 | 9.67e-01 |
| Regulation by c-FLIP | 11 | 9.55e-01 | -9.91e-03 | 9.67e-01 |
| DNA Damage Recognition in GG-NER | 38 | 9.16e-01 | -9.86e-03 | 9.48e-01 |
| Mitochondrial translation elongation | 91 | 8.78e-01 | -9.27e-03 | 9.22e-01 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 9.54e-01 | -8.64e-03 | 9.67e-01 |
| Deadenylation-dependent mRNA decay | 53 | 9.16e-01 | -8.41e-03 | 9.48e-01 |
| Synthesis of PIPs at the early endosome membrane | 16 | 9.54e-01 | -8.25e-03 | 9.67e-01 |
| Regulation of FZD by ubiquitination | 15 | 9.56e-01 | -8.14e-03 | 9.68e-01 |
| Nucleotide Excision Repair | 110 | 8.85e-01 | -8.00e-03 | 9.27e-01 |
| PECAM1 interactions | 12 | 9.62e-01 | -7.90e-03 | 9.71e-01 |
| Cell Cycle | 624 | 7.42e-01 | -7.73e-03 | 8.22e-01 |
| RMTs methylate histone arginines | 37 | 9.37e-01 | 7.53e-03 | 9.58e-01 |
| Tight junction interactions | 18 | 9.57e-01 | 7.28e-03 | 9.68e-01 |
| Defective B3GAT3 causes JDSSDHD | 11 | 9.69e-01 | -6.88e-03 | 9.76e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 9.50e-01 | 6.49e-03 | 9.67e-01 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 9.33e-01 | -6.36e-03 | 9.55e-01 |
| Metabolism of amino acids and derivatives | 326 | 8.50e-01 | -6.08e-03 | 9.01e-01 |
| Regulation of TP53 Degradation | 35 | 9.51e-01 | 6.03e-03 | 9.67e-01 |
| Cardiac conduction | 86 | 9.24e-01 | 5.96e-03 | 9.52e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 9.29e-01 | -5.87e-03 | 9.53e-01 |
| G1/S Transition | 130 | 9.10e-01 | 5.77e-03 | 9.43e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 9.72e-01 | 5.64e-03 | 9.79e-01 |
| Collagen chain trimerization | 27 | 9.60e-01 | 5.54e-03 | 9.70e-01 |
| Resolution of Sister Chromatid Cohesion | 104 | 9.23e-01 | -5.49e-03 | 9.52e-01 |
| Mitochondrial translation initiation | 91 | 9.42e-01 | -4.45e-03 | 9.61e-01 |
| Mitochondrial translation | 97 | 9.40e-01 | 4.40e-03 | 9.61e-01 |
| Kinesins | 39 | 9.64e-01 | 4.16e-03 | 9.73e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 169 | 9.27e-01 | 4.07e-03 | 9.53e-01 |
| Leishmania parasite growth and survival | 169 | 9.27e-01 | 4.07e-03 | 9.53e-01 |
| SLC transporter disorders | 77 | 9.52e-01 | 3.97e-03 | 9.67e-01 |
| Synaptic adhesion-like molecules | 15 | 9.79e-01 | 3.89e-03 | 9.85e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 9.78e-01 | -3.15e-03 | 9.84e-01 |
| mRNA Splicing - Major Pathway | 179 | 9.58e-01 | -2.29e-03 | 9.68e-01 |
| DCC mediated attractive signaling | 13 | 9.92e-01 | 1.61e-03 | 9.96e-01 |
| Protein-protein interactions at synapses | 58 | 9.88e-01 | 1.16e-03 | 9.92e-01 |
| mRNA Splicing | 187 | 9.80e-01 | 1.05e-03 | 9.85e-01 |
| Glyoxylate metabolism and glycine degradation | 24 | 9.93e-01 | -1.02e-03 | 9.96e-01 |
| Nuclear Receptor transcription pathway | 38 | 9.93e-01 | -7.77e-04 | 9.96e-01 |
| Gene Silencing by RNA | 88 | 9.96e-01 | 3.02e-04 | 9.98e-01 |
| Glutathione synthesis and recycling | 10 | 9.99e-01 | -2.37e-04 | 1.00e+00 |
| Ion homeostasis | 41 | 1.00e+00 | -1.34e-05 | 1.00e+00 |
Detailed Gene set reports
IRAK4 deficiency (TLR2/4)
| 514 | |
|---|---|
| set | IRAK4 deficiency (TLR2/4) |
| setSize | 10 |
| pANOVA | 8.37e-07 |
| s.dist | 0.899 |
| p.adjustANOVA | 1.05e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
MyD88 deficiency (TLR2/4)
| 687 | |
|---|---|
| set | MyD88 deficiency (TLR2/4) |
| setSize | 10 |
| pANOVA | 8.37e-07 |
| s.dist | 0.899 |
| p.adjustANOVA | 1.05e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| BTK | 7206 |
| TIRAP | 5640 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism
| 1333 | |
|---|---|
| set | alpha-linolenic (omega3) and linoleic (omega6) acid metabolism |
| setSize | 12 |
| pANOVA | 2.46e-06 |
| s.dist | 0.785 |
| p.adjustANOVA | 2.63e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
alpha-linolenic acid (ALA) metabolism
| 1334 | |
|---|---|
| set | alpha-linolenic acid (ALA) metabolism |
| setSize | 12 |
| pANOVA | 2.46e-06 |
| s.dist | 0.785 |
| p.adjustANOVA | 2.63e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ACSL1 | 9217 |
| ACOX1 | 8859 |
| HSD17B4 | 8858 |
| ELOVL3 | 8710 |
| ACAA1 | 8292 |
| ACOT8 | 8018 |
| FADS1 | 7699 |
| ABCD1 | 7346 |
| ELOVL1 | 7088 |
| ELOVL5 | 6011 |
| SCP2 | 4454 |
| FADS2 | 1486 |
Regulation of TLR by endogenous ligand
| 969 | |
|---|---|
| set | Regulation of TLR by endogenous ligand |
| setSize | 11 |
| pANOVA | 1.93e-05 |
| s.dist | 0.744 |
| p.adjustANOVA | 0.000145 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| HMGB1 | -252 |
| S100A1 | -8108 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CD36 | 9444 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| HMGB1 | -252 |
| S100A1 | -8108 |
Translocation of ZAP-70 to Immunological synapse
| 1280 | |
|---|---|
| set | Translocation of ZAP-70 to Immunological synapse |
| setSize | 24 |
| pANOVA | 2.81e-10 |
| s.dist | -0.744 |
| p.adjustANOVA | 8.34e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PTPN22 | -1208 |
Hyaluronan uptake and degradation
| 506 | |
|---|---|
| set | Hyaluronan uptake and degradation |
| setSize | 12 |
| pANOVA | 8.85e-06 |
| s.dist | 0.741 |
| p.adjustANOVA | 7.24e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| HEXA | 1261 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| HEXA | 1261 |
Uptake and function of anthrax toxins
| 1308 | |
|---|---|
| set | Uptake and function of anthrax toxins |
| setSize | 10 |
| pANOVA | 0.000114 |
| s.dist | 0.705 |
| p.adjustANOVA | 0.000652 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FURIN | 9075 |
| MAP2K1 | 9063 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| ANTXR2 | 7331 |
| MAP2K4 | 6866 |
| MAP2K2 | 6794 |
| PDCD6IP | 6528 |
| MAP2K7 | 1654 |
| CALM1 | -2081 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FURIN | 9075 |
| MAP2K1 | 9063 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| ANTXR2 | 7331 |
| MAP2K4 | 6866 |
| MAP2K2 | 6794 |
| PDCD6IP | 6528 |
| MAP2K7 | 1654 |
| CALM1 | -2081 |
Erythrocytes take up carbon dioxide and release oxygen
| 346 | |
|---|---|
| set | Erythrocytes take up carbon dioxide and release oxygen |
| setSize | 11 |
| pANOVA | 9.46e-05 |
| s.dist | 0.68 |
| p.adjustANOVA | 0.000553 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
O2/CO2 exchange in erythrocytes
| 766 | |
|---|---|
| set | O2/CO2 exchange in erythrocytes |
| setSize | 11 |
| pANOVA | 9.46e-05 |
| s.dist | 0.68 |
| p.adjustANOVA | 0.000553 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CYB5R1 | 9460 |
| CA1 | 9380 |
| SLC4A1 | 9141 |
| HBB | 9054 |
| HBA1 | 8990 |
| CYB5R2 | 8600 |
| CYB5R4 | 8421 |
| AQP1 | 7476 |
| CA2 | 3570 |
| CA4 | 2826 |
| CYB5RL | -10762 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
| 1326 | |
|---|---|
| set | WNT5A-dependent internalization of FZD2, FZD5 and ROR2 |
| setSize | 11 |
| pANOVA | 0.000117 |
| s.dist | 0.671 |
| p.adjustANOVA | 0.000658 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FZD5 | 9513 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| FZD2 | 6462 |
| CLTB | 6084 |
| ROR1 | -2376 |
| AP2B1 | -2709 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FZD5 | 9513 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| FZD2 | 6462 |
| CLTB | 6084 |
| ROR1 | -2376 |
| AP2B1 | -2709 |
p130Cas linkage to MAPK signaling for integrins
| 1345 | |
|---|---|
| set | p130Cas linkage to MAPK signaling for integrins |
| setSize | 11 |
| pANOVA | 0.000132 |
| s.dist | 0.665 |
| p.adjustANOVA | 0.000722 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SRC | -8820 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SRC | -8820 |
Advanced glycosylation endproduct receptor signaling
| 61 | |
|---|---|
| set | Advanced glycosylation endproduct receptor signaling |
| setSize | 12 |
| pANOVA | 9.48e-05 |
| s.dist | 0.651 |
| p.adjustANOVA | 0.000553 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| APP | 9177 |
| MAPK3 | 8953 |
| LGALS3 | 8752 |
| CAPZA2 | 8597 |
| CAPZA1 | 8135 |
| MAPK1 | 7493 |
| DDOST | 6931 |
| PRKCSH | 5220 |
| AGER | 1294 |
| HMGB1 | -252 |
| S100B | -5457 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| APP | 9177 |
| MAPK3 | 8953 |
| LGALS3 | 8752 |
| CAPZA2 | 8597 |
| CAPZA1 | 8135 |
| MAPK1 | 7493 |
| DDOST | 6931 |
| PRKCSH | 5220 |
| AGER | 1294 |
| HMGB1 | -252 |
| S100B | -5457 |
Unwinding of DNA
| 1306 | |
|---|---|
| set | Unwinding of DNA |
| setSize | 12 |
| pANOVA | 0.000132 |
| s.dist | -0.637 |
| p.adjustANOVA | 0.000722 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| MCM7 | -12129 |
| MCM8 | -10944 |
| GINS3 | -10508 |
| GINS4 | -10236 |
| MCM6 | -9715 |
| MCM4 | -8701 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| GINS2 | -4815 |
| GINS1 | -4401 |
| CDC45 | -2659 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| MCM7 | -12129 |
| MCM8 | -10944 |
| GINS3 | -10508 |
| GINS4 | -10236 |
| MCM6 | -9715 |
| MCM4 | -8701 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| GINS2 | -4815 |
| GINS1 | -4401 |
| CDC45 | -2659 |
RNA Polymerase I Promoter Opening
| 903 | |
|---|---|
| set | RNA Polymerase I Promoter Opening |
| setSize | 19 |
| pANOVA | 3.29e-06 |
| s.dist | 0.616 |
| p.adjustANOVA | 3.28e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| MAPK3 | 8953.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| MBD2 | 6581.0 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| H2AZ2 | -1209.0 |
| H2BU1 | -6555.0 |
| UBTF | -10033.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| MAPK3 | 8953.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| MBD2 | 6581.0 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| H2AZ2 | -1209.0 |
| H2BU1 | -6555.0 |
| UBTF | -10033.0 |
RHO GTPases Activate WASPs and WAVEs
| 890 | |
|---|---|
| set | RHO GTPases Activate WASPs and WAVEs |
| setSize | 35 |
| pANOVA | 4.57e-10 |
| s.dist | 0.609 |
| p.adjustANOVA | 1.33e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| WASF1 | 9520 |
| GRB2 | 9304 |
| CYFIP1 | 9265 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| MAPK3 | 8953 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| WAS | 8560 |
| WASF2 | 8369 |
| ARPC3 | 8277 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| NCKAP1L | 7673 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| MAPK1 | 7493 |
| NCKAP1 | 7462 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| WASF1 | 9520 |
| GRB2 | 9304 |
| CYFIP1 | 9265 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| MAPK3 | 8953 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| WAS | 8560 |
| WASF2 | 8369 |
| ARPC3 | 8277 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| NCKAP1L | 7673 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| MAPK1 | 7493 |
| NCKAP1 | 7462 |
| ARPC2 | 7390 |
| BTK | 7206 |
| ABI1 | 7082 |
| BRK1 | 7032 |
| WASF3 | 6808 |
| WIPF2 | 5713 |
| PTK2 | 4462 |
| WIPF1 | 569 |
| NCKIPSD | 328 |
| WASL | 299 |
| ABL1 | 226 |
| BAIAP2 | -215 |
| CYFIP2 | -10367 |
| ABI2 | -10915 |
| NCK1 | -11454 |
ROS and RNS production in phagocytes
| 926 | |
|---|---|
| set | ROS and RNS production in phagocytes |
| setSize | 31 |
| pANOVA | 8.23e-09 |
| s.dist | 0.598 |
| p.adjustANOVA | 1.76e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| NCF4 | 9268 |
| ATP6V0D1 | 9245 |
| NCF2 | 9190 |
| SLC11A1 | 9169 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| CYBB | 9031 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MPO | 7437 |
| NCF1 | 7334 |
| TCIRG1 | 7188 |
| CYBA | 6922 |
| LPO | 6502 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| NCF4 | 9268 |
| ATP6V0D1 | 9245 |
| NCF2 | 9190 |
| SLC11A1 | 9169 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| CYBB | 9031 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MPO | 7437 |
| NCF1 | 7334 |
| TCIRG1 | 7188 |
| CYBA | 6922 |
| LPO | 6502 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| RAC2 | 5163 |
| HVCN1 | 4912 |
| ATP6V1G1 | 3931 |
| NOS1 | 1365 |
| NOS3 | -2059 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| ATP6V0E2 | -11555 |
| ATP6V0A2 | -12211 |
Neutrophil degranulation
| 737 | |
|---|---|
| set | Neutrophil degranulation |
| setSize | 457 |
| pANOVA | 1.32e-103 |
| s.dist | 0.587 |
| p.adjustANOVA | 1.8e-100 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A12 | 9515 |
| CTSA | 9514 |
| SIRPA | 9510 |
| IDH1 | 9507 |
| RNASE2 | 9506 |
| MCEMP1 | 9504 |
| S100A8 | 9503 |
| CD93 | 9496 |
| CR1 | 9486 |
| CREG1 | 9483 |
| MGST1 | 9482 |
| BST1 | 9480 |
| TIMP2 | 9458 |
| HP | 9454 |
| CD36 | 9444 |
| GCA | 9436 |
| PGAM1 | 9435 |
| SERPINB1 | 9434 |
| CTSD | 9433 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A12 | 9515 |
| CTSA | 9514 |
| SIRPA | 9510 |
| IDH1 | 9507 |
| RNASE2 | 9506 |
| MCEMP1 | 9504 |
| S100A8 | 9503 |
| CD93 | 9496 |
| CR1 | 9486 |
| CREG1 | 9483 |
| MGST1 | 9482 |
| BST1 | 9480 |
| TIMP2 | 9458 |
| HP | 9454 |
| CD36 | 9444 |
| GCA | 9436 |
| PGAM1 | 9435 |
| SERPINB1 | 9434 |
| CTSD | 9433 |
| ATP6V0A1 | 9423 |
| PYGL | 9417 |
| LAMTOR1 | 9411 |
| ITGAM | 9398 |
| PKM | 9391 |
| DOK3 | 9388 |
| HK3 | 9385 |
| SIGLEC9 | 9383 |
| CKAP4 | 9370 |
| CTSB | 9364 |
| GNS | 9360 |
| RAB31 | 9356 |
| PTAFR | 9355 |
| ANPEP | 9350 |
| PGM2 | 9344 |
| QPCT | 9327 |
| SDCBP | 9311 |
| CDA | 9310 |
| GRN | 9308 |
| PLD1 | 9306 |
| QSOX1 | 9298 |
| FPR1 | 9295 |
| IMPDH1 | 9294 |
| CD63 | 9287 |
| MNDA | 9277 |
| VAT1 | 9276 |
| CYFIP1 | 9265 |
| LTA4H | 9261 |
| PADI2 | 9257 |
| AGPAT2 | 9256 |
| ALDOA | 9249 |
| MMP8 | 9232 |
| RAB3D | 9207 |
| TOM1 | 9200 |
| NCSTN | 9186 |
| CLEC4D | 9185 |
| SLC11A1 | 9169 |
| SERPINA1 | 9168 |
| CD55 | 9145 |
| GPR84 | 9133 |
| C5AR1 | 9129 |
| ATP6V0C | 9127 |
| CAT | 9123 |
| FCN1 | 9113 |
| FCAR | 9111 |
| CRISPLD2 | 9106 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| TRPM2 | 9102 |
| CD14 | 9097 |
| FPR2 | 9095 |
| VNN1 | 9092 |
| NFAM1 | 9086 |
| CYSTM1 | 9077 |
| OSCAR | 9068 |
| GM2A | 9059 |
| HBB | 9054 |
| MGAM | 9050 |
| ATP6V1D | 9047 |
| VAPA | 9033 |
| CYBB | 9031 |
| NEU1 | 9029 |
| SLC2A3 | 9021 |
| BRI3 | 9017 |
| APAF1 | 9015 |
| GYG1 | 9013 |
| PRKCD | 9008 |
| ALOX5 | 9001 |
| RETN | 8998 |
| CTSZ | 8975 |
| S100A11 | 8946 |
| ITGB2 | 8942 |
| PRDX6 | 8937 |
| SERPINB10 | 8933 |
| RAB10 | 8926 |
| SELL | 8912 |
| CYB5R3 | 8903 |
| LILRB3 | 8871 |
| FCGR2A | 8845 |
| RAC1 | 8793 |
| ADAM10 | 8791 |
| LAMP2 | 8786 |
| HEXB | 8776 |
| ARG1 | 8759 |
| LGALS3 | 8752 |
| GSN | 8749 |
| RAB7A | 8742 |
| TNFAIP6 | 8738 |
| AMPD3 | 8732 |
| GLB1 | 8725 |
| OLFM4 | 8724 |
| ARPC5 | 8686 |
| DNAJC5 | 8679 |
| LRG1 | 8674 |
| FTL | 8665 |
| ALDH3B1 | 8663 |
| RAB5C | 8655 |
| PYCARD | 8638 |
| PDXK | 8635 |
| DNASE1L1 | 8632 |
| SNAP23 | 8628 |
| TOLLIP | 8572 |
| GLA | 8570 |
| CAPN1 | 8563 |
| ANXA2 | 8544 |
| CD68 | 8533 |
| ASAH1 | 8529 |
| MMP25 | 8515 |
| ALAD | 8514 |
| DERA | 8500 |
| RHOG | 8487 |
| PSMB7 | 8485 |
| FGR | 8478 |
| HPSE | 8476 |
| CLEC5A | 8473 |
| PLAC8 | 8452 |
| P2RX1 | 8436 |
| DNAJC3 | 8435 |
| CEACAM1 | 8429 |
| PLAUR | 8424 |
| PNP | 8419 |
| RAB27A | 8411 |
| HEBP2 | 8398 |
| ATP11A | 8394 |
| CTSS | 8372 |
| TMBIM1 | 8361 |
| CPPED1 | 8357 |
| CD44 | 8333 |
| S100P | 8331 |
| RHOA | 8319 |
| FUCA2 | 8304 |
| ACAA1 | 8292 |
| CAB39 | 8276 |
| DNAJC13 | 8263 |
| GMFG | 8259 |
| MOSPD2 | 8252 |
| ARL8A | 8249 |
| PRCP | 8218 |
| ADGRG3 | 8204 |
| SIGLEC5 | 8161 |
| IQGAP1 | 8152 |
| RAB6A | 8148 |
| ATG7 | 8134 |
| RAB3A | 8133 |
| FCER1G | 8131 |
| CAP1 | 8111 |
| HSPA1A | 8071 |
| CD33 | 8069 |
| PLEKHO2 | 8059 |
| LILRB2 | 8057 |
| ANO6 | 8048 |
| TMEM30A | 8036 |
| ATP6AP2 | 8034 |
| C3AR1 | 8012 |
| ORM1 | 7971 |
| GAA | 7968 |
| COMMD9 | 7967 |
| PSEN1 | 7961 |
| COTL1 | 7933 |
| PGLYRP1 | 7910 |
| CMTM6 | 7891 |
| CD53 | 7884 |
| ACTR2 | 7870 |
| KCMF1 | 7869 |
| PECAM1 | 7855 |
| PSMD6 | 7846 |
| SIRPB1 | 7843 |
| TRAPPC1 | 7806 |
| RAB18 | 7801 |
| PGRMC1 | 7795 |
| PTPRJ | 7783 |
| LCN2 | 7755 |
| DBNL | 7749 |
| GLIPR1 | 7739 |
| DOCK2 | 7725 |
| GUSB | 7723 |
| CANT1 | 7707 |
| NCKAP1L | 7673 |
| LAMP1 | 7631 |
| UNC13D | 7607 |
| ACTR10 | 7605 |
| LAMTOR3 | 7574 |
| ARSB | 7572 |
| LAMTOR2 | 7567 |
| CRISP3 | 7552 |
| TYROBP | 7539 |
| MAPK1 | 7493 |
| ROCK1 | 7489 |
| RNASE3 | 7471 |
| FOLR3 | 7451 |
| CFP | 7445 |
| MPO | 7437 |
| OSTF1 | 7426 |
| NAPRT | 7412 |
| PSMD2 | 7411 |
| FUCA1 | 7408 |
| MANBA | 7386 |
| ITGAX | 7337 |
| VCL | 7328 |
| COPB1 | 7321 |
| ELANE | 7320 |
| RAP1A | 7305 |
| GDI2 | 7282 |
| AP2A2 | 7257 |
| PSMD1 | 7241 |
| TUBB4B | 7240 |
| LYZ | 7213 |
| TCIRG1 | 7188 |
| LAIR1 | 7184 |
| IGF2R | 7149 |
| PSAP | 7145 |
| GALNS | 7102 |
| RAB14 | 7095 |
| NBEAL2 | 7086 |
| SURF4 | 7058 |
| MVP | 7053 |
| TSPAN14 | 6971 |
| ATP8B4 | 6970 |
| PAFAH1B2 | 6942 |
| DYNC1LI1 | 6941 |
| DDOST | 6931 |
| CYBA | 6922 |
| METTL7A | 6920 |
| ERP44 | 6905 |
| CSTB | 6904 |
| VCP | 6886 |
| MAN2B1 | 6878 |
| CXCR1 | 6864 |
| CEACAM3 | 6838 |
| PRTN3 | 6762 |
| AP1M1 | 6711 |
| STOM | 6704 |
| RAB5B | 6690 |
| YPEL5 | 6684 |
| BPI | 6666 |
| CD58 | 6647 |
| CNN2 | 6645 |
| DDX3X | 6614 |
| IQGAP2 | 6599 |
| PSMD12 | 6556 |
| CCT8 | 6552 |
| HSPA6 | 6514 |
| AOC1 | 6509 |
| HSPA1B | 6470 |
| ARMC8 | 6398 |
| SNAP29 | 6390 |
| CTSH | 6360 |
| TICAM2 | 6335 |
| SRP14 | 6320 |
| LTF | 6306 |
| GPI | 6284 |
| NFKB1 | 6277 |
| ARHGAP9 | 6256 |
| PSMD11 | 6231 |
| GGH | 6205 |
| C6orf120 | 6192 |
| TCN1 | 6182 |
| DEGS1 | 6169 |
| VPS35L | 6118 |
| ITGAV | 6106 |
| PTPN6 | 6096 |
| NDUFC2 | 6093 |
| ATP11B | 6064 |
| DEFA1 | 6061 |
| DEFA4 | 6057 |
| TNFRSF1B | 6045 |
| PPBP | 6042 |
| FABP5 | 6021 |
| CHIT1 | 6012 |
| PSMD7 | 5963 |
| DYNLL1 | 5952 |
| PSMD13 | 5948 |
| RNASET2 | 5922 |
| PDAP1 | 5908 |
| CPNE3 | 5872 |
| IST1 | 5862 |
| CXCR2 | 5861 |
| CD59 | 5859 |
| SERPINB6 | 5854 |
| PGM1 | 5843 |
| CXCL1 | 5824 |
| PTX3 | 5797 |
| BIN2 | 5745 |
| ADAM8 | 5634 |
| A1BG | 5559 |
| FAF2 | 5554 |
| STBD1 | 5544 |
| AZU1 | 5507 |
| NPC2 | 5458 |
| XRCC5 | 5384 |
| NRAS | 5363 |
| RAB24 | 5354 |
| PSMA2 | 5339 |
| TARM1 | 5307 |
| DGAT1 | 5306 |
| SLPI | 5298 |
| VAMP8 | 5218 |
| PTPRN2 | 5183 |
| ACLY | 5159 |
| CTSG | 5115 |
| SIGLEC14 | 5087 |
| CEACAM8 | 4956 |
| HVCN1 | 4912 |
| PLAU | 4903 |
| FTH1 | 4902 |
| STING1 | 4791 |
| CAMP | 4785 |
| ABCA13 | 4768 |
| PSMD3 | 4618 |
| RAP2C | 4599 |
| KRT1 | 4537 |
| CLEC12A | 4535 |
| CEACAM6 | 4509 |
| DYNLT1 | 4450 |
| FCGR3B | 4313 |
| B4GALT1 | 4292 |
| GHDC | 4158 |
| GOLGA7 | 4055 |
| CSNK2B | 3969 |
| SLC15A4 | 3724 |
| STK11IP | 3586 |
| ARSA | 3486 |
| PSMB1 | 3374 |
| SLCO4C1 | 3212 |
| RAP1B | 3206 |
| RAB4B | 3137 |
| SLC44A2 | 2700 |
| MAGT1 | 2613 |
| PSMD14 | 2611 |
| PSMC2 | 2598 |
| OLR1 | 2486 |
| CD177 | 2457 |
| KPNB1 | 2430 |
| MS4A3 | 2361 |
| CTSC | 2326 |
| MLEC | 2322 |
| PTPRC | 2240 |
| CST3 | 2206 |
| SLC2A5 | 2044 |
| SVIP | 2035 |
| CFD | 1984 |
| PSMC3 | 1976 |
| GSDMD | 1955 |
| SCAMP1 | 1868 |
| HGSNAT | 1867 |
| NME2 | 1850 |
| MMP9 | 1690 |
| HSP90AA1 | 1326 |
| NHLRC3 | 1276 |
| HLA-C | 1018 |
| APEH | 997 |
| MME | 916 |
| NFASC | 866 |
| FGL2 | 675 |
| HLA-B | 649 |
| RAB44 | 573 |
| PYGB | 492 |
| TMEM179B | 449 |
| ADGRE3 | 408 |
| TXNDC5 | 393 |
| EEF2 | 306 |
| GSTP1 | 135 |
| FRK | -24 |
| KCNAB2 | -101 |
| PRDX4 | -144 |
| HMGB1 | -252 |
| PIGR | -487 |
| CHI3L1 | -650 |
| RAP2B | -771 |
| DIAPH1 | -854 |
| COMMD3 | -1363 |
| DSP | -1812 |
| LRRC7 | -1966 |
| ILF2 | -1979 |
| UBR4 | -2086 |
| CD300A | -2133 |
| ORM2 | -2564 |
| ADGRE5 | -2571 |
| HLA-A | -2573 |
| APRT | -2766 |
| AGL | -3136 |
| PFKL | -3277 |
| CPNE1 | -3397 |
| ALDOC | -3438 |
| SLC27A2 | -3831 |
| MIF | -3863 |
| HLA-H | -3889 |
| STK10 | -3898 |
| PA2G4 | -3916 |
| XRCC6 | -4471 |
| DPP7 | -4586 |
| SYNGR1 | -4629 |
| AGA | -4632 |
| EPX | -4838 |
| EEF1A1 | -5087 |
| JUP | -5353 |
| PSMA5 | -6053 |
| RAB9B | -6552 |
| CAND1 | -6554 |
| PPIA | -6766 |
| HSP90AB1 | -6863 |
| B2M | -6920 |
| PTGES2 | -6926 |
| DSC1 | -6927 |
| TUBB | -6956 |
| HRNR | -7349 |
| BST2 | -7385 |
| LPCAT1 | -7428 |
| PTPRB | -7607 |
| DYNC1H1 | -7685 |
| HUWE1 | -7977 |
| CDK13 | -8392 |
| CCT2 | -8825 |
| PPIE | -9002 |
| CRACR2A | -9069 |
| TMEM63A | -9137 |
| CEP290 | -9182 |
| ENPP4 | -9583 |
| IMPDH2 | -9916 |
| ORMDL3 | -9997 |
| ATAD3B | -10079 |
| ACTR1B | -10514 |
| TMC6 | -10606 |
| DSN1 | -10773 |
| ITGAL | -10847 |
| HSPA8 | -10922 |
| SPTAN1 | -11426 |
| FRMPD3 | -11469 |
| NIT2 | -11695 |
| RAB37 | -11793 |
| CLEC4C | -11809 |
| HMOX2 | -11819 |
| ATP8A1 | -11842 |
| TBC1D10C | -11861 |
| CD47 | -12114 |
| C3 | -12262 |
| RHOF | -12344 |
GRB2:SOS provides linkage to MAPK signaling for Integrins
| 435 | |
|---|---|
| set | GRB2:SOS provides linkage to MAPK signaling for Integrins |
| setSize | 12 |
| pANOVA | 0.000497 |
| s.dist | 0.58 |
| p.adjustANOVA | 0.00229 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SOS1 | -5700 |
| SRC | -8820 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PTK2 | 4462 |
| RAP1B | 3206 |
| SOS1 | -5700 |
| SRC | -8820 |
PD-1 signaling
| 780 | |
|---|---|
| set | PD-1 signaling |
| setSize | 28 |
| pANOVA | 1.11e-07 |
| s.dist | -0.579 |
| p.adjustANOVA | 1.87e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| CD274 | -7563 |
| TRAV8-4 | -7261 |
| PDCD1 | -6792 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| CD274 | -7563 |
| TRAV8-4 | -7261 |
| PDCD1 | -6792 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PDCD1LG2 | -3326 |
| CSK | 5219 |
| PTPN11 | 5314 |
| PTPN6 | 6096 |
Insulin receptor recycling
| 541 | |
|---|---|
| set | Insulin receptor recycling |
| setSize | 21 |
| pANOVA | 6.43e-06 |
| s.dist | 0.569 |
| p.adjustANOVA | 5.7e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| INSR | 8282 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| TCIRG1 | 7188 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| ATP6V0E2 | -11555 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| INSR | 8282 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| TCIRG1 | 7188 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| ATP6V0E2 | -11555 |
| ATP6V0A2 | -12211 |
Dissolution of Fibrin Clot
| 302 | |
|---|---|
| set | Dissolution of Fibrin Clot |
| setSize | 12 |
| pANOVA | 0.00067 |
| s.dist | 0.567 |
| p.adjustANOVA | 0.00293 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SERPINB2 | 9438 |
| SERPINB8 | 9205 |
| ANXA2 | 8544 |
| PLAUR | 8424 |
| SERPINE1 | 7483 |
| S100A10 | 6860 |
| SERPINE2 | 6451 |
| SERPINB6 | 5854 |
| PLAU | 4903 |
| PLAT | -1242 |
| PLG | -1977 |
| SERPINF2 | -6574 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SERPINB2 | 9438 |
| SERPINB8 | 9205 |
| ANXA2 | 8544 |
| PLAUR | 8424 |
| SERPINE1 | 7483 |
| S100A10 | 6860 |
| SERPINE2 | 6451 |
| SERPINB6 | 5854 |
| PLAU | 4903 |
| PLAT | -1242 |
| PLG | -1977 |
| SERPINF2 | -6574 |
Retrograde neurotrophin signalling
| 1013 | |
|---|---|
| set | Retrograde neurotrophin signalling |
| setSize | 12 |
| pANOVA | 0.000674 |
| s.dist | 0.567 |
| p.adjustANOVA | 0.00293 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| DNM3 | 7045 |
| AP2A1 | 6832 |
| DNM2 | 6089 |
| DNM1 | 3587 |
| DNAL4 | 3398 |
| AP2B1 | -2709 |
| NTRK1 | -8193 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| DNM3 | 7045 |
| AP2A1 | 6832 |
| DNM2 | 6089 |
| DNM1 | 3587 |
| DNAL4 | 3398 |
| AP2B1 | -2709 |
| NTRK1 | -8193 |
Signaling by Leptin
| 1106 | |
|---|---|
| set | Signaling by Leptin |
| setSize | 10 |
| pANOVA | 0.00197 |
| s.dist | 0.565 |
| p.adjustANOVA | 0.00707 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SOCS3 | 9476 |
| IRS2 | 8569 |
| STAT3 | 8098 |
| STAT5A | 6965 |
| STAT5B | 6925 |
| LEPR | 6485 |
| PTPN11 | 5314 |
| JAK2 | 2691 |
| IRS1 | 1741 |
| SH2B1 | -8670 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SOCS3 | 9476 |
| IRS2 | 8569 |
| STAT3 | 8098 |
| STAT5A | 6965 |
| STAT5B | 6925 |
| LEPR | 6485 |
| PTPN11 | 5314 |
| JAK2 | 2691 |
| IRS1 | 1741 |
| SH2B1 | -8670 |
COPI-independent Golgi-to-ER retrograde traffic
| 133 | |
|---|---|
| set | COPI-independent Golgi-to-ER retrograde traffic |
| setSize | 33 |
| pANOVA | 2.11e-08 |
| s.dist | 0.563 |
| p.adjustANOVA | 4.24e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| DCTN2 | 9157 |
| GALNT2 | 8843 |
| BICD2 | 8746 |
| CAPZA2 | 8597 |
| DCTN4 | 8387 |
| RAB6A | 8148 |
| CAPZA1 | 8135 |
| CAPZB | 8015 |
| RAB18 | 7801 |
| DYNC1I2 | 7735 |
| ACTR10 | 7605 |
| DCTN6 | 7300 |
| ACTR1A | 7002 |
| PAFAH1B2 | 6942 |
| DYNC1LI1 | 6941 |
| GALNT1 | 6508 |
| RAB6B | 6053 |
| DCTN3 | 5994 |
| DYNLL1 | 5952 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| DCTN2 | 9157 |
| GALNT2 | 8843 |
| BICD2 | 8746 |
| CAPZA2 | 8597 |
| DCTN4 | 8387 |
| RAB6A | 8148 |
| CAPZA1 | 8135 |
| CAPZB | 8015 |
| RAB18 | 7801 |
| DYNC1I2 | 7735 |
| ACTR10 | 7605 |
| DCTN6 | 7300 |
| ACTR1A | 7002 |
| PAFAH1B2 | 6942 |
| DYNC1LI1 | 6941 |
| GALNT1 | 6508 |
| RAB6B | 6053 |
| DCTN3 | 5994 |
| DYNLL1 | 5952 |
| RAB3GAP1 | 5768 |
| PAFAH1B1 | 5470 |
| DCTN1 | 5078 |
| AGPAT3 | 4809 |
| RAB3GAP2 | 4429 |
| PAFAH1B3 | 4417 |
| DYNC1LI2 | 4273 |
| DYNC1I1 | 4187 |
| DYNLL2 | -3980 |
| DCTN5 | -4086 |
| BICD1 | -7365 |
| DYNC1H1 | -7685 |
| PLA2G6 | -12122 |
Detoxification of Reactive Oxygen Species
| 279 | |
|---|---|
| set | Detoxification of Reactive Oxygen Species |
| setSize | 32 |
| pANOVA | 3.64e-08 |
| s.dist | 0.562 |
| p.adjustANOVA | 6.9e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PRDX3 | 9366 |
| GPX1 | 9314 |
| NCF4 | 9268 |
| GSR | 9235 |
| NCF2 | 9190 |
| CAT | 9123 |
| CYBB | 9031 |
| ERO1A | 8943 |
| PRDX6 | 8937 |
| PRDX5 | 8531 |
| P4HB | 8440 |
| TXN | 8285 |
| TXNRD1 | 8192 |
| TXNRD2 | 7526 |
| NCF1 | 7334 |
| PRDX1 | 7030 |
| CYBA | 6922 |
| TXN2 | 4651 |
| SOD2 | 4390 |
| ATOX1 | 4338 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PRDX3 | 9366 |
| GPX1 | 9314 |
| NCF4 | 9268 |
| GSR | 9235 |
| NCF2 | 9190 |
| CAT | 9123 |
| CYBB | 9031 |
| ERO1A | 8943 |
| PRDX6 | 8937 |
| PRDX5 | 8531 |
| P4HB | 8440 |
| TXN | 8285 |
| TXNRD1 | 8192 |
| TXNRD2 | 7526 |
| NCF1 | 7334 |
| PRDX1 | 7030 |
| CYBA | 6922 |
| TXN2 | 4651 |
| SOD2 | 4390 |
| ATOX1 | 4338 |
| PRDX2 | 3428 |
| NUDT2 | 2988 |
| CCS | 1538 |
| NOX5 | 1175 |
| NOX4 | 1114 |
| ATP7A | 694 |
| GPX3 | 680 |
| GSTP1 | 135 |
| CYCS | -1334 |
| GPX2 | -3533 |
| SOD1 | -4862 |
| GPX7 | -8901 |
RHO GTPases Activate NADPH Oxidases
| 888 | |
|---|---|
| set | RHO GTPases Activate NADPH Oxidases |
| setSize | 21 |
| pANOVA | 9.01e-06 |
| s.dist | 0.56 |
| p.adjustANOVA | 7.33e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| NCF4 | 9268 |
| NCF2 | 9190 |
| MAPK14 | 9104 |
| CYBB | 9031 |
| PRKCD | 9008 |
| MAPK3 | 8953 |
| RAC1 | 8793 |
| MAPK1 | 7493 |
| NCF1 | 7334 |
| PRKCB | 7097 |
| CYBA | 6922 |
| RAC2 | 5163 |
| MAPK11 | 3826 |
| PIK3C3 | 1619 |
| PRKCA | 1132 |
| PIN1 | -3188 |
| PIK3R4 | -4062 |
| NOXA1 | -5464 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| NCF4 | 9268 |
| NCF2 | 9190 |
| MAPK14 | 9104 |
| CYBB | 9031 |
| PRKCD | 9008 |
| MAPK3 | 8953 |
| RAC1 | 8793 |
| MAPK1 | 7493 |
| NCF1 | 7334 |
| PRKCB | 7097 |
| CYBA | 6922 |
| RAC2 | 5163 |
| MAPK11 | 3826 |
| PIK3C3 | 1619 |
| PRKCA | 1132 |
| PIN1 | -3188 |
| PIK3R4 | -4062 |
| NOXA1 | -5464 |
| PRKCZ | -11629 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
| 802 | |
|---|---|
| set | PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases |
| setSize | 13 |
| pANOVA | 0.000515 |
| s.dist | 0.556 |
| p.adjustANOVA | 0.00235 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| RAC1 | 8793 |
| RHOA | 8319 |
| DOCK1 | 7314 |
| ELMO1 | 6258 |
| PXN | 6230 |
| PTK6 | 5956 |
| NRAS | 5363 |
| ELMO2 | 4397 |
| KRAS | 3702 |
| RASA1 | 2106 |
| ARHGAP35 | -3359 |
| HRAS | -3382 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CRK | 8906 |
| RAC1 | 8793 |
| RHOA | 8319 |
| DOCK1 | 7314 |
| ELMO1 | 6258 |
| PXN | 6230 |
| PTK6 | 5956 |
| NRAS | 5363 |
| ELMO2 | 4397 |
| KRAS | 3702 |
| RASA1 | 2106 |
| ARHGAP35 | -3359 |
| HRAS | -3382 |
Platelet sensitization by LDL
| 834 | |
|---|---|
| set | Platelet sensitization by LDL |
| setSize | 16 |
| pANOVA | 0.000128 |
| s.dist | 0.553 |
| p.adjustANOVA | 0.000708 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| FGR | 8478 |
| PPP2CA | 8234 |
| PECAM1 | 7855 |
| PPP2CB | 7712 |
| PPP2R5B | 6774 |
| PTPN6 | 6096 |
| PPP2R5A | 5897 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| LRP8 | 4568 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PPP2R5E | -680 |
| PPP2R5C | -11265 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| FGR | 8478 |
| PPP2CA | 8234 |
| PECAM1 | 7855 |
| PPP2CB | 7712 |
| PPP2R5B | 6774 |
| PTPN6 | 6096 |
| PPP2R5A | 5897 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| LRP8 | 4568 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PPP2R5E | -680 |
| PPP2R5C | -11265 |
Hyaluronan metabolism
| 505 | |
|---|---|
| set | Hyaluronan metabolism |
| setSize | 15 |
| pANOVA | 0.00022 |
| s.dist | 0.551 |
| p.adjustANOVA | 0.00113 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| ABCC5 | 2477 |
| HEXA | 1261 |
| HAS3 | -6197 |
| CEMIP | -7418 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHP1 | 9258 |
| HYAL2 | 9088 |
| LYVE1 | 8999 |
| HEXB | 8776 |
| CD44 | 8333 |
| SLC9A1 | 7969 |
| GUSB | 7723 |
| STAB2 | 5569 |
| HYAL3 | 5229 |
| HYAL1 | 4164 |
| HMMR | 3808 |
| ABCC5 | 2477 |
| HEXA | 1261 |
| HAS3 | -6197 |
| CEMIP | -7418 |
Golgi Cisternae Pericentriolar Stack Reorganization
| 469 | |
|---|---|
| set | Golgi Cisternae Pericentriolar Stack Reorganization |
| setSize | 14 |
| pANOVA | 0.000365 |
| s.dist | 0.55 |
| p.adjustANOVA | 0.00175 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAB1A | 9052 |
| MAPK3 | 8953 |
| RAB2A | 8604 |
| RAB1B | 8313 |
| MAPK1 | 7493 |
| GORASP1 | 6606 |
| GOLGA2 | 6203 |
| USO1 | 4154 |
| CCNB2 | 3683 |
| BLZF1 | 3281 |
| PLK1 | 3002 |
| CDK1 | 1540 |
| CCNB1 | 467 |
| GORASP2 | -7034 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RAB1A | 9052 |
| MAPK3 | 8953 |
| RAB2A | 8604 |
| RAB1B | 8313 |
| MAPK1 | 7493 |
| GORASP1 | 6606 |
| GOLGA2 | 6203 |
| USO1 | 4154 |
| CCNB2 | 3683 |
| BLZF1 | 3281 |
| PLK1 | 3002 |
| CDK1 | 1540 |
| CCNB1 | 467 |
| GORASP2 | -7034 |
RHO GTPases Activate ROCKs
| 889 | |
|---|---|
| set | RHO GTPases Activate ROCKs |
| setSize | 18 |
| pANOVA | 6.85e-05 |
| s.dist | 0.542 |
| p.adjustANOVA | 0.00042 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MYL6 | 8576 |
| RHOA | 8319 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| MYL9 | 7703 |
| ROCK1 | 7489 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| ROCK2 | 6138 |
| PPP1R12A | 6050 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| RHOB | 1254 |
| MYH10 | 653 |
| MYH11 | -3522 |
| RHOC | -11360 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MYL6 | 8576 |
| RHOA | 8319 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| MYL9 | 7703 |
| ROCK1 | 7489 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| ROCK2 | 6138 |
| PPP1R12A | 6050 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| RHOB | 1254 |
| MYH10 | 653 |
| MYH11 | -3522 |
| RHOC | -11360 |
Phosphorylation of CD3 and TCR zeta chains
| 822 | |
|---|---|
| set | Phosphorylation of CD3 and TCR zeta chains |
| setSize | 27 |
| pANOVA | 1.38e-06 |
| s.dist | -0.537 |
| p.adjustANOVA | 1.62e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| LCK | -11838 |
| CD3G | -11526 |
| TRAC | -11482 |
| CD3D | -11401 |
| CD3E | -11302 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PTPN22 | -1208 |
| PTPRC | 2240 |
| CSK | 5219 |
| PAG1 | 5268 |
| PTPRJ | 7783 |
Diseases associated with the TLR signaling cascade
| 289 | |
|---|---|
| set | Diseases associated with the TLR signaling cascade |
| setSize | 23 |
| pANOVA | 8.79e-06 |
| s.dist | 0.535 |
| p.adjustANOVA | 7.23e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
| IKBKB | -5386 |
| TRAF3 | -5576 |
| TLR3 | -11525 |
Diseases of Immune System
| 291 | |
|---|---|
| set | Diseases of Immune System |
| setSize | 23 |
| pANOVA | 8.79e-06 |
| s.dist | 0.535 |
| p.adjustANOVA | 7.23e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD36 | 9444 |
| TLR5 | 9201 |
| TLR2 | 9103 |
| CD14 | 9097 |
| TLR4 | 9016 |
| TLR1 | 8932 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MYD88 | 8136 |
| CHUK | 7966 |
| BTK | 7206 |
| NFKBIA | 6807 |
| TICAM1 | 6307 |
| NFKB1 | 6277 |
| TIRAP | 5640 |
| IKBKG | 5377 |
| UNC93B1 | 4170 |
| NFKB2 | -1165 |
| RELA | -1803 |
| TLR10 | -2961 |
| IKBKB | -5386 |
| TRAF3 | -5576 |
| TLR3 | -11525 |
IRAK1 recruits IKK complex
| 510 | |
|---|---|
| set | IRAK1 recruits IKK complex |
| setSize | 10 |
| pANOVA | 0.00346 |
| s.dist | 0.534 |
| p.adjustANOVA | 0.0114 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
| 511 | |
|---|---|
| set | IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation |
| setSize | 10 |
| pANOVA | 0.00346 |
| s.dist | 0.534 |
| p.adjustANOVA | 0.0114 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PELI2 | 8314 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PELI1 | 6715 |
| IRAK1 | 6131 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| UBE2N | 1936 |
| TRAF6 | -229 |
| IKBKB | -5386 |
MET activates RAP1 and RAC1
| 621 | |
|---|---|
| set | MET activates RAP1 and RAC1 |
| setSize | 10 |
| pANOVA | 0.00366 |
| s.dist | 0.531 |
| p.adjustANOVA | 0.0119 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| CRK | 8906 |
| HGF | 8863 |
| RAC1 | 8793 |
| RAP1A | 7305 |
| GAB1 | 5679 |
| CRKL | 3966 |
| RAP1B | 3206 |
| DOCK7 | -2369 |
| RAPGEF1 | -9826 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| CRK | 8906 |
| HGF | 8863 |
| RAC1 | 8793 |
| RAP1A | 7305 |
| GAB1 | 5679 |
| CRKL | 3966 |
| RAP1B | 3206 |
| DOCK7 | -2369 |
| RAPGEF1 | -9826 |
NOTCH4 Activation and Transmission of Signal to the Nucleus
| 708 | |
|---|---|
| set | NOTCH4 Activation and Transmission of Signal to the Nucleus |
| setSize | 10 |
| pANOVA | 0.00385 |
| s.dist | 0.528 |
| p.adjustANOVA | 0.0123 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NCSTN | 9186 |
| ADAM10 | 8791 |
| JAG1 | 8743 |
| PSEN1 | 7961 |
| APH1B | 6280 |
| PSENEN | 5735 |
| YWHAZ | 5624 |
| APH1A | 4133 |
| NOTCH4 | -5229 |
| PSEN2 | -7718 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NCSTN | 9186 |
| ADAM10 | 8791 |
| JAG1 | 8743 |
| PSEN1 | 7961 |
| APH1B | 6280 |
| PSENEN | 5735 |
| YWHAZ | 5624 |
| APH1A | 4133 |
| NOTCH4 | -5229 |
| PSEN2 | -7718 |
Negative regulation of MET activity
| 724 | |
|---|---|
| set | Negative regulation of MET activity |
| setSize | 18 |
| pANOVA | 0.000111 |
| s.dist | 0.526 |
| p.adjustANOVA | 0.000639 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| HGF | 8863 |
| PTPRJ | 7783 |
| SH3GL1 | 7625 |
| PTPN2 | 7615 |
| CBL | 7480 |
| UBB | 6639 |
| USP8 | 6418 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| PTPN1 | 5722 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| LRIG1 | -10389 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| HGF | 8863 |
| PTPRJ | 7783 |
| SH3GL1 | 7625 |
| PTPN2 | 7615 |
| CBL | 7480 |
| UBB | 6639 |
| USP8 | 6418 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| PTPN1 | 5722 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| LRIG1 | -10389 |
Budding and maturation of HIV virion
| 117 | |
|---|---|
| set | Budding and maturation of HIV virion |
| setSize | 26 |
| pANOVA | 3.45e-06 |
| s.dist | 0.526 |
| p.adjustANOVA | 3.41e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| NEDD4L | 7875 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| PDCD6IP | 6528 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| NEDD4L | 7875 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| PDCD6IP | 6528 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| CHMP4A | 2400 |
| UBA52 | 1121 |
| VPS4A | 784 |
| PPIA | -6766 |
| RPS27A | -6938 |
| CHMP7 | -8802 |
InlB-mediated entry of Listeria monocytogenes into host cell
| 536 | |
|---|---|
| set | InlB-mediated entry of Listeria monocytogenes into host cell |
| setSize | 12 |
| pANOVA | 0.00161 |
| s.dist | 0.526 |
| p.adjustANOVA | 0.00605 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SH3GL1 | 7625 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SH3GL1 | 7625 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| STAM | 1285 |
| UBA52 | 1121 |
| RPS27A | -6938 |
DNA strand elongation
| 247 | |
|---|---|
| set | DNA strand elongation |
| setSize | 32 |
| pANOVA | 3.21e-07 |
| s.dist | -0.522 |
| p.adjustANOVA | 4.92e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| MCM8 | -10944 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| GINS3 | -10508 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| GINS4 | -10236 |
| PRIM1 | -10191 |
| MCM6 | -9715 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| RFC1 | -7437 |
| MCM5 | -7292 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| MCM8 | -10944 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| GINS3 | -10508 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| GINS4 | -10236 |
| PRIM1 | -10191 |
| MCM6 | -9715 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| RFC1 | -7437 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PRIM2 | -5575 |
| GINS2 | -4815 |
| GINS1 | -4401 |
| DNA2 | -2858 |
| CDC45 | -2659 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLD4 | 6336 |
| POLD3 | 8885 |
Cargo concentration in the ER
| 147 | |
|---|---|
| set | Cargo concentration in the ER |
| setSize | 30 |
| pANOVA | 7.76e-07 |
| s.dist | 0.521 |
| p.adjustANOVA | 1.03e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| SERPINA1 | 9168 |
| CTSZ | 8975 |
| TGFA | 8889 |
| SEC24D | 8115 |
| CNIH1 | 7779 |
| SEC24A | 7660 |
| SEC23A | 7335 |
| STX5 | 7166 |
| MCFD2 | 7099 |
| LMAN2 | 7080 |
| F8 | 7022 |
| LMAN2L | 6937 |
| SAR1B | 6479 |
| PREB | 6368 |
| COL7A1 | 6304 |
| TMED2 | 6052 |
| AREG | 5977 |
| SEC22B | 5873 |
| CD59 | 5859 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| SERPINA1 | 9168 |
| CTSZ | 8975 |
| TGFA | 8889 |
| SEC24D | 8115 |
| CNIH1 | 7779 |
| SEC24A | 7660 |
| SEC23A | 7335 |
| STX5 | 7166 |
| MCFD2 | 7099 |
| LMAN2 | 7080 |
| F8 | 7022 |
| LMAN2L | 6937 |
| SAR1B | 6479 |
| PREB | 6368 |
| COL7A1 | 6304 |
| TMED2 | 6052 |
| AREG | 5977 |
| SEC22B | 5873 |
| CD59 | 5859 |
| MIA2 | 5574 |
| SEC24B | 3608 |
| CTSC | 2326 |
| CNIH2 | 654 |
| TMED10 | 323 |
| GOSR2 | -1456 |
| SEC24C | -2569 |
| MIA3 | -6245 |
| CNIH3 | -9011 |
| LMAN1 | -10630 |
Endosomal Sorting Complex Required For Transport (ESCRT)
| 341 | |
|---|---|
| set | Endosomal Sorting Complex Required For Transport (ESCRT) |
| setSize | 29 |
| pANOVA | 1.25e-06 |
| s.dist | 0.52 |
| p.adjustANOVA | 1.49e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| VPS25 | 7638 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| STAM2 | 6159 |
| SNF8 | 5973 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| HGS | 4513 |
| UBC | 4439 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CHMP4B | 8866 |
| CHMP2A | 8780 |
| UBAP1 | 8701 |
| CHMP3 | 8349 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| VPS25 | 7638 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| VTA1 | 6185 |
| STAM2 | 6159 |
| SNF8 | 5973 |
| CHMP2B | 5714 |
| CHMP6 | 5499 |
| VPS4B | 5212 |
| MVB12B | 5175 |
| CHMP5 | 4943 |
| HGS | 4513 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| CHMP4A | 2400 |
| STAM | 1285 |
| UBA52 | 1121 |
| VPS4A | 784 |
| VPS36 | -6848 |
| RPS27A | -6938 |
| CHMP7 | -8802 |
DNA methylation
| 246 | |
|---|---|
| set | DNA methylation |
| setSize | 20 |
| pANOVA | 6.16e-05 |
| s.dist | 0.517 |
| p.adjustANOVA | 0.000382 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| DNMT3B | 4294.0 |
| UHRF1 | 170.0 |
| H2AZ2 | -1209.0 |
| DNMT3A | -3039.0 |
| H2BU1 | -6555.0 |
| DNMT1 | -12257.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| DNMT3B | 4294.0 |
| UHRF1 | 170.0 |
| H2AZ2 | -1209.0 |
| DNMT3A | -3039.0 |
| H2BU1 | -6555.0 |
| DNMT1 | -12257.0 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models
| 278 | |
|---|---|
| set | Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models |
| setSize | 21 |
| pANOVA | 4.1e-05 |
| s.dist | 0.517 |
| p.adjustANOVA | 0.000274 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
| FASLG | -12371 |
Neurodegenerative Diseases
| 733 | |
|---|---|
| set | Neurodegenerative Diseases |
| setSize | 21 |
| pANOVA | 4.1e-05 |
| s.dist | 0.517 |
| p.adjustANOVA | 0.000274 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| LMNB1 | 9345 |
| APP | 9177 |
| YWHAE | 9045 |
| FOXO3 | 8682 |
| CDK5 | 8616 |
| CAPN1 | 8563 |
| CAST | 8164 |
| CAPNS1 | 7729 |
| BCL2L11 | 7384 |
| PRDX1 | 7030 |
| GOLGA2 | 6203 |
| CDC25C | 4969 |
| SOD2 | 4390 |
| LMNA | 3887 |
| JUN | 3722 |
| PRDX2 | 3428 |
| CDC25A | 2911 |
| CAPN2 | 1064 |
| CDK5R1 | -1089 |
| CDC25B | -12017 |
| FASLG | -12371 |
MAP2K and MAPK activation
| 612 | |
|---|---|
| set | MAP2K and MAPK activation |
| setSize | 34 |
| pANOVA | 1.81e-07 |
| s.dist | 0.517 |
| p.adjustANOVA | 2.91e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| LAMTOR3 | 7574 |
| LAMTOR2 | 7567 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| LAMTOR3 | 7574 |
| LAMTOR2 | 7567 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| WDR83 | 3718 |
| KRAS | 3702 |
| RAP1B | 3206 |
| ARAF | 2644 |
| ARRB1 | 1998 |
| BRAF | 1308 |
| KSR2 | -3361 |
| HRAS | -3382 |
| CNKSR2 | -4781 |
| CNKSR1 | -7089 |
| SRC | -8820 |
| PEBP1 | -11270 |
VLDLR internalisation and degradation
| 1312 | |
|---|---|
| set | VLDLR internalisation and degradation |
| setSize | 12 |
| pANOVA | 0.00216 |
| s.dist | 0.511 |
| p.adjustANOVA | 0.00759 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PCSK9 | 9208 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| NR1H2 | 7415 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| AP2B1 | -2709 |
| NR1H3 | -3597 |
| MYLIP | -3991 |
| VLDLR | -4385 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PCSK9 | 9208 |
| CLTC | 9000 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| NR1H2 | 7415 |
| AP2A2 | 7257 |
| AP2A1 | 6832 |
| AP2B1 | -2709 |
| NR1H3 | -3597 |
| MYLIP | -3991 |
| VLDLR | -4385 |
Transferrin endocytosis and recycling
| 1269 | |
|---|---|
| set | Transferrin endocytosis and recycling |
| setSize | 26 |
| pANOVA | 6.92e-06 |
| s.dist | 0.509 |
| p.adjustANOVA | 5.98e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| HFE | 8777 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MCOLN1 | 7740 |
| TCIRG1 | 7188 |
| STEAP3 | 5996 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| TFRC | 1524 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ATP6V0A1 | 9423 |
| ATP6V1A | 9302 |
| ATP6V0D1 | 9245 |
| ATP6V0C | 9127 |
| ATP6V1B2 | 9057 |
| ATP6V1D | 9047 |
| HFE | 8777 |
| ATP6V0B | 8598 |
| ATP6V0E1 | 8596 |
| ATP6V1C1 | 8539 |
| ATP6AP1 | 8160 |
| ATP6V1H | 8064 |
| ATP6V1E1 | 8035 |
| MCOLN1 | 7740 |
| TCIRG1 | 7188 |
| STEAP3 | 5996 |
| ATP6V1F | 5878 |
| ATP6V1E2 | 5730 |
| ATP6V1G1 | 3931 |
| TFRC | 1524 |
| TF | 1102 |
| ATP6V1C2 | -2219 |
| ATP6V1G2 | -9515 |
| TFR2 | -9789 |
| ATP6V0E2 | -11555 |
| ATP6V0A2 | -12211 |
EPHB-mediated forward signaling
| 326 | |
|---|---|
| set | EPHB-mediated forward signaling |
| setSize | 32 |
| pANOVA | 7.98e-07 |
| s.dist | 0.504 |
| p.adjustANOVA | 1.03e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITSN1 | 9289 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| RHOA | 8319 |
| ARPC3 | 8277 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| LYN | 7809 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| ROCK1 | 7489 |
| ARPC2 | 7390 |
| ROCK2 | 6138 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ITSN1 | 9289 |
| ARPC1B | 9259 |
| ACTB | 9011 |
| ARPC1A | 8894 |
| RAC1 | 8793 |
| ARPC5 | 8686 |
| ACTG1 | 8562 |
| RHOA | 8319 |
| ARPC3 | 8277 |
| PAK1 | 8230 |
| CFL1 | 8186 |
| LIMK2 | 8074 |
| ACTR2 | 7870 |
| ACTR3 | 7818 |
| LYN | 7809 |
| CDC42 | 7537 |
| ARPC4 | 7516 |
| ROCK1 | 7489 |
| ARPC2 | 7390 |
| ROCK2 | 6138 |
| SDC2 | 5397 |
| LIMK1 | 4679 |
| PTK2 | 4462 |
| RASA1 | 2106 |
| TIAM1 | 651 |
| WASL | 299 |
| HRAS | -3382 |
| KALRN | -3692 |
| SRC | -8820 |
| ARHGEF28 | -10288 |
| FYN | -11675 |
| YES1 | -12142 |
Gap junction trafficking
| 438 | |
|---|---|
| set | Gap junction trafficking |
| setSize | 14 |
| pANOVA | 0.00116 |
| s.dist | 0.501 |
| p.adjustANOVA | 0.00458 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| CLTCL1 | 8965 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| DAB2 | 8112 |
| GJD3 | 7996 |
| DNM2 | 6089 |
| CLTB | 6084 |
| GJB6 | 4761 |
| DNM1 | 3587 |
| GJC2 | 1083 |
| GJC1 | 518 |
| GJA3 | -4935 |
| MYO6 | -11410 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| CLTCL1 | 8965 |
| AP2M1 | 8627 |
| CLTA | 8376 |
| DAB2 | 8112 |
| GJD3 | 7996 |
| DNM2 | 6089 |
| CLTB | 6084 |
| GJB6 | 4761 |
| DNM1 | 3587 |
| GJC2 | 1083 |
| GJC1 | 518 |
| GJA3 | -4935 |
| MYO6 | -11410 |
Platelet Adhesion to exposed collagen
| 828 | |
|---|---|
| set | Platelet Adhesion to exposed collagen |
| setSize | 13 |
| pANOVA | 0.00176 |
| s.dist | 0.501 |
| p.adjustANOVA | 0.00649 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITGA1 | 8729 |
| FCER1G | 8131 |
| LYN | 7809 |
| GP9 | 7506 |
| GP1BB | 7470 |
| GP6 | 6818 |
| VWF | 6641 |
| GP1BA | 6279 |
| ITGA2 | 4168 |
| GP5 | 1295 |
| ITGB1 | -94 |
| ITGA10 | -322 |
| FYN | -11675 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ITGA1 | 8729 |
| FCER1G | 8131 |
| LYN | 7809 |
| GP9 | 7506 |
| GP1BB | 7470 |
| GP6 | 6818 |
| VWF | 6641 |
| GP1BA | 6279 |
| ITGA2 | 4168 |
| GP5 | 1295 |
| ITGB1 | -94 |
| ITGA10 | -322 |
| FYN | -11675 |
Signaling by high-kinase activity BRAF mutants
| 1144 | |
|---|---|
| set | Signaling by high-kinase activity BRAF mutants |
| setSize | 31 |
| pANOVA | 1.54e-06 |
| s.dist | 0.499 |
| p.adjustANOVA | 1.77e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| KRAS | 3702 |
| RAP1B | 3206 |
| ARAF | 2644 |
| ARRB1 | 1998 |
| BRAF | 1308 |
| KSR2 | -3361 |
| HRAS | -3382 |
| CNKSR2 | -4781 |
| CNKSR1 | -7089 |
| SRC | -8820 |
| PEBP1 | -11270 |
Smooth Muscle Contraction
| 1151 | |
|---|---|
| set | Smooth Muscle Contraction |
| setSize | 31 |
| pANOVA | 1.87e-06 |
| s.dist | 0.495 |
| p.adjustANOVA | 2.1e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| DYSF | 9464 |
| TPM4 | 9242 |
| ITGA1 | 8729 |
| MYL6 | 8576 |
| ANXA2 | 8544 |
| TLN1 | 8525 |
| PAK1 | 8230 |
| CALD1 | 8216 |
| PAK2 | 8185 |
| MYL6B | 8178 |
| TPM3 | 8051 |
| TPM1 | 8041 |
| ANXA1 | 7842 |
| MYL9 | 7703 |
| VCL | 7328 |
| ITGB5 | 6923 |
| MYL12A | 6899 |
| MYLK | 6618 |
| PXN | 6230 |
| MYL12B | 5088 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| DYSF | 9464 |
| TPM4 | 9242 |
| ITGA1 | 8729 |
| MYL6 | 8576 |
| ANXA2 | 8544 |
| TLN1 | 8525 |
| PAK1 | 8230 |
| CALD1 | 8216 |
| PAK2 | 8185 |
| MYL6B | 8178 |
| TPM3 | 8051 |
| TPM1 | 8041 |
| ANXA1 | 7842 |
| MYL9 | 7703 |
| VCL | 7328 |
| ITGB5 | 6923 |
| MYL12A | 6899 |
| MYLK | 6618 |
| PXN | 6230 |
| MYL12B | 5088 |
| MYL5 | 3273 |
| TRIM72 | 1879 |
| SORBS1 | 1475 |
| ANXA6 | 327 |
| ACTA2 | -429 |
| CALM1 | -2081 |
| MYH11 | -3522 |
| GUCY1B2 | -5054 |
| MYLPF | -8871 |
| TPM2 | -9185 |
| SORBS3 | -10978 |
Pentose phosphate pathway
| 808 | |
|---|---|
| set | Pentose phosphate pathway |
| setSize | 13 |
| pANOVA | 0.00226 |
| s.dist | 0.489 |
| p.adjustANOVA | 0.00794 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PGD | 9481 |
| TALDO1 | 9456 |
| PGM2 | 9344 |
| TKT | 9342 |
| G6PD | 9004 |
| DERA | 8500 |
| PGLS | 6079 |
| PRPS2 | 3562 |
| RPE | 2589 |
| RPIA | 1441 |
| SHPK | -2528 |
| RBKS | -3142 |
| PRPS1 | -12077 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PGD | 9481 |
| TALDO1 | 9456 |
| PGM2 | 9344 |
| TKT | 9342 |
| G6PD | 9004 |
| DERA | 8500 |
| PGLS | 6079 |
| PRPS2 | 3562 |
| RPE | 2589 |
| RPIA | 1441 |
| SHPK | -2528 |
| RBKS | -3142 |
| PRPS1 | -12077 |
RHO GTPases activate PAKs
| 894 | |
|---|---|
| set | RHO GTPases activate PAKs |
| setSize | 20 |
| pANOVA | 0.00017 |
| s.dist | 0.486 |
| p.adjustANOVA | 0.000902 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAC1 | 8793 |
| MYL6 | 8576 |
| PAK1 | 8230 |
| PAK2 | 8185 |
| MYL9 | 7703 |
| CDC42 | 7537 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| MYLK | 6618 |
| PPP1R12A | 6050 |
| CTTN | 5930 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| MYH10 | 653 |
| FLNA | 483 |
| CALM1 | -2081 |
| MYH11 | -3522 |
| PAK3 | -4184 |
| NF2 | -6540 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RAC1 | 8793 |
| MYL6 | 8576 |
| PAK1 | 8230 |
| PAK2 | 8185 |
| MYL9 | 7703 |
| CDC42 | 7537 |
| PPP1CB | 7064 |
| MYH9 | 6685 |
| MYLK | 6618 |
| PPP1R12A | 6050 |
| CTTN | 5930 |
| MYL12B | 5088 |
| LIMK1 | 4679 |
| PPP1R12B | 1775 |
| MYH10 | 653 |
| FLNA | 483 |
| CALM1 | -2081 |
| MYH11 | -3522 |
| PAK3 | -4184 |
| NF2 | -6540 |
RHO GTPases activate PKNs
| 895 | |
|---|---|
| set | RHO GTPases activate PKNs |
| setSize | 48 |
| pANOVA | 6.95e-09 |
| s.dist | 0.483 |
| p.adjustANOVA | 1.56e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| YWHAG | 9264.0 |
| H2BC12 | 9051.0 |
| YWHAE | 9045.0 |
| RAC1 | 8793.0 |
| H3-3A | 8661.0 |
| YWHAH | 8649.0 |
| MYL6 | 8576.0 |
| RHOA | 8319.0 |
| PAK1 | 8230.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| MYL9 | 7703.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| PPP1CB | 7064.0 |
| PPP1R14A | 6839.0 |
| H3C15 | 6699.5 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| YWHAG | 9264.0 |
| H2BC12 | 9051.0 |
| YWHAE | 9045.0 |
| RAC1 | 8793.0 |
| H3-3A | 8661.0 |
| YWHAH | 8649.0 |
| MYL6 | 8576.0 |
| RHOA | 8319.0 |
| PAK1 | 8230.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| MYL9 | 7703.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| PPP1CB | 7064.0 |
| PPP1R14A | 6839.0 |
| H3C15 | 6699.5 |
| MYH9 | 6685.0 |
| YWHAB | 6385.0 |
| PDPK1 | 6136.0 |
| PPP1R12A | 6050.0 |
| H2AZ1 | 6036.0 |
| YWHAZ | 5624.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| MYL12B | 5088.0 |
| H2AC20 | 4972.0 |
| CDC25C | 4969.0 |
| AR | 4840.0 |
| KLK2 | 3029.0 |
| PPP1R12B | 1775.0 |
| SFN | 1615.0 |
| RHOB | 1254.0 |
| NCOA2 | 1092.0 |
| MYH10 | 653.0 |
| PKN2 | 98.0 |
| H2AZ2 | -1209.0 |
| PKN1 | -2208.0 |
| MYH11 | -3522.0 |
| PKN3 | -3793.0 |
| H2BU1 | -6555.0 |
| YWHAQ | -7340.0 |
| KDM1A | -9430.0 |
| KDM4C | -10749.0 |
| RHOC | -11360.0 |
Amyloid fiber formation
| 70 | |
|---|---|
| set | Amyloid fiber formation |
| setSize | 51 |
| pANOVA | 2.44e-09 |
| s.dist | 0.483 |
| p.adjustANOVA | 5.64e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SNCA | 9354.0 |
| H2BC21 | 9283.0 |
| NCSTN | 9186.0 |
| APP | 9177.0 |
| FURIN | 9075.0 |
| H2BC12 | 9051.0 |
| ADAM10 | 8791.0 |
| GSN | 8749.0 |
| H3-3A | 8661.0 |
| SIAH2 | 8578.0 |
| TGFBI | 8211.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| LYZ | 7213.0 |
| TSPAN14 | 6971.0 |
| H3C15 | 6699.5 |
| UBB | 6639.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SNCA | 9354.0 |
| H2BC21 | 9283.0 |
| NCSTN | 9186.0 |
| APP | 9177.0 |
| FURIN | 9075.0 |
| H2BC12 | 9051.0 |
| ADAM10 | 8791.0 |
| GSN | 8749.0 |
| H3-3A | 8661.0 |
| SIAH2 | 8578.0 |
| TGFBI | 8211.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| LYZ | 7213.0 |
| TSPAN14 | 6971.0 |
| H3C15 | 6699.5 |
| UBB | 6639.0 |
| SORL1 | 6530.0 |
| LTF | 6306.0 |
| APH1B | 6280.0 |
| TSPAN33 | 6170.0 |
| H2AZ1 | 6036.0 |
| ITM2B | 5982.0 |
| PSENEN | 5735.0 |
| USP9X | 5464.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| UBC | 4439.0 |
| APH1A | 4133.0 |
| GGA3 | 3816.0 |
| BACE1 | 3609.0 |
| MFGE8 | 3534.0 |
| GGA1 | 2310.0 |
| CST3 | 2206.0 |
| UBA52 | 1121.0 |
| TSPAN5 | 1028.0 |
| NPPA | -584.0 |
| TSPAN15 | -1876.0 |
| CALB1 | -2832.0 |
| SIAH1 | -3000.0 |
| NAT8B | -3939.0 |
| H2BU1 | -6555.0 |
| GGA2 | -6587.0 |
| B2M | -6920.0 |
| RPS27A | -6938.0 |
| HSPG2 | -7779.0 |
| UBE2L6 | -11293.0 |
Activation of the pre-replicative complex
| 51 | |
|---|---|
| set | Activation of the pre-replicative complex |
| setSize | 32 |
| pANOVA | 2.43e-06 |
| s.dist | -0.481 |
| p.adjustANOVA | 2.63e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| POLE3 | -11581 |
| POLA2 | -11575 |
| MCM8 | -10944 |
| DBF4 | -10925 |
| ORC3 | -10713 |
| PRIM1 | -10191 |
| POLE2 | -9941 |
| ORC2 | -9922 |
| MCM6 | -9715 |
| ORC5 | -9479 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| CDC7 | -7855 |
| POLE | -7579 |
| MCM5 | -7292 |
| MCM2 | -7223 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MCM3 | -12200 |
| POLA1 | -12150 |
| MCM7 | -12129 |
| RPA1 | -12004 |
| POLE3 | -11581 |
| POLA2 | -11575 |
| MCM8 | -10944 |
| DBF4 | -10925 |
| ORC3 | -10713 |
| PRIM1 | -10191 |
| POLE2 | -9941 |
| ORC2 | -9922 |
| MCM6 | -9715 |
| ORC5 | -9479 |
| RPA3 | -8911 |
| MCM4 | -8701 |
| CDC7 | -7855 |
| POLE | -7579 |
| MCM5 | -7292 |
| MCM2 | -7223 |
| RPA2 | -6306 |
| PRIM2 | -5575 |
| CDK2 | -5006 |
| CDC45 | -2659 |
| ORC1 | -2520 |
| ORC4 | -2028 |
| CDT1 | -287 |
| MCM10 | 776 |
| ORC6 | 1184 |
| GMNN | 1422 |
| CDC6 | 2370 |
| POLE4 | 5518 |
SHC1 events in EGFR signaling
| 1033 | |
|---|---|
| set | SHC1 events in EGFR signaling |
| setSize | 12 |
| pANOVA | 0.00392 |
| s.dist | 0.481 |
| p.adjustANOVA | 0.0125 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| SHC1 | 4161 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| SHC1 | 4161 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS)
| 266 | |
|---|---|
| set | Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) |
| setSize | 12 |
| pANOVA | 0.00412 |
| s.dist | 0.478 |
| p.adjustANOVA | 0.013 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
Diseases of hemostasis
| 294 | |
|---|---|
| set | Diseases of hemostasis |
| setSize | 12 |
| pANOVA | 0.00412 |
| s.dist | 0.478 |
| p.adjustANOVA | 0.013 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| F12 | 9492 |
| TPST1 | 9251 |
| GP9 | 7506 |
| GP1BB | 7470 |
| F8 | 7022 |
| VWF | 6641 |
| GP1BA | 6279 |
| TPST2 | 5725 |
| GGCX | 5237 |
| GP5 | 1295 |
| KLKB1 | -9019 |
| SERPING1 | -11197 |
GRB2 events in EGFR signaling
| 433 | |
|---|---|
| set | GRB2 events in EGFR signaling |
| setSize | 11 |
| pANOVA | 0.00602 |
| s.dist | 0.478 |
| p.adjustANOVA | 0.0177 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| AREG | 5977 |
| NRAS | 5363 |
| HBEGF | 5013 |
| KRAS | 3702 |
| EPGN | 2662 |
| EREG | 1888 |
| HRAS | -3382 |
| SOS1 | -5700 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
| 347 | |
|---|---|
| set | Erythropoietin activates Phosphoinositide-3-kinase (PI3K) |
| setSize | 11 |
| pANOVA | 0.00619 |
| s.dist | 0.477 |
| p.adjustANOVA | 0.0181 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIK3CB | 9038 |
| IRS2 | 8569 |
| LYN | 7809 |
| EPOR | 7223 |
| PIK3CD | 6046 |
| GAB1 | 5679 |
| PIK3CA | 4629 |
| JAK2 | 2691 |
| PIK3CG | 1833 |
| PIK3R5 | -2304 |
| PIK3R1 | -9505 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PIK3CB | 9038 |
| IRS2 | 8569 |
| LYN | 7809 |
| EPOR | 7223 |
| PIK3CD | 6046 |
| GAB1 | 5679 |
| PIK3CA | 4629 |
| JAK2 | 2691 |
| PIK3CG | 1833 |
| PIK3R5 | -2304 |
| PIK3R1 | -9505 |
Platelet Aggregation (Plug Formation)
| 829 | |
|---|---|
| set | Platelet Aggregation (Plug Formation) |
| setSize | 28 |
| pANOVA | 1.27e-05 |
| s.dist | 0.477 |
| p.adjustANOVA | 1e-04 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| GP9 | 7506 |
| GP1BB | 7470 |
| RAP1A | 7305 |
| VWF | 6641 |
| GP1BA | 6279 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| GP9 | 7506 |
| GP1BB | 7470 |
| RAP1A | 7305 |
| VWF | 6641 |
| GP1BA | 6279 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
| MPL | 2634 |
| ADRA2A | 2271 |
| GP5 | 1295 |
| RAPGEF3 | -2911 |
| SOS1 | -5700 |
| RASGRP2 | -8529 |
| SRC | -8820 |
| RASGRP1 | -11974 |
Spry regulation of FGF signaling
| 1154 | |
|---|---|
| set | Spry regulation of FGF signaling |
| setSize | 16 |
| pANOVA | 0.000996 |
| s.dist | 0.475 |
| p.adjustANOVA | 0.00405 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| MAPK3 | 8953 |
| PPP2CA | 8234 |
| MKNK1 | 8170 |
| PPP2CB | 7712 |
| MAPK1 | 7493 |
| CBL | 7480 |
| UBB | 6639 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| BRAF | 1308 |
| UBA52 | 1121 |
| SPRY2 | -4603 |
| RPS27A | -6938 |
| SRC | -8820 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| MAPK3 | 8953 |
| PPP2CA | 8234 |
| MKNK1 | 8170 |
| PPP2CB | 7712 |
| MAPK1 | 7493 |
| CBL | 7480 |
| UBB | 6639 |
| PTPN11 | 5314 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| BRAF | 1308 |
| UBA52 | 1121 |
| SPRY2 | -4603 |
| RPS27A | -6938 |
| SRC | -8820 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
| 32 | |
|---|---|
| set | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| setSize | 22 |
| pANOVA | 0.000129 |
| s.dist | 0.472 |
| p.adjustANOVA | 0.000708 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| AR | 4840.0 |
| KLK2 | 3029.0 |
| NCOA2 | 1092.0 |
| H2AZ2 | -1209.0 |
| PKN1 | -2208.0 |
| H2BU1 | -6555.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374.0 |
| H2BC21 | 9283.0 |
| H2BC12 | 9051.0 |
| H3-3A | 8661.0 |
| H2BC5 | 8003.0 |
| H2AC6 | 7934.0 |
| H2BC11 | 7912.0 |
| H2BC4 | 7389.0 |
| H2BC17 | 7285.0 |
| H3C15 | 6699.5 |
| H2AZ1 | 6036.0 |
| H2BC9 | 5394.0 |
| H2BC15 | 5312.0 |
| H2AC20 | 4972.0 |
| AR | 4840.0 |
| KLK2 | 3029.0 |
| NCOA2 | 1092.0 |
| H2AZ2 | -1209.0 |
| PKN1 | -2208.0 |
| H2BU1 | -6555.0 |
| KDM1A | -9430.0 |
| KDM4C | -10749.0 |
Signaling by RAF1 mutants
| 1130 | |
|---|---|
| set | Signaling by RAF1 mutants |
| setSize | 34 |
| pANOVA | 1.94e-06 |
| s.dist | 0.472 |
| p.adjustANOVA | 2.16e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| MARK3 | 8697 |
| TLN1 | 8525 |
| ARRB2 | 8490 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| IQGAP1 | 8152 |
| RAF1 | 7879 |
| MAPK1 | 7493 |
| VCL | 7328 |
| RAP1A | 7305 |
| MAP2K2 | 6794 |
| VWF | 6641 |
| YWHAB | 6385 |
| NRAS | 5363 |
| CSK | 5219 |
| KSR1 | 4167 |
| KRAS | 3702 |
| RAP1B | 3206 |
| JAK2 | 2691 |
| ARAF | 2644 |
| ARRB1 | 1998 |
| CAMK2G | 1921 |
| BRAF | 1308 |
| CALM1 | -2081 |
| KSR2 | -3361 |
| HRAS | -3382 |
| CNKSR2 | -4781 |
| CNKSR1 | -7089 |
| SRC | -8820 |
| CAMK2D | -11816 |
Josephin domain DUBs
| 584 | |
|---|---|
| set | Josephin domain DUBs |
| setSize | 10 |
| pANOVA | 0.00989 |
| s.dist | 0.471 |
| p.adjustANOVA | 0.0261 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAD23B | 8886 |
| JOSD2 | 7931 |
| VCP | 6886 |
| UBB | 6639 |
| RAD23A | 6512 |
| UBC | 4439 |
| ATXN3 | 1601 |
| UBA52 | 1121 |
| JOSD1 | 227 |
| RPS27A | -6938 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RAD23B | 8886 |
| JOSD2 | 7931 |
| VCP | 6886 |
| UBB | 6639 |
| RAD23A | 6512 |
| UBC | 4439 |
| ATXN3 | 1601 |
| UBA52 | 1121 |
| JOSD1 | 227 |
| RPS27A | -6938 |
GAB1 signalosome
| 424 | |
|---|---|
| set | GAB1 signalosome |
| setSize | 15 |
| pANOVA | 0.00159 |
| s.dist | 0.471 |
| p.adjustANOVA | 0.00597 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PXN | 6230 |
| AREG | 5977 |
| GAB1 | 5679 |
| PTPN11 | 5314 |
| PAG1 | 5268 |
| CSK | 5219 |
| HBEGF | 5013 |
| PIK3CA | 4629 |
| EPGN | 2662 |
| EREG | 1888 |
| SRC | -8820 |
| PIK3R1 | -9505 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PXN | 6230 |
| AREG | 5977 |
| GAB1 | 5679 |
| PTPN11 | 5314 |
| PAG1 | 5268 |
| CSK | 5219 |
| HBEGF | 5013 |
| PIK3CA | 4629 |
| EPGN | 2662 |
| EREG | 1888 |
| SRC | -8820 |
| PIK3R1 | -9505 |
Trafficking of GluR2-containing AMPA receptors
| 1250 | |
|---|---|
| set | Trafficking of GluR2-containing AMPA receptors |
| setSize | 12 |
| pANOVA | 0.00479 |
| s.dist | 0.47 |
| p.adjustANOVA | 0.0148 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NSF | 8829 |
| AP2M1 | 8627 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| TSPAN7 | 6469 |
| PICK1 | 3594 |
| PRKCA | 1132 |
| GRIA4 | -97 |
| AP2B1 | -2709 |
| GRIP1 | -10411 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NSF | 8829 |
| AP2M1 | 8627 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| TSPAN7 | 6469 |
| PICK1 | 3594 |
| PRKCA | 1132 |
| GRIA4 | -97 |
| AP2B1 | -2709 |
| GRIP1 | -10411 |
Generation of second messenger molecules
| 446 | |
|---|---|
| set | Generation of second messenger molecules |
| setSize | 38 |
| pANOVA | 7.2e-07 |
| s.dist | -0.464 |
| p.adjustANOVA | 9.74e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| EVL | -12207 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| LAT | -11694 |
| CD3G | -11526 |
| TRAC | -11482 |
| NCK1 | -11454 |
| CD3D | -11401 |
| CD3E | -11302 |
| ITK | -11223 |
| PLCG1 | -11120 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD247 | -12345 |
| HLA-DPA1 | -12316 |
| HLA-DPB1 | -12248 |
| EVL | -12207 |
| HLA-DRA | -12009 |
| TRBC1 | -12006 |
| HLA-DQA1 | -11992 |
| ZAP70 | -11949 |
| LCK | -11838 |
| LAT | -11694 |
| CD3G | -11526 |
| TRAC | -11482 |
| NCK1 | -11454 |
| CD3D | -11401 |
| CD3E | -11302 |
| ITK | -11223 |
| PLCG1 | -11120 |
| TRBV12-3 | -10436 |
| TRAV19 | -9915 |
| TRAV29DV5 | -9673 |
| TRBV7-9 | -9539 |
| HLA-DQB2 | -9401 |
| HLA-DRB1 | -8075 |
| TRAV8-4 | -7261 |
| HLA-DQB1 | -6416 |
| CD4 | -5406 |
| HLA-DRB5 | -4971 |
| HLA-DQA2 | -4806 |
| PAK3 | -4184 |
| ENAH | -2707 |
| LCP2 | -1156 |
| CD101 | 4146 |
| GRAP2 | 4690 |
| PLCG2 | 5006 |
| VASP | 8027 |
| PAK2 | 8185 |
| PAK1 | 8230 |
| WAS | 8560 |
EGFR downregulation
| 320 | |
|---|---|
| set | EGFR downregulation |
| setSize | 27 |
| pANOVA | 3.34e-05 |
| s.dist | 0.461 |
| p.adjustANOVA | 0.000228 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PTPN12 | 8151 |
| EPN1 | 8045 |
| SH3GL1 | 7625 |
| CDC42 | 7537 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| AREG | 5977 |
| HBEGF | 5013 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| EPS15L1 | 3655 |
| EPGN | 2662 |
| SPRY1 | 2302 |
| EREG | 1888 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| TGFA | 8889 |
| EGF | 8179 |
| PTPN12 | 8151 |
| EPN1 | 8045 |
| SH3GL1 | 7625 |
| CDC42 | 7537 |
| CBL | 7480 |
| UBB | 6639 |
| SH3KBP1 | 6173 |
| STAM2 | 6159 |
| AREG | 5977 |
| HBEGF | 5013 |
| HGS | 4513 |
| UBC | 4439 |
| EPS15 | 4138 |
| EPS15L1 | 3655 |
| EPGN | 2662 |
| SPRY1 | 2302 |
| EREG | 1888 |
| STAM | 1285 |
| UBA52 | 1121 |
| PTPN3 | -85 |
| ARHGEF7 | -4583 |
| SPRY2 | -4603 |
| RPS27A | -6938 |
| PTPRK | -7262 |
Response of Mtb to phagocytosis
| 1010 | |
|---|---|
| set | Response of Mtb to phagocytosis |
| setSize | 22 |
| pANOVA | 0.000191 |
| s.dist | 0.459 |
| p.adjustANOVA | 0.00099 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
| UBA52 | 1121 |
| VPS33B | -2091 |
| DUSP16 | -6655 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
| UBA52 | 1121 |
| VPS33B | -2091 |
| DUSP16 | -6655 |
| RPS27A | -6938 |
| RNF213 | -11905 |
Antimicrobial peptides
| 77 | |
|---|---|
| set | Antimicrobial peptides |
| setSize | 33 |
| pANOVA | 4.93e-06 |
| s.dist | 0.459 |
| p.adjustANOVA | 4.52e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CCR2 | 9449 |
| CLU | 9371 |
| SLC11A1 | 9169 |
| TLR2 | 9103 |
| TLR1 | 8932 |
| PGLYRP1 | 7910 |
| LCN2 | 7755 |
| RNASE3 | 7471 |
| ELANE | 7320 |
| LYZ | 7213 |
| RNASE6 | 6837 |
| PRTN3 | 6762 |
| BPI | 6666 |
| LTF | 6306 |
| DEFA1 | 6061 |
| DEFA4 | 6057 |
| DEFA3 | 5385 |
| CTSG | 5115 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A9 | 9516 |
| S100A8 | 9503 |
| CCR2 | 9449 |
| CLU | 9371 |
| SLC11A1 | 9169 |
| TLR2 | 9103 |
| TLR1 | 8932 |
| PGLYRP1 | 7910 |
| LCN2 | 7755 |
| RNASE3 | 7471 |
| ELANE | 7320 |
| LYZ | 7213 |
| RNASE6 | 6837 |
| PRTN3 | 6762 |
| BPI | 6666 |
| LTF | 6306 |
| DEFA1 | 6061 |
| DEFA4 | 6057 |
| DEFA3 | 5385 |
| CTSG | 5115 |
| CAMP | 4785 |
| ATOX1 | 4338 |
| PI3 | 3023 |
| EPPIN | 2251 |
| ATP7A | 694 |
| PGLYRP2 | -2281 |
| HTN1 | -3453 |
| LEAP2 | -4703 |
| CD4 | -5406 |
| PDZD11 | -6288 |
| ITLN1 | -6873 |
| CCR6 | -7862 |
| GNLY | -11428 |
The NLRP3 inflammasome
| 1228 | |
|---|---|
| set | The NLRP3 inflammasome |
| setSize | 15 |
| pANOVA | 0.00213 |
| s.dist | 0.458 |
| p.adjustANOVA | 0.00751 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| APP | 9177 |
| NLRP3 | 8901 |
| PYCARD | 8638 |
| MEFV | 8605 |
| TXN | 8285 |
| PSTPIP1 | 7841 |
| NFKB1 | 6277 |
| PANX1 | 6267 |
| CASP1 | 4224 |
| P2RX7 | 3475 |
| SUGT1 | 1544 |
| NFKB2 | -1165 |
| RELA | -1803 |
| HSP90AB1 | -6863 |
| TXNIP | -9600 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| APP | 9177 |
| NLRP3 | 8901 |
| PYCARD | 8638 |
| MEFV | 8605 |
| TXN | 8285 |
| PSTPIP1 | 7841 |
| NFKB1 | 6277 |
| PANX1 | 6267 |
| CASP1 | 4224 |
| P2RX7 | 3475 |
| SUGT1 | 1544 |
| NFKB2 | -1165 |
| RELA | -1803 |
| HSP90AB1 | -6863 |
| TXNIP | -9600 |
Integrin signaling
| 545 | |
|---|---|
| set | Integrin signaling |
| setSize | 22 |
| pANOVA | 0.000208 |
| s.dist | 0.457 |
| p.adjustANOVA | 0.00108 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
| RAPGEF3 | -2911 |
| SOS1 | -5700 |
| RASGRP2 | -8529 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GRB2 | 9304 |
| SYK | 9076 |
| CRK | 8906 |
| ITGA2B | 8893 |
| APBB1IP | 8744 |
| TLN1 | 8525 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| RAP1A | 7305 |
| VWF | 6641 |
| PDPK1 | 6136 |
| PTPN1 | 5722 |
| CSK | 5219 |
| PTK2 | 4462 |
| SHC1 | 4161 |
| AKT1 | 3614 |
| RAP1B | 3206 |
| RAPGEF3 | -2911 |
| SOS1 | -5700 |
| RASGRP2 | -8529 |
| SRC | -8820 |
| RASGRP1 | -11974 |
Response to elevated platelet cytosolic Ca2+
| 1011 | |
|---|---|
| set | Response to elevated platelet cytosolic Ca2+ |
| setSize | 110 |
| pANOVA | 1.25e-16 |
| s.dist | 0.457 |
| p.adjustANOVA | 1.22e-14 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
| SRGN | 8761 |
| TIMP1 | 8677 |
| TLN1 | 8525 |
| CLEC3B | 8480 |
| SELP | 8457 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| SYTL4 | 8256 |
| ANXA5 | 8210 |
| CFL1 | 8186 |
| EGF | 8179 |
| CAP1 | 8111 |
| GAS6 | 8063 |
| LY6G6F | 8023 |
| ORM1 | 7971 |
| CALU | 7894 |
| PECAM1 | 7855 |
| SCCPDH | 7787 |
| PROS1 | 7758 |
| MMRN1 | 7714 |
| SERPINE1 | 7483 |
| VEGFA | 7467 |
| ABCC4 | 7434 |
| STXBP3 | 7424 |
| TAGLN2 | 7367 |
| SPARC | 7339 |
| VCL | 7328 |
| PSAP | 7145 |
| PRKCB | 7097 |
| HSPA5 | 7029 |
| F8 | 7022 |
| WDR1 | 6976 |
| VEGFC | 6906 |
| VWF | 6641 |
| TUBA4A | 6484 |
| GTPBP2 | 6331 |
| TMSB4X | 6295 |
| PPBP | 6042 |
| THBS1 | 5951 |
| CD9 | 5940 |
| PF4 | 5707 |
| A1BG | 5559 |
| PFN1 | 5459 |
| PHACTR2 | 5410 |
| PDGFA | 5293 |
| ECM1 | 5176 |
| TGFB1 | 5153 |
| ACTN4 | 5049 |
| OLA1 | 4914 |
| CD109 | 4316 |
| ALB | 3668 |
| RAB27B | 3386 |
| ENDOD1 | 3361 |
| TIMP3 | 3296 |
| CHID1 | 2811 |
| MANF | 2550 |
| PLEK | 1999 |
| CFD | 1984 |
| APOOL | 1609 |
| TTN | 1195 |
| PRKCA | 1132 |
| TF | 1102 |
| STX4 | 606 |
| FLNA | 483 |
| TMX3 | -775 |
| PLG | -1977 |
| PCYOX1L | -2009 |
| CALM1 | -2081 |
| ORM2 | -2564 |
| MAGED2 | -2687 |
| ITIH3 | -3017 |
| SOD1 | -4862 |
| ITIH4 | -6208 |
| SERPINF2 | -6574 |
| BRPF3 | -6615 |
| PPIA | -6766 |
| TGFB2 | -7492 |
| SELENOP | -7771 |
| NHLRC2 | -7835 |
| TGFB3 | -7891 |
| VEGFB | -7929 |
| TEX264 | -8366 |
| CDC37L1 | -8470 |
| PDGFB | -8577 |
| A2M | -9870 |
| FAM3C | -10062 |
| HABP4 | -10921 |
| CTSW | -11117 |
| SERPING1 | -11197 |
| LGALS3BP | -11459 |
activated TAK1 mediates p38 MAPK activation
| 1332 | |
|---|---|
| set | activated TAK1 mediates p38 MAPK activation |
| setSize | 19 |
| pANOVA | 0.000578 |
| s.dist | 0.456 |
| p.adjustANOVA | 0.0026 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK14 | 9104 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| TAB2 | 6964 |
| IRAK1 | 6131 |
| TAB1 | 5681 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| MAPKAPK2 | 4054 |
| MAPK11 | 3826 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBE2N | 1936 |
| RIPK2 | 1025 |
| TRAF6 | -229 |
| IRAK2 | -9548 |
| NOD1 | -12263 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAPK14 | 9104 |
| MAP2K6 | 8887 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| TAB2 | 6964 |
| IRAK1 | 6131 |
| TAB1 | 5681 |
| UBE2V1 | 5637 |
| IKBKG | 5377 |
| MAPKAPK2 | 4054 |
| MAPK11 | 3826 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBE2N | 1936 |
| RIPK2 | 1025 |
| TRAF6 | -229 |
| IRAK2 | -9548 |
| NOD1 | -12263 |
Mucopolysaccharidoses
| 684 | |
|---|---|
| set | Mucopolysaccharidoses |
| setSize | 11 |
| pANOVA | 0.00883 |
| s.dist | 0.456 |
| p.adjustANOVA | 0.0241 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNS | 9360 |
| GLB1 | 8725 |
| GUSB | 7723 |
| ARSB | 7572 |
| GALNS | 7102 |
| SGSH | 5912 |
| HYAL1 | 4164 |
| HGSNAT | 1867 |
| IDS | -2621 |
| NAGLU | -4761 |
| IDUA | -5830 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNS | 9360 |
| GLB1 | 8725 |
| GUSB | 7723 |
| ARSB | 7572 |
| GALNS | 7102 |
| SGSH | 5912 |
| HYAL1 | 4164 |
| HGSNAT | 1867 |
| IDS | -2621 |
| NAGLU | -4761 |
| IDUA | -5830 |
Platelet degranulation
| 832 | |
|---|---|
| set | Platelet degranulation |
| setSize | 106 |
| pANOVA | 5.81e-16 |
| s.dist | 0.455 |
| p.adjustANOVA | 5.29e-14 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| F5 | 9485 |
| CYB5R1 | 9460 |
| CD36 | 9444 |
| CLU | 9371 |
| APLP2 | 9347 |
| QSOX1 | 9298 |
| CD63 | 9287 |
| ALDOA | 9249 |
| LHFPL2 | 9224 |
| FERMT3 | 9223 |
| APP | 9177 |
| SERPINA1 | 9168 |
| ACTN1 | 9094 |
| STXBP2 | 9035 |
| ITGA2B | 8893 |
| F13A1 | 8876 |
| HGF | 8863 |
| TOR4A | 8861 |
| VTI1B | 8850 |
| LAMP2 | 8786 |
| SRGN | 8761 |
| TIMP1 | 8677 |
| TLN1 | 8525 |
| CLEC3B | 8480 |
| SELP | 8457 |
| ITGB3 | 8291 |
| FN1 | 8284 |
| SYTL4 | 8256 |
| ANXA5 | 8210 |
| CFL1 | 8186 |
| EGF | 8179 |
| CAP1 | 8111 |
| GAS6 | 8063 |
| LY6G6F | 8023 |
| ORM1 | 7971 |
| CALU | 7894 |
| PECAM1 | 7855 |
| SCCPDH | 7787 |
| PROS1 | 7758 |
| MMRN1 | 7714 |
| SERPINE1 | 7483 |
| VEGFA | 7467 |
| ABCC4 | 7434 |
| TAGLN2 | 7367 |
| SPARC | 7339 |
| VCL | 7328 |
| PSAP | 7145 |
| HSPA5 | 7029 |
| F8 | 7022 |
| WDR1 | 6976 |
| VEGFC | 6906 |
| VWF | 6641 |
| TUBA4A | 6484 |
| GTPBP2 | 6331 |
| TMSB4X | 6295 |
| PPBP | 6042 |
| THBS1 | 5951 |
| CD9 | 5940 |
| PF4 | 5707 |
| A1BG | 5559 |
| PFN1 | 5459 |
| PHACTR2 | 5410 |
| PDGFA | 5293 |
| ECM1 | 5176 |
| TGFB1 | 5153 |
| ACTN4 | 5049 |
| OLA1 | 4914 |
| CD109 | 4316 |
| ALB | 3668 |
| RAB27B | 3386 |
| ENDOD1 | 3361 |
| TIMP3 | 3296 |
| CHID1 | 2811 |
| MANF | 2550 |
| PLEK | 1999 |
| CFD | 1984 |
| APOOL | 1609 |
| TTN | 1195 |
| TF | 1102 |
| FLNA | 483 |
| TMX3 | -775 |
| PLG | -1977 |
| PCYOX1L | -2009 |
| CALM1 | -2081 |
| ORM2 | -2564 |
| MAGED2 | -2687 |
| ITIH3 | -3017 |
| SOD1 | -4862 |
| ITIH4 | -6208 |
| SERPINF2 | -6574 |
| BRPF3 | -6615 |
| PPIA | -6766 |
| TGFB2 | -7492 |
| SELENOP | -7771 |
| NHLRC2 | -7835 |
| TGFB3 | -7891 |
| VEGFB | -7929 |
| TEX264 | -8366 |
| CDC37L1 | -8470 |
| PDGFB | -8577 |
| A2M | -9870 |
| FAM3C | -10062 |
| HABP4 | -10921 |
| CTSW | -11117 |
| SERPING1 | -11197 |
| LGALS3BP | -11459 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
| 513 | |
|---|---|
| set | IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation |
| setSize | 15 |
| pANOVA | 0.0023 |
| s.dist | 0.455 |
| p.adjustANOVA | 0.00805 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CD14 | 9097 |
| TLR4 | 9016 |
| LY96 | 8795 |
| TAB2 | 6964 |
| UBB | 6639 |
| TICAM2 | 6335 |
| TICAM1 | 6307 |
| TAB1 | 5681 |
| UBC | 4439 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBA52 | 1121 |
| TRAF6 | -229 |
| RPS27A | -6938 |
| IRAK2 | -9548 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CD14 | 9097 |
| TLR4 | 9016 |
| LY96 | 8795 |
| TAB2 | 6964 |
| UBB | 6639 |
| TICAM2 | 6335 |
| TICAM1 | 6307 |
| TAB1 | 5681 |
| UBC | 4439 |
| TAB3 | 3160 |
| MAP3K7 | 2395 |
| UBA52 | 1121 |
| TRAF6 | -229 |
| RPS27A | -6938 |
| IRAK2 | -9548 |
Lagging Strand Synthesis
| 593 | |
|---|---|
| set | Lagging Strand Synthesis |
| setSize | 20 |
| pANOVA | 0.000463 |
| s.dist | -0.452 |
| p.adjustANOVA | 0.00215 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| POLA1 | -12150 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| PRIM1 | -10191 |
| RPA3 | -8911 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PRIM2 | -5575 |
| DNA2 | -2858 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLD4 | 6336 |
| POLD3 | 8885 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| POLA1 | -12150 |
| RPA1 | -12004 |
| RFC5 | -11712 |
| POLA2 | -11575 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| PRIM1 | -10191 |
| RPA3 | -8911 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PRIM2 | -5575 |
| DNA2 | -2858 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLD4 | 6336 |
| POLD3 | 8885 |
Prolonged ERK activation events
| 864 | |
|---|---|
| set | Prolonged ERK activation events |
| setSize | 13 |
| pANOVA | 0.00476 |
| s.dist | 0.452 |
| p.adjustANOVA | 0.0147 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| CRK | 8906 |
| MAPK1 | 7493 |
| RAP1A | 7305 |
| KIDINS220 | 7069 |
| MAP2K2 | 6794 |
| YWHAB | 6385 |
| CRKL | 3966 |
| BRAF | 1308 |
| FRS2 | -3433 |
| NTRK1 | -8193 |
| RAPGEF1 | -9826 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAP2K1 | 9063 |
| MAPK3 | 8953 |
| CRK | 8906 |
| MAPK1 | 7493 |
| RAP1A | 7305 |
| KIDINS220 | 7069 |
| MAP2K2 | 6794 |
| YWHAB | 6385 |
| CRKL | 3966 |
| BRAF | 1308 |
| FRS2 | -3433 |
| NTRK1 | -8193 |
| RAPGEF1 | -9826 |
Infection with Mycobacterium tuberculosis
| 525 | |
|---|---|
| set | Infection with Mycobacterium tuberculosis |
| setSize | 26 |
| pANOVA | 7.2e-05 |
| s.dist | 0.45 |
| p.adjustANOVA | 0.000439 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TLR2 | 9103 |
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| LTF | 6306 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| MRC1 | 3109 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TLR2 | 9103 |
| MAPK3 | 8953 |
| ENO1 | 8890 |
| RAB7A | 8742 |
| PGK1 | 8672 |
| TRIM27 | 8142 |
| ATP6V1H | 8064 |
| GSK3A | 7760 |
| MAPK1 | 7493 |
| RAB5A | 7103 |
| UBB | 6639 |
| LTF | 6306 |
| CORO1A | 5178 |
| CTSG | 5115 |
| HGS | 4513 |
| UBC | 4439 |
| MRC1 | 3109 |
| KPNB1 | 2430 |
| SFPQ | 2253 |
| KPNA1 | 1296 |
| UBA52 | 1121 |
| VPS33B | -2091 |
| DUSP16 | -6655 |
| B2M | -6920 |
| RPS27A | -6938 |
| RNF213 | -11905 |
WNT5A-dependent internalization of FZD4
| 1327 | |
|---|---|
| set | WNT5A-dependent internalization of FZD4 |
| setSize | 13 |
| pANOVA | 0.00502 |
| s.dist | 0.449 |
| p.adjustANOVA | 0.0153 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| ARRB2 | 8490 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| CLTB | 6084 |
| PRKCA | 1132 |
| AP2B1 | -2709 |
| DVL2 | -11152 |
| FZD4 | -11650 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CLTC | 9000 |
| AP2M1 | 8627 |
| ARRB2 | 8490 |
| CLTA | 8376 |
| AP2S1 | 8026 |
| AP2A2 | 7257 |
| PRKCB | 7097 |
| AP2A1 | 6832 |
| CLTB | 6084 |
| PRKCA | 1132 |
| AP2B1 | -2709 |
| DVL2 | -11152 |
| FZD4 | -11650 |
Packaging Of Telomere Ends
| 803 | |
|---|---|
| set | Packaging Of Telomere Ends |
| setSize | 20 |
| pANOVA | 0.000517 |
| s.dist | 0.448 |
| p.adjustANOVA | 0.00235 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374 |
| H2BC21 | 9283 |
| H2BC12 | 9051 |
| H2BC5 | 8003 |
| H2AC6 | 7934 |
| H2BC11 | 7912 |
| H2BC4 | 7389 |
| H2BC17 | 7285 |
| H2AZ1 | 6036 |
| H2BC9 | 5394 |
| H2BC15 | 5312 |
| TERF2IP | 5040 |
| H2AC20 | 4972 |
| TINF2 | 4592 |
| H2AZ2 | -1209 |
| TERF1 | -3601 |
| POT1 | -4355 |
| TERF2 | -4464 |
| H2BU1 | -6555 |
| ACD | -7800 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| H2AJ | 9374 |
| H2BC21 | 9283 |
| H2BC12 | 9051 |
| H2BC5 | 8003 |
| H2AC6 | 7934 |
| H2BC11 | 7912 |
| H2BC4 | 7389 |
| H2BC17 | 7285 |
| H2AZ1 | 6036 |
| H2BC9 | 5394 |
| H2BC15 | 5312 |
| TERF2IP | 5040 |
| H2AC20 | 4972 |
| TINF2 | 4592 |
| H2AZ2 | -1209 |
| TERF1 | -3601 |
| POT1 | -4355 |
| TERF2 | -4464 |
| H2BU1 | -6555 |
| ACD | -7800 |
ATF6 (ATF6-alpha) activates chaperone genes
| 20 | |
|---|---|
| set | ATF6 (ATF6-alpha) activates chaperone genes |
| setSize | 10 |
| pANOVA | 0.0144 |
| s.dist | 0.447 |
| p.adjustANOVA | 0.0352 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATF6 | 8464 |
| NFYC | 7653 |
| HSPA5 | 7029 |
| CALR | 6340 |
| ATF4 | 6237 |
| DDIT3 | 4906 |
| NFYA | 3506 |
| HSP90B1 | 2059 |
| XBP1 | -1579 |
| NFYB | -9964 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ATF6 | 8464 |
| NFYC | 7653 |
| HSPA5 | 7029 |
| CALR | 6340 |
| ATF4 | 6237 |
| DDIT3 | 4906 |
| NFYA | 3506 |
| HSP90B1 | 2059 |
| XBP1 | -1579 |
| NFYB | -9964 |
Membrane binding and targetting of GAG proteins
| 633 | |
|---|---|
| set | Membrane binding and targetting of GAG proteins |
| setSize | 13 |
| pANOVA | 0.0054 |
| s.dist | 0.446 |
| p.adjustANOVA | 0.0162 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins
| 1164 | |
|---|---|
| set | Synthesis And Processing Of GAG, GAGPOL Polyproteins |
| setSize | 13 |
| pANOVA | 0.0054 |
| s.dist | 0.446 |
| p.adjustANOVA | 0.0162 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| UBAP1 | 8701 |
| VPS37C | 8010 |
| TSG101 | 7786 |
| MVB12A | 7400 |
| UBB | 6639 |
| VPS37A | 6467 |
| MVB12B | 5175 |
| UBC | 4439 |
| VPS28 | 4199 |
| VPS37B | 3908 |
| UBA52 | 1121 |
| RPS27A | -6938 |
| NMT2 | -12035 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway
| 1000 | |
|---|---|
| set | Resolution of AP sites via the multiple-nucleotide patch replacement pathway |
| setSize | 24 |
| pANOVA | 0.000157 |
| s.dist | -0.446 |
| p.adjustANOVA | 0.000844 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PARP2 | -12221 |
| RPA1 | -12004 |
| PARP1 | -11764 |
| RFC5 | -11712 |
| POLE3 | -11581 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| APEX1 | -10332 |
| POLE2 | -9941 |
| RPA3 | -8911 |
| POLE | -7579 |
| POLB | -7537 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PARG | -658 |
| POLD1 | 204 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PARP2 | -12221 |
| RPA1 | -12004 |
| PARP1 | -11764 |
| RFC5 | -11712 |
| POLE3 | -11581 |
| LIG1 | -11053 |
| RFC4 | -10702 |
| FEN1 | -10593 |
| RFC3 | -10489 |
| POLD2 | -10351 |
| APEX1 | -10332 |
| POLE2 | -9941 |
| RPA3 | -8911 |
| POLE | -7579 |
| POLB | -7537 |
| RFC1 | -7437 |
| RPA2 | -6306 |
| PCNA | -5969 |
| PARG | -658 |
| POLD1 | 204 |
| RFC2 | 4948 |
| POLE4 | 5518 |
| POLD4 | 6336 |
| POLD3 | 8885 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
| 984 | |
|---|---|
| set | Regulation of glycolysis by fructose 2,6-bisphosphate metabolism |
| setSize | 11 |
| pANOVA | 0.0109 |
| s.dist | 0.443 |
| p.adjustANOVA | 0.0279 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PRKACA | 9429 |
| PFKFB4 | 9271 |
| PFKFB3 | 8656 |
| PPP2CA | 8234 |
| PFKFB2 | 7946 |
| PPP2CB | 7712 |
| PPP2R1A | 4589 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PFKFB1 | -8393 |
| PRKACB | -11959 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PRKACA | 9429 |
| PFKFB4 | 9271 |
| PFKFB3 | 8656 |
| PPP2CA | 8234 |
| PFKFB2 | 7946 |
| PPP2CB | 7712 |
| PPP2R1A | 4589 |
| PPP2R5D | 2421 |
| PPP2R1B | -241 |
| PFKFB1 | -8393 |
| PRKACB | -11959 |
Signal amplification
| 1072 | |
|---|---|
| set | Signal amplification |
| setSize | 28 |
| pANOVA | 5.41e-05 |
| s.dist | 0.441 |
| p.adjustANOVA | 0.000345 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNA15 | 9452 |
| GNG10 | 9349 |
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| GNAQ | 8993 |
| GNG5 | 8815 |
| GNB1 | 8294 |
| GNB2 | 8141 |
| GNAI2 | 8075 |
| GNAI3 | 7953 |
| P2RY1 | 7852 |
| GNB4 | 7336 |
| GNG11 | 6495 |
| GNA13 | 5836 |
| TBXA2R | 5148 |
| P2RY12 | 4821 |
| GNG8 | 4296 |
| GNAI1 | 3329 |
| GNA11 | 3259 |
| GNG3 | 890 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNA15 | 9452 |
| GNG10 | 9349 |
| PLA2G4A | 9180 |
| MAPK14 | 9104 |
| GNAQ | 8993 |
| GNG5 | 8815 |
| GNB1 | 8294 |
| GNB2 | 8141 |
| GNAI2 | 8075 |
| GNAI3 | 7953 |
| P2RY1 | 7852 |
| GNB4 | 7336 |
| GNG11 | 6495 |
| GNA13 | 5836 |
| TBXA2R | 5148 |
| P2RY12 | 4821 |
| GNG8 | 4296 |
| GNAI1 | 3329 |
| GNA11 | 3259 |
| GNG3 | 890 |
| GNB5 | 512 |
| GNG4 | -2154 |
| GNB3 | -2397 |
| AAMP | -3636 |
| GNG7 | -5198 |
| GNG2 | -7795 |
| SRC | -8820 |
| GNGT2 | -12086 |
Biotin transport and metabolism
| 114 | |
|---|---|
| set | Biotin transport and metabolism |
| setSize | 11 |
| pANOVA | 0.0116 |
| s.dist | -0.44 |
| p.adjustANOVA | 0.0291 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| BTD | -12170 |
| MCCC2 | -11857 |
| HLCS | -11710 |
| ACACB | -9957 |
| MCCC1 | -8976 |
| PCCA | -8664 |
| PCCB | -7976 |
| PDZD11 | -6288 |
| SLC5A6 | -5629 |
| ACACA | 5315 |
| PC | 9263 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| BTD | -12170 |
| MCCC2 | -11857 |
| HLCS | -11710 |
| ACACB | -9957 |
| MCCC1 | -8976 |
| PCCA | -8664 |
| PCCB | -7976 |
| PDZD11 | -6288 |
| SLC5A6 | -5629 |
| ACACA | 5315 |
| PC | 9263 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane
| 690 | |
|---|---|
| set | MyD88:MAL(TIRAP) cascade initiated on plasma membrane |
| setSize | 92 |
| pANOVA | 3.03e-13 |
| s.dist | 0.44 |
| p.adjustANOVA | 1.53e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| PPP2CA | 8234 |
| MYD88 | 8136 |
| MEF2A | 8009 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PPP2CB | 7712 |
| RPS6KA1 | 7695 |
| MAPK1 | 7493 |
| BTK | 7206 |
| TAB2 | 6964 |
| MAP2K4 | 6866 |
| NFKBIA | 6807 |
| PELI1 | 6715 |
| UBB | 6639 |
| NFKB1 | 6277 |
| FBXW11 | 6196 |
| MAP3K8 | 6160 |
| IRAK1 | 6131 |
| ATF1 | 5706 |
| TAB1 | 5681 |
| TIRAP | 5640 |
| UBE2V1 | 5637 |
| TNIP2 | 5552 |
| FOS | 5460 |
| IKBKG | 5377 |
| MAP3K1 | 5121 |
| ECSIT | 4918 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| DUSP6 | 4357 |
| MAPK10 | 4325 |
| SKP1 | 4287 |
| MAPKAPK2 | 4054 |
| SOCS1 | 3947 |
| MAPK11 | 3826 |
| JUN | 3722 |
| TAB3 | 3160 |
| RPS6KA2 | 3087 |
| RPS6KA3 | 2973 |
| PPP2R5D | 2421 |
| MAP3K7 | 2395 |
| ATF2 | 2085 |
| UBE2N | 1936 |
| MAP2K7 | 1654 |
| AGER | 1294 |
| VRK3 | 1281 |
| UBA52 | 1121 |
| ELK1 | 1040 |
| RIPK2 | 1025 |
| NKIRAS1 | 375 |
| NFKBIB | -152 |
| TRAF6 | -229 |
| PPP2R1B | -241 |
| HMGB1 | -252 |
| MEF2C | -293 |
| NFKB2 | -1165 |
| MAPK7 | -1337 |
| CREB1 | -1378 |
| RELA | -1803 |
| DUSP7 | -3211 |
| BTRC | -4924 |
| IKBKB | -5386 |
| S100B | -5457 |
| DUSP4 | -6287 |
| RPS27A | -6938 |
| MAPK9 | -7068 |
| MAPK8 | -9428 |
| IRAK2 | -9548 |
| SIGIRR | -10752 |
| CUL1 | -11330 |
| RPS6KA5 | -11594 |
| NOD1 | -12263 |
Toll Like Receptor 2 (TLR2) Cascade
| 1239 | |
|---|---|
| set | Toll Like Receptor 2 (TLR2) Cascade |
| setSize | 92 |
| pANOVA | 3.03e-13 |
| s.dist | 0.44 |
| p.adjustANOVA | 1.53e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| PPP2CA | 8234 |
| MYD88 | 8136 |
| MEF2A | 8009 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PPP2CB | 7712 |
| RPS6KA1 | 7695 |
| MAPK1 | 7493 |
| BTK | 7206 |
| TAB2 | 6964 |
| MAP2K4 | 6866 |
| NFKBIA | 6807 |
| PELI1 | 6715 |
| UBB | 6639 |
| NFKB1 | 6277 |
| FBXW11 | 6196 |
| MAP3K8 | 6160 |
| IRAK1 | 6131 |
| ATF1 | 5706 |
| TAB1 | 5681 |
| TIRAP | 5640 |
| UBE2V1 | 5637 |
| TNIP2 | 5552 |
| FOS | 5460 |
| IKBKG | 5377 |
| MAP3K1 | 5121 |
| ECSIT | 4918 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| DUSP6 | 4357 |
| MAPK10 | 4325 |
| SKP1 | 4287 |
| MAPKAPK2 | 4054 |
| SOCS1 | 3947 |
| MAPK11 | 3826 |
| JUN | 3722 |
| TAB3 | 3160 |
| RPS6KA2 | 3087 |
| RPS6KA3 | 2973 |
| PPP2R5D | 2421 |
| MAP3K7 | 2395 |
| ATF2 | 2085 |
| UBE2N | 1936 |
| MAP2K7 | 1654 |
| AGER | 1294 |
| VRK3 | 1281 |
| UBA52 | 1121 |
| ELK1 | 1040 |
| RIPK2 | 1025 |
| NKIRAS1 | 375 |
| NFKBIB | -152 |
| TRAF6 | -229 |
| PPP2R1B | -241 |
| HMGB1 | -252 |
| MEF2C | -293 |
| NFKB2 | -1165 |
| MAPK7 | -1337 |
| CREB1 | -1378 |
| RELA | -1803 |
| DUSP7 | -3211 |
| BTRC | -4924 |
| IKBKB | -5386 |
| S100B | -5457 |
| DUSP4 | -6287 |
| RPS27A | -6938 |
| MAPK9 | -7068 |
| MAPK8 | -9428 |
| IRAK2 | -9548 |
| SIGIRR | -10752 |
| CUL1 | -11330 |
| RPS6KA5 | -11594 |
| NOD1 | -12263 |
Toll Like Receptor TLR1:TLR2 Cascade
| 1245 | |
|---|---|
| set | Toll Like Receptor TLR1:TLR2 Cascade |
| setSize | 92 |
| pANOVA | 3.03e-13 |
| s.dist | 0.44 |
| p.adjustANOVA | 1.53e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| PPP2CA | 8234 |
| MYD88 | 8136 |
| MEF2A | 8009 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PPP2CB | 7712 |
| RPS6KA1 | 7695 |
| MAPK1 | 7493 |
| BTK | 7206 |
| TAB2 | 6964 |
| MAP2K4 | 6866 |
| NFKBIA | 6807 |
| PELI1 | 6715 |
| UBB | 6639 |
| NFKB1 | 6277 |
| FBXW11 | 6196 |
| MAP3K8 | 6160 |
| IRAK1 | 6131 |
| ATF1 | 5706 |
| TAB1 | 5681 |
| TIRAP | 5640 |
| UBE2V1 | 5637 |
| TNIP2 | 5552 |
| FOS | 5460 |
| IKBKG | 5377 |
| MAP3K1 | 5121 |
| ECSIT | 4918 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| DUSP6 | 4357 |
| MAPK10 | 4325 |
| SKP1 | 4287 |
| MAPKAPK2 | 4054 |
| SOCS1 | 3947 |
| MAPK11 | 3826 |
| JUN | 3722 |
| TAB3 | 3160 |
| RPS6KA2 | 3087 |
| RPS6KA3 | 2973 |
| PPP2R5D | 2421 |
| MAP3K7 | 2395 |
| ATF2 | 2085 |
| UBE2N | 1936 |
| MAP2K7 | 1654 |
| AGER | 1294 |
| VRK3 | 1281 |
| UBA52 | 1121 |
| ELK1 | 1040 |
| RIPK2 | 1025 |
| NKIRAS1 | 375 |
| NFKBIB | -152 |
| TRAF6 | -229 |
| PPP2R1B | -241 |
| HMGB1 | -252 |
| MEF2C | -293 |
| NFKB2 | -1165 |
| MAPK7 | -1337 |
| CREB1 | -1378 |
| RELA | -1803 |
| DUSP7 | -3211 |
| BTRC | -4924 |
| IKBKB | -5386 |
| S100B | -5457 |
| DUSP4 | -6287 |
| RPS27A | -6938 |
| MAPK9 | -7068 |
| MAPK8 | -9428 |
| IRAK2 | -9548 |
| SIGIRR | -10752 |
| CUL1 | -11330 |
| RPS6KA5 | -11594 |
| NOD1 | -12263 |
Toll Like Receptor TLR6:TLR2 Cascade
| 1246 | |
|---|---|
| set | Toll Like Receptor TLR6:TLR2 Cascade |
| setSize | 92 |
| pANOVA | 3.03e-13 |
| s.dist | 0.44 |
| p.adjustANOVA | 1.53e-11 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| S100A12 | 9515 |
| CD36 | 9444 |
| NKIRAS2 | 9353 |
| DUSP3 | 9280 |
| APP | 9177 |
| IRAK3 | 9107 |
| MAPK14 | 9104 |
| TLR2 | 9103 |
| CD14 | 9097 |
| MAP2K1 | 9063 |
| TLR4 | 9016 |
| MAPK3 | 8953 |
| TLR1 | 8932 |
| MAP2K6 | 8887 |
| TLR6 | 8840 |
| LY96 | 8795 |
| MAP2K3 | 8748 |
| NOD2 | 8442 |
| MAPKAPK3 | 8382 |
| PELI2 | 8314 |
| PPP2CA | 8234 |
| MYD88 | 8136 |
| MEF2A | 8009 |
| CHUK | 7966 |
| PELI3 | 7716 |
| PPP2CB | 7712 |
| RPS6KA1 | 7695 |
| MAPK1 | 7493 |
| BTK | 7206 |
| TAB2 | 6964 |
| MAP2K4 | 6866 |
| NFKBIA | 6807 |
| PELI1 | 6715 |
| UBB | 6639 |
| NFKB1 | 6277 |
| FBXW11 | 6196 |
| MAP3K8 | 6160 |
| IRAK1 | 6131 |
| ATF1 | 5706 |
| TAB1 | 5681 |
| TIRAP | 5640 |
| UBE2V1 | 5637 |
| TNIP2 | 5552 |
| FOS | 5460 |
| IKBKG | 5377 |
| MAP3K1 | 5121 |
| ECSIT | 4918 |
| PPP2R1A | 4589 |
| UBC | 4439 |
| DUSP6 | 4357 |
| MAPK10 | 4325 |
| SKP1 | 4287 |
| MAPKAPK2 | 4054 |
| SOCS1 | 3947 |
| MAPK11 | 3826 |
| JUN | 3722 |
| TAB3 | 3160 |
| RPS6KA2 | 3087 |
| RPS6KA3 | 2973 |
| PPP2R5D | 2421 |
| MAP3K7 | 2395 |
| ATF2 | 2085 |
| UBE2N | 1936 |
| MAP2K7 | 1654 |
| AGER | 1294 |
| VRK3 | 1281 |
| UBA52 | 1121 |
| ELK1 | 1040 |
| RIPK2 | 1025 |
| NKIRAS1 | 375 |
| NFKBIB | -152 |
| TRAF6 | -229 |
| PPP2R1B | -241 |
| HMGB1 | -252 |
| MEF2C | -293 |
| NFKB2 | -1165 |
| MAPK7 | -1337 |
| CREB1 | -1378 |
| RELA | -1803 |
| DUSP7 | -3211 |
| BTRC | -4924 |
| IKBKB | -5386 |
| S100B | -5457 |
| DUSP4 | -6287 |
| RPS27A | -6938 |
| MAPK9 | -7068 |
| MAPK8 | -9428 |
| IRAK2 | -9548 |
| SIGIRR | -10752 |
| CUL1 | -11330 |
| RPS6KA5 | -11594 |
| NOD1 | -12263 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.0.3 (2020-10-10)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.2 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.2.0 GGally_2.1.1
## [3] beeswarm_0.3.1 gtools_3.8.2
## [5] echarts4r_0.4.0 topconfects_1.6.0
## [7] limma_3.46.0 eulerr_6.1.0
## [9] mitch_1.2.2 MASS_7.3-53.1
## [11] fgsea_1.16.0 gplots_3.1.1
## [13] DESeq2_1.30.0 SummarizedExperiment_1.20.0
## [15] Biobase_2.50.0 MatrixGenerics_1.2.0
## [17] matrixStats_0.58.0 GenomicRanges_1.42.0
## [19] GenomeInfoDb_1.26.0 IRanges_2.24.0
## [21] S4Vectors_0.28.0 BiocGenerics_0.36.0
## [23] reshape2_1.4.4 forcats_0.5.1
## [25] stringr_1.4.0 dplyr_1.0.5
## [27] purrr_0.3.4 readr_1.4.0
## [29] tidyr_1.1.3 tibble_3.1.0
## [31] ggplot2_3.3.3 tidyverse_1.3.0
## [33] zoo_1.8-9
##
## loaded via a namespace (and not attached):
## [1] colorspace_2.0-0 ellipsis_0.3.1 rprojroot_2.0.2
## [4] XVector_0.30.0 fs_1.5.0 rstudioapi_0.13
## [7] farver_2.1.0 bit64_4.0.5 AnnotationDbi_1.52.0
## [10] fansi_0.4.2 lubridate_1.7.10 xml2_1.3.2
## [13] splines_4.0.3 cachem_1.0.4 geneplotter_1.68.0
## [16] knitr_1.31 polyclip_1.10-0 jsonlite_1.7.2
## [19] broom_0.7.5 annotate_1.68.0 dbplyr_2.1.0
## [22] shiny_1.6.0 compiler_4.0.3 httr_1.4.2
## [25] backports_1.2.1 assertthat_0.2.1 Matrix_1.3-2
## [28] fastmap_1.1.0 cli_2.3.1 later_1.1.0.1
## [31] htmltools_0.5.1.1 tools_4.0.3 gtable_0.3.0
## [34] glue_1.4.2 GenomeInfoDbData_1.2.4 fastmatch_1.1-0
## [37] Rcpp_1.0.6 cellranger_1.1.0 jquerylib_0.1.3
## [40] vctrs_0.3.6 polylabelr_0.2.0 xfun_0.22
## [43] ps_1.6.0 testthat_3.0.2 rvest_1.0.0
## [46] mime_0.10 lifecycle_1.0.0 XML_3.99-0.6
## [49] zlibbioc_1.36.0 scales_1.1.1 promises_1.2.0.1
## [52] hms_1.0.0 RColorBrewer_1.1-2 yaml_2.2.1
## [55] memoise_2.0.0 gridExtra_2.3 sass_0.3.1
## [58] reshape_0.8.8 stringi_1.5.3 RSQLite_2.2.4
## [61] highr_0.8 genefilter_1.72.0 desc_1.3.0
## [64] caTools_1.18.1 BiocParallel_1.24.1 rlang_0.4.10
## [67] pkgconfig_2.0.3 bitops_1.0-6 evaluate_0.14
## [70] lattice_0.20-41 labeling_0.4.2 htmlwidgets_1.5.3
## [73] bit_4.0.4 tidyselect_1.1.0 plyr_1.8.6
## [76] magrittr_2.0.1 R6_2.5.0 generics_0.1.0
## [79] DelayedArray_0.16.0 DBI_1.1.1 pillar_1.5.1
## [82] haven_2.3.1 withr_2.4.1 survival_3.2-10
## [85] RCurl_1.98-1.3 modelr_0.1.8 crayon_1.4.1
## [88] KernSmooth_2.23-18 utf8_1.2.1 rmarkdown_2.7
## [91] locfit_1.5-9.4 grid_4.0.3 readxl_1.3.1
## [94] data.table_1.14.0 blob_1.2.1 reprex_1.0.0
## [97] digest_0.6.27 xtable_1.8-4 httpuv_1.5.5
## [100] munsell_0.5.0 bslib_0.2.4END of report